var title_f13_25_13712="Computed tomography scan of bilateral acute pyelonephritis";
var content_f13_25_13712=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F51244&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F51244&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Computed tomography scan of bilateral acute pyelonephritis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 242px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCADyAWgDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwDxPTPDk10AzJFtPqorqdP8NWsEkP2m0t5FHDHyVIP6V0CWSxtut8JGPmIBqWJmTci5AYj5cf59KAIbfSNHTiHT9ObkkiW2jP4Diri6HoryF5tL06PbztW1j5/8dqnF5ahyyhJeW3ipXvlQAud8akfMT19sUAaA8NaVdRFoNM0xVxnDWcYYfpXGeL9K0axypsrVJcceVCqjP4CtHUfEE8sg+yFowOgU9a5PWHmuiWuckk8Me1AHG32xpSI4o1UdNqgVTaPaeVFaF5tjk4GRnrVW4kEhBHagCHI7qn/fIqVjBsGIju79KixRigAwmD8o/Km7R6CpkgdsbUb8qlFlNkAqQTQBUAH90flSkD+6Pyq01oyZLDkU0QMcnoKAK+wHoox9KeseQPkGPpU6Q4GW6d6GJBGzgCgCIwqpHAx16U5Y4zzsXH0qSNd5wfwp/k5I6r7mgCuYhxhBj6VIltvBYRj6kcVdjjCxgD5jW3HF/oavN8qeh7/SgDnDalST5SYHsKdbbImJkton56FAa1rS4iluDGkOQOpzV2PT0MpKpuDcnHagDJae1KsBY2qnGQfKFEa2snzG3twenCCtq/0BWXfHIA2KzZ9EvUUtAjSJ0JWgCzbw6fIVR7S2APQiMZqrd6PAZcQxR4PTArNkjuLaTDqUYevUVJHqdxEu0fN6Z7UAQyQQWuVkhRmPHI6VnlFz90AfSrdw73DkyElveoWUg4P0oAhCL/dFGxcfdH5VIFYnpT4beaeQJDC8jngKoyaAINi+go2J6Cuy034a+LtSszcWmiXLRdQcAbvoDVObwN4ribafDuqsRx8lszD9KAOZ2L/dH5VJE/kn5UjbP95A386u6ho2p6cSNQ068tSOvnQsmPzqhxk5FADt4x/q4s/7gqe2u1hOGtbSUHqGiBqr1FHrQB2fhqTR5vMkks7bzkwdkkSsD9ARW/pmq+H45il/o2kuue1pHn+VeYwSvC++MkH2pzzl2JYnP160Ae4Wul+HdVBl0/TtJRiMhHto+n0xQdK0mNhHNoelEAj5hZxjP6V43Zavd2cqvBM6hegBrrdJ8dS741vhvRcck0AdfeeGdLkJeCw09F54+zoP6VlX2g2UIKx6banuW+zJ/PFXoPEEF8c25KxkHOD0rcsdUiKGOWFWQjPIoA4OTQtMnLKYIEcDJ2xqP6Vzep6Msco+zwpt9do6V60NLsrm4faqq7DgCqN5p0MBMcgCoO+KAPIWtRHNENqeZvXG0Yzkiiu8utFtYdRtLhSrYuYTj1G9aKAOr8zMLqVYHpz9aR5lMAXBDDjcf5VRltZ02stw5GM7c8df1pXLqm4u5HcjjFABJG8J3xvg45BPOaypmuDlQMjJYg1qeXIWGF6j/WZ/WomtihLRSO6gfMQOlAGMFkkQlsYUE4z0pJkdYgSdxIBGTWpHbQzkmN8J0yR+dRxWzM+AS8Y6cdOKAPOdZl8y4xt2444qrZ2c97OsVvGzsxxwK7/UvDlvL++jYHPYjFVYbpNHVxYqI5QPvjqfagCjJ4N/s5N+s3kERHWOOQFqqSDSrdisUbuo/iODmqWqXst5KXmcuxySSc1ngnOcewoA3211SghSBEQdCFGaV9UhAKiJSSOuM4rFjjwNzcLQ5VQdvXHJoA0YJFmuT5u0pkdelabQ2EqBQ4yBywNcwGfaeetWbWMr8xOSaALd5bQq2AxHoPas+SMKSVPBP5VsiyL2/mMT1HWqN1bKsYbBB7UAVY0UsApwamYqOeCRUEYUE7iSR0qwyKYgysCT296AJ4HDEAoox3HpXR2kPnoqn7p9elccHIOc/Wuo0u/L26IvUnBA7CgDb+w2sFrmGKIOAcnHJPrmrnh+y8xiXEZTuGx9aoTTIqoiDcw7+nPpWnpMseAGZSSeR3oAl1IW4DbQoIJHHXPpTNPUyQhfm49F6D0qbUoo0CiJDg/zq1b2VzHClwMgOQAMYz7UAZOo6bYmIi7RldjxtXrXKat4ae2UTW48yJwCpHJHsa72/wDIlYNfEktn5W4H51XlguIIBLbboYyR8vB//VQB5LJbzRyHejKQcYI6UsjAoN4Gcdq9IvTbXsXlatD5EpyVkPf06VxOt6Q1nJ1Dpn5T0yKAMSQgkDp9Kt6UkgukeJmyvPBqsF55HSuh0a3VAHJ2jGc0Ab0fjPWNJt/stpf3AXPQuSBV6Px94hsIFZL+Td7uTmuOupbeSflgwHc8VV1N2YAqPlHSgDb8Q+P9Y1cMl80Mqn1XJ/Oub0+9jiv1mltoJBuyVZeKz2+Y8k1KqAKSDlqANTxFqkWpFPKtLe32/wDPJNuaxGA55zTmJNJ3oAlhhLxuwGcUzZkhR1qxbM0cbgEKGHNMPDZJ5xQAz7O4GQM/SmtGy561ajuHHCnj2pJZGZskZoAdZahcWrZjYgdx2rrtI8UMoVXxu4Xp1rjceYoGBmlQMj8HBoA9dstXV2VonHmLzjOc+1dA19HeQKZ41Mm0YwOleKWV+9vL5icnvzXpPhrV7XULVIpZAszAZYnkUARaxZOtzDcRgmMTxt/4+tFaeotJFaPGJC8RljBbHGN45ooAhjimjISRgY+ozTpIt7sJOCO3Q1IIyW3NKY1PIHUCpJ41niAZyc87unNAFFtOMpO+Tah6Hd2HpUkdolurIrHd3ycirKQKiATzB0wT8wqxcCFLZEKhxgYkwcigCpHp+yMGKSMSd1J6j6VJb28xk3PHkIRuGPypsdoUAMSGQEnLZxWtbSPGMSL5oB5zxQBla1cwvaeWsTRgdCoHPHf/ABrzbWVCu5iLFe5JzXqfiCKG5sXKARyY+UeteXatHPCzhl+UdfegDnShbJJA+tOt4PM7E+lWIRHLIEYD09q2rWC3g+VpACORxQBRt9OmMbM64T0NZ9xE+84XC5rrI7i4kdYokZ1B6jvTrywa5iBigIkUfNjvQByJQhBlST7Cr+mWSkeZNvwCOMda6rwzokM8jC9UhgOF75rqr7RLMWeyKHY5/iz370AedLMC+EBGOxqjeOWGGHOTkAdK7qPw1E8mPMVDnjjOBW7B4CsJv+PmVASvPt70AeLgLwcdPWmyysMg4Htiu28U+F49OuCLVxMmeNoIxXL3NgcjIwx7d6AKCDI9zW5o9uUjBC85yT2qK90ie0tEnZG2HHatjRjBNp8aHAlL4z1oAhvnCRyySFiTyCpqvo+uQWDCWUPIGbbywJ4wemcjr178+hre1PTraK2SFFMr8lgD0rT0T4cWd9pL31xL5JOMRk+tAGrpes6Xr08CW0kcWAAyykdq6G80lby9ZUmHlwru/dPwfpXmeoeAp9MT7Ra6ghkydqAHdg1v+Axqml2spnkk+f5Of0oA09Ttk/eSfIEh+7u61j/anRGMhG1T0AyD/wDrqXVEuGmKzOdrHnI/KskW+26Rc71I5AoAv34S/USOhzwPqKr6rHItnEXhRyeCQuePWtSJUe2ClRGqnnnNXYik2nlI7cO+DznrQBz2heEbfWGSZwIg3qMV2snwl02ayDC/lQBem4VN4Zs5DHG8sJj2t1Hf61p+INVgsYkScDDpyhzyKAPEtT8JwR6g9vaTO5QnLHGP51i6zavYuImAYDqe9dvcajHJdsLaPYSfvA5qlqtlG6DcPnJI9TQBwLQK6B+h7j0qCT5cKvT3rpL7T0jDGA7m9Qtc7dAea3QHNAFcDtQFPp+dOBIPHBqRF39W4FACwNs68nHAp27IPH0qSOFR8xPA4xUbFlbpxQA0EA9APoMUrMScCh0ZiDnilCKYy272xQA0N2wBVmJFZdxYfSqu31HHrUkKI5+8cj0FAFhniJ+XPPFLb3cmn3IkjZsA8e4piqiRjI+YNTp1823X5fmUetAHp9r4nGreHkhdEQpJEOEyxPmL/nNFeceHbya21WzQEhXniUjPBG8UUAetSwyZQSKN2PmcDCg1M9vFCqlJCZBySOhPpUjIQyr9uYwk/dK+v8qdcC3i2bVDknOB2/xoAhjkQQ4vI5GBPIj7Gmi2WZg1szLnna55FXVjlktmES+U5OVx3FMhScfu/KO4clvXvQBKtrLHHvRw0gHReantUvCE8xoFGP4+p96zzd+W5VWETg5LDNPjuGu5F34lxjDZwKAGeIHRYFcHMi5z6V5RrE8xkbL5znvXofiENDAzPkNnFeeX8b3Em5Vz/SgDERnMg29favQPC+nQNAst2G3Y4BHFZWieG7h1894m2gccda7HTGitoES5VXQjn29qALtrYQWVyJhERGeQQOoNFyrLu+zxxtGyemSKsJf27wvBJjy/4D7VXju2tcLA5MbcA+9AGVDAROGjEwbcCc8A1ujxG2nQ7DAssgHUruFUZ2u4pt/mkxvwpAGKvafDA8p8xR5jE9uhoAwrK5utQ1Brxh5ZVvuDgf8A667Ky1Nr5lSULuJxmP8Ama5+M2y3BjcrCuT75P8AhVmzmS03T2ZH90nrxQBp+IbRYbeSb5X+XO0jOD/SvI7+F47lrmd1SMHGAcZFdN4r166UAhyQ3UnvXH34utTgWXazAfxetAG9H4n0u40trGaGcMFJRsgjOOK4oXcyMdjEKGziug0vwhc3kRlmnjgj6fMDmtK58DJa6UbwahDcvyPJjBDCgDml128WQuGVsjHzjNes/D3xHa61ZGC/kEMtsoGCwUNk9a8w0Pwpqut3gtrC3Yue7dAPevRIfhbqOh26PNMkl045WMH5fbmgCzrGpCXUxGCTAOhA59qtq0csQtoJ4hGBuAd8MSetcbNNd6cXSWFmcEryfu1zd/d3AcTIzKfSgD0W/wBGu2kPlSiRATuy2ahj0EqnmyTEDHIU/wAq5LR/FNxHEIbmQ46ZrpLLWLNbUSNdgsMfLj+vegB95ZMqqIpHKlgcMetagMyQKUiUIeMjIOa5y48XWQuAZIPNCdMt1q9N8RbJ44hFp6kqcnL0AdloMTTjM08gVDjO7k/hWd4sZwQNglIHynBJ/GsVPH9rG4l+yhT/AHAccVh6r42uLq682CLCHjYDnj0oAkjCzS7Nhj+bnPA9quXUFs8f7yRgT6e3bNczceIXlf5gVyMcVV1TXHkiVI1Kr1znvQBPrES7H8uUCMDIwcE1yU5XzDsyfc1ZuJ5JgMsfpVQ9MUANwT7mlAIJ24ox3pyjDdMmgCa3d1BG0HPY0SK7HsKmhHTb0/nRKpDj5sDvmgCLIjYYyeM0SSgjAXAHt1qT/VjCncx4wBUTRuQxYmgBiNvYqSAKfuWP7mT60wKFbLc05WBOAuPpQBJ5isowvI5p8L5POAoPOaEaOMMSoPHGOKQKMg7wM44oAsafF/xPdOCkDddRY/77FFTaeI01zSzg5F1CTjr98UUAewHZKW8ySMHaOhzSSQT2/wA0TRPk8Z5xVNIU3LmIMp+7itrQrm2s77dewRz2rLskiY4IB7oezDHB/OgCsk1yJo3wNgU/L+farP2wTkI6mJuuCMZ/Gtm48N3gSS60YSahppia4W5jT7qr94OOzDuv4jIrCkljZgpHmuQD6GgB8NrwXugjZOBtAOahubeTc8m6NU9h70l1dOsMaJCYwCNxyDx6ViazqTQnyoJfMRuuDjigDC11/Kuj+8d85OC2RVSzK3KMCAD1GBUV9ObomMrz0z6VJYabd7t0UTsnXIHGfWgDpNOhkhhjfc4BPHPateC+tRatvg+dRg8df89aq6St2scaSRmQDgL/AFratbGORt0lmVUjDZJxQBmmOAqJIVwpP/LT6c1NiER/KA5APvVi/wBJWK3kZmDR7uEHbI4rOjtlgDTC6CZ/5Z4oAVUjuZsTF0A4wOPyrRisYVlQiWMAA7vmxk+uayLiOSRDLES4br2IxTPKaOJBIpI9SOlADtYnktQ+6OJ0JzuwCfSks5J2td+xFh5+9x9aZLGVQPPJ5kQA+UjpWBrmozTExxzbIhn5aAK+t3Md5OEUAoDjJrsvBukWs0Co7L06dq87ibLBTyc9a7Lwywt13RzeW/OM85oA3NSgjuZv7PhZYwDkkcdKqeI2tNH09IoJllkzyCfaq0zoDKHQmRmyXzXNanol7e/vYDvG77o5NAE2ja5JbX6zwu8TjH3DgYrpNT8bXV8GWW4RApwcP8zf/XrkbbQruBC0sLFcZ6VgTWh+2yGRGUZ79qAOyk8SQSK0M0Ykd+rEZrn9WsZJ8vEUCN05xWVbIWuMK3FaLpMcLk4AzigDEltDFndzj07VEHUrjew9a0p3VBhhh+c5qkY1YhnGKAHWsO9xwWzV17TyzkR4z0yKTS7hbRxIBuAPQd6377WbS+iC/ZvKkx13Zz7UAc0TCAxnyCem0Utppsl5MiwsVU9CTin3AiMjB124PGa6bw5BFKpS2XdKB1649aACDwf5MSPcSqxJ9c4qbVPCbi2SSFUMfOBmugNs0caeeWhG7HzdK0L/AMmWSOKGUZB5OM9qAPIdT0W4tlL7QE+tYhBzgDnOK9a8T6Wske1GUEZzXGRaIGlwTkE5zQBzkcLSEAA8e1WljKjBTBHfFdtY6Cvl71Td2OBwKtnw4lyxWJN2B1AoA4O3yDyoAHPArRntIfs4fPJHcV0UnhmdJjGsD5HGatL4Qv7rn7PIoHGSOKAPPvLfO2MLnvmknilRcydT2zmu7vvh5qUSCQOpOCcAdK5HVNNvbJ3W5Rwo6kjigDJZiMHIb2qVpVlj+ZVVhjoKiCnJOMUwj/61AErNuIC9zzUsJTevmA89ahXcD8gBHpUsIYsS0ZOD+VAF60Mceu6YYmPFzEc+nziiorBw2uaf8mMXMX/oYooA9qDxTuAqtkAnoB+H8qrosTzO0hbaBzt71LcbbQJmH7wOVzmmu0TtvgjO58cA0AeifDn4gweHohpl7YKdPZsmeNcSZPUuDww7eox3rl/HUFjZa6ZdKlS40q5UyW7xfwD+JCOoKnsecEetYn2d3lX5woxgDFdR4f8ADaTH/SYSMjhicUAcVsWa5MUTSlm9auweGJm+d1DL146g16Ta+GLJGysIXggtircVtFbKUhYSDvjvQBwEPhSJpUJijw3OQtXDptnBtt4A2QvO4Yrp7yZ7ZiwcKMciufvr+2huJElUBiMH1wTQBNBp0VoBh42A9xxVqO4UttaPcg4JQZ/Cso29sQpjjYMT3bqK09OeWzhO2By/UEjpQAXdmqqZZVxFndtPX8q5PxFJBKimBQjqMkkdq6vUdQF5HtnjKkdc964fxPf24smTySsnKgE9aAMyHUbVd0cr7X7BD/Orseuq7i2SBZIzxuKk4rzzyGnfMaknPPFaema6+mEwyRcNxuNAE3iG5Nvcgl3wRjap4rJAuNRk4i+Tp8q81rRiO+u1Zoy6Mc4Br0fRbS200K2FxjBTAyPegDz7Q/DMsjL82W9G4zXQx+Hna6Cs6xhePlbGfWuhv/sNzN5tsFt3P32ycYqrfQWlsqS3FwrxjgKvGOwoAdcW8VtAuFjdQNu44JrLvnVnCwAxoGGcLjn3q1pZS/uSEXEI556Zq7MsUku37QqruHyjg/560AMtJ4/sioVMhQHIIrkPF2nQSZuISQeSVA4zXoGj2zvM4MqiI5IyOtcl8QIJrafMbZT+8BQB5tLH5POCDnsOtSW7TMMq/HfPWtGGzublWYoSgJ+fb+lU5LPy5P3nzNmgC4Etp1USKPNHXHrWVcxbpTuTEfb1rstB0/TGtJTdq6zsMIScc/Sq8+khmZEI8sHGcfd/GgDjmCKwEQGfcVahhSRB5g2yD0rRu9LiRyUfGDiq7WkkmFV1yOPrQBFKluMhgSR3xV3SJ5ILgfZsDPQmrNn4bvLsAghiTxxW7BpB00RLcphz1NAGl/acheJb63LBsHO0kkVo+Ir61iu41sbU5YDkoQOa6nw7DFKYi8kJjKjC45/zxXTJ4cutYmL2sS+X2YqKAPANckuGmPnGRVPZc4qjo7wrdCOZiVJx0r2/xV4J123jcxWhuFUdUQdK8VvtJvl1CYTWssUkbY+YYoA73RNO+Uyod0RGcdjXQxoiIgtoY1ycAqvJrgtF1iWALA7GMDjceldZYJdyzwzSXiGDdkjGPrQBvWs9nHC6TRN5hxhvLJxUiagNpVYuM9SMGk/tqOJhGHjEXHbOankvLPYXjniUEZbODzQBGt2nkKGj3A5HIrP1jw7Y6zbypKpV3GQRirbXaPGEt08054ZOfxq7b7xGuUKP6kUAfMHi3RH0TVZLZ8lQxCn1FY6FScNk8d69m+NOlSPFBeCI9DucDvXjUqgAYI4oAesZ3ZQYHXNTrGoUuZWz6VBCzKfl4z1pblSoBPOepFAE2kNt17T29LqI/wDj4oo0Jc63po/6eouv++KKAParaW2CHzWd2PADDoKkJWS5/chAqkEbe/vS3IsGUxyJ5hwcOrUzQLCSe+VQ4RSchGHJoA3dKt723Ac28L7vmUtziun0xrqSIrIqIfQHHFXkt7aztgbjAyMgn/PSs+7vYJ24QkZwGBwKANdblIX+d8nvk8Yqvca1ZK4iO0McZK81yl/dSH9zE5dMkkCsadkt23eXJ52Ac56UAdRfBGEhWSRskkBfp+lc2QXuS00KsRzyDkCpra+NmVllO5fvEdKZdeIILudZFh2uo249f89aAND7dbGOExIUbdyNpAras7pGh8yQMU55VeornoJ11NlSUqhDDkgDrWxPdNYWXkwyKXPA4z+NAGL4m1uxSQmBZCQCPmXHNeZ6o6XUxzI5LdjWtrt7qN1et9omQgHaAFxXMTyNbXKmQFwvOAefxoA29FgFj5iyxowxkMwrK8Q/ZbiVcFQ/+z3p2q+IIbuAJGmxu+W7VQ0uOJrgO58wDtmgDT0bTvNKskrhQei9a77T41W1OJWY8klh+Arn9NuLO0JZopA3YluKvS6pFcKTEREucnJ9KAC71GyjTyZSUkHHyjgj3rB8T38IS2ELsy4y1V9TRpblpAGaEdCP5VR1BLaa0YRqwdMdWzQBv+FNaSL5Y42fsTgntXSRpDPPkoVYDOMVyXgvXrbRrW4VoPMmbp0rd8NW/iXxRq8jaZZzGLkFhH8q/jQB0ln9litnN5O0RUZCg9eeleeeK7t7i8K+c3kfwgHsK9Tg+C3iLUpfP1K/hg44Urk/Tg1X1f4E64yhre8tpSvG0DaTQB4+L64SHy4wRH0znmo2uYNjMV3S+rV2ur+APEnhq2eS9sH+zL1fGVHavOdSRPPJUc+goAnju3WbLnag6AV0FmDdADzpEQ8ZFcek7JgMDtrqdHvIJ4MSAgJzgHrQA/VtNZgfs+NgHUmtT4d+Er3xLqSWsUR8oH5pDxtFYOrX80ZIgYeT6dSK+if2asTeG5pQq7g2Mgc0Adp4W+H2kaDbqiq1w/dpMH8q0dY8IaPqlu8ctoisRjcg6Gug5xVHWNWstHtTcajcRwxjuxAzQB5xpfw3lsdZ3eYJLMdCeuK9Ps7aO1gSKJQFUYwBXO6V440PVZGW2uhkHGTW/HewOQFljJPP3hQBaPPAxiuA8e6BbXAEpggjQ53PwOa71XVxwQfpXkn7SVnqFx4QjfT5diI371RwSPagDmb34U2+sQrLpd9iQehGDVaH4S+JLKIP55dF52h85rxfwzrviHRr5JdOupgynO3JYEemK+x/hp4sXxV4bt55sR6iihbiIjac+oHpQB4/b+ELy3bF4CQfXsfWtaTw+LaENDAkhIBOeK9L8Y6cVQXsX3B/rFx29a5D7R9oj2LKAecZoA56wiu7ViptIwvJHzf0qS4N+Yd3kgRkZyDnFV77zY7/AHQJK5x1Xpmr9pJcTJiUBFHYrg0AcT45t7q78Pyp5rghQdvXIrwCWErK4Y9Divp7xZGtxbMkuSuCfk4r5q1eIR6hOsYIG40AQAoMbsZzzU1w6vEpAwB2qusZYgKMMT1NSNBsjzJgn2oAk0Vj/bOnALx9pi49fnFFS6EFTW9OZjhFuoSfXAcUUAdm13NdXccVuxznAA4Ar2r4caN9ki867VWkcdxnH415X8NtNl1XVo3MbEL824Dp/wDXr6EtUgtrdUfpjB2jHNAFm/sLa6RWYgqB0I4Nc9f6MHUi2RRHjBXPFas0jMGCHYmMYbvWXfXI8jYjgOcUAcrf6ZLZ3O1CWLHG3P8AWojbZc7UV5B03Ec57VtSxzlcPtds5Bzmsi7ijDuDvWT64x9fSgCG+ae3jUzWMLLnnJrNWOM/P9niWTP3f/r1X8Q+IDBiGBuV4JbnI9qx4dSDpuSRPOYfQflQB01os11eBEiWMgjJX0H9a34dMe/uIrTy2Xb1YDke9Ufh/omsapeieRoWQAFSB3r3DQtDawPmTujyH0XpQB5Bq/wvnt4zdbmlUAthvpXkGv6NdLdyjy2ypPAr7G8S3kNjo8805UBV4BrwHxFf2E8MsigFix6dee9AHib2TBnEkGG9aW1VLSU5c/l1rpdbt0lmJjYK2Sdp4rCMVy7AFBj1AoAe940xAU7u3PalsbiUXBDKGT3q1Hp8flbdrb+uR0rIkZrWYqCMH1oA05tTkc+RAgVe+D0qSezP2XMS/M33hxVa2aGJN8p5A7d67v4SeH4fF3iy3hnDmyjBeYA9QOg/GgDvfg/8IrcWsWr+JIA5k+eK3fnI9TXuMENtYQCKzt4oI1HCRKFH6UXM0VnBGg+VQAiKPQdhWa1080gUfLxQBdF+xcjy8Ae9WEuUYbg3Tr7VTtUeMsDgjHWkkJYspGAe4oAvMYLqFopkSSJuCjjIYfQ189fH74dWWlWo1zRLURxu+yaJBwpPevc1LY+Y4QfnUt9a2uvaLcWd2oeGVCrc8g+tAHwDOrnJYfL1xSQvIH2xyMufSvQPHfguXw/fXEJjdkUnafavPpIirYwwAP40Aa+m53E3P7wE42sa9h+Eni1/C7yQ+T5to/JRTjHPUV41ZQ2hjzNJMGGM4IxXRW17aGNFs5mVxjhmxmgD6kufidoyWm+3WSWcjiLPQ+5rx/xnquoeKLln1O32QgnYmchR2qXwxKLO1Se+ijfdyAorak1cXG/7LaowY/8ALRP88UAcJHp01vbebYgxY5O3j8a07HxVdpFiKZ3lx1x2/wDrV2U6iaNUeBc4GcLxU2n2lnDOxSBAD14oA5PUPiZrOnaeNlwyTY4PBrE1rx3rviDQHiv5yUYfeHFWfilYRvdwG3QBckNxxWHa2bta7UikCjGNwOKAMfw7dQ2sxEsalyc7if0ruNIvr465FeaQGjdCGLjv+Fcdb6Q76mA4YDtgc16Jok0Gn4gkjdW6fdx29aAPQpvF1/eaZ5NxbhiVIkIIGayEgjuozJCfJfvgd6saXMjRsyKGyP4hV2VIXj3hXz32DigDm3t7+IE2sjEHOTxmrUCyNADNMWk7k9zWjJp7XEWYXZcDkMcDFZU9qYCAJCWXggEUAYniUXUUW5ASpBz7+nNfOusuTqUrMpzkk/nXvnjD7XFpbvG4GFIwT0Br5/v3JvnJAJzQBDJIXB2/KPSmOWyAWyOlIcs3yjGfelaMqSCc+mKALGmbhf27Iu4rLG30wworofB2g3Gp2msXsIKxafZvcO306D86KAPavhvawadoyMkoSVu4HP412CyHeWkut23n04rL062023srdIRPvCDGVqG/neNXManYQBuYYx2H60ATXt088rBb0xL3asOZCZCq6oZ3J6FfSlv5GuFRQjbjxkKRmpIbK0E0SsZFkK9cUAJA07M3nXvlAD7rDH58cVWvblJb140l8/eQMgYzWtLbxxZYgEbSAW5rJS8IlYRW6YznIXGBQBDf+FWu41ljtPNb6+tO8P8AgGKW6EuoRG1hU4O7mt+w1fVLYFY7e2dAe59qq3Ws3txd7LhVQZ6JQB6PYaro3h22igtEj25AJXgmqfiP4k29oBBYp/pD5CsecH6VyOrS7Ifk8v5eVLnHb3rhxqF3cap5rxW7w59aAOk8W67qOq2oWe988OBwBjB9K5abSL43CSLbSMjAZ+hrs/Jt9Qt1WQGIf7A74qG9cWscUdq8jkdCTx19aAOd1Dwmr4kZSremKhTRrgKqJbF1xjIwK7bTNVjIC6gqb8gALg81syxwySq6LyCThRxQB5+mgeRbStPa7MDgsf1ryHxGqJqkixNlQe1e9eMtRbSrGViqtuXGD6dOK8Sa0a+nllCoTyRk0AYyebKFUdK+rf2cvD0OmeE5NQaIfabt/vkc7cdBXzXoVqLvVo7bozEADtX2n4Js0sPDNlbIAAiAHHrQBa1Ly3fbI2KhgVGwQgbnrU13EPtDFuQaII9+AMKoOeKALCkpyi5pjruyTw3pUhDIuFGRUKqzuTuORQBVuY9zjeSFqbS9qu237vfFWpAMDKg0WiqG4ByPagDjfippWnto09/eRqSo65weK+VbjTVvpZpIGVUzlRX1H8eZoofAE6yOyPJIFj29zg14B4fgVdHJkjHmOAFyP69qAPO7uAW0rJMrKRx1p2hMg1SHfAZk3fcBNX/FOl3FndeZcn5X5U55rH065NnfRTR4YqwPI680Ae/6JBHdFWeEwhSMR5z/AJ4rrYfs+ERbIl+eQa5vwXrNtrVtH5af6ScDbtwAeldnb2l1bTB5UG3HAzxQBUvIZ/JGW8vnjjNZbTtaSHf83GcgdKs+JdQCP5SOckfXmsC7nAhYmQu4zgNwKAOV8bapJeXypFuPb5ea6jw1a3dxpSI4ZEUc5XnOa4m5tZ9R1VONgU4YjtXoGm6ReWNsqx3Uro3IycYFAFG4ggt5QyRAHP388dasS3ttcyIkqeacj7vAqWCzuoiySoro3PzHpStaToyulpFtyM89KAL3mSIgEUTCMj1/rXQabeTx2xVUK9Mg96wYzeLZsTH8ijqeKZC0vDLduCOqjoaAOkukeQBzEwBHJxis+5toUYFYGdjzkdqlg1Fok2XMpZCOprP8QXdpaWEt1Feuq4z04oA8y+L+sJbRJbW8oEjjLKK8WkdmYknknPNbniy+bUNYnmaQyAscFvSsMkZAwDj3oAlt4i+5mjZkA7VGBvk+TjJGBWpNcLDpkcMYBkb71XfBPh+fXtZt7aDIZ3AHFAHuHgbwr/Y/wC8T39zAUu723fBIwRHxiivWPHltb6R8KbuxkJMSW8VuPVmZlXH1JNFAGFpunSSWELGaM/LnOKW50iZg48xXXHAAqr8Ktei1zw9CXRRIi7CM8118phQLzsPpQBw66PdJOpVwo/2l5/z1qW50bzCA0ybs8kDvW/qO45eNm/DvWXqd7aWqqJCBLjvQBka1ZeTCoEyADrkVz0t20UJ3rtTHORitG/ZrkLK0rAbuPpVW4kthE3nuuF/hPc0AZn2qZzuQ9eBgZycVZtYWVt88gLkgY6EH1ojW33qVk8vB4IFWfs0cH72STzSB0PHFAGJ4uSOfK/aYwV6pnrisTS7L5lZAzAcgjua3bmDTL65dHkSKXHHGcio9MBtNQSFziE9G7UAb+joJkEVzjaMDHSrWqWywx4tEKDkbjz+tX/7Mt4I1mW6Zyfm2gc1oyTQ3WnhRGA4PbqaAOHs7JBLlWWNyRgt/StzT728shI10huEHRkHSrkNgz3H7y0Ue5qvrS3tnaymOEmAg5zQB558UNZXUGSOKVRGByuec1zGk2zPHwGZD/d61neKLg3uqEIgiUcED1rodDRY7VdkvzgZ4GORQBjGA6brtrOIJYoxIG+b0zX2D4AvrfUNAhntDlG6jNfK2t3klxZJFO5aQcAmvU/2bNamNze6RcuxBTzYlJ6Y60Ae6TQrI4LjikS2ROVBzVjH51x3jb4gaV4ZDW5dbm/HHkI33frQB1E6FgVDBfrTYIcKVLhu3FeBat8Rtcvgz2xMGc8DqBWNY/ETxBp9yrNfMS3JDKDQB9PBPUZp6rjmvNvh98SV1u5Sw1WLyrhvuTcBWPpivS8daAPDf2ndbjg0/TdKGfMdvOb6civNPDU0l1pUUKsiKijO6tv8AaWE8njuNGBaIW8ewenXNc74Y+yLp7xznZLwNpBoAo+K9LW7QlJdxQ44ORXBXFs1uw+YZB4r1u90+Y2DfZIWYnJ345NeV6lBcQ3TLcqwbJ4PBoA7r4V+J0stQWC5T7xAU9MV71cXrTW7yeaFTGc9K+SLWeS0mEkakNnIxXqfhzxVeanaJZyOwCjGfSgDr55ZHu2d2BBOR7CqesXEJjKKkhcjt3pbaynmuBtuTwM7McjNaVnZtLdHfCSq8ljQBk+H9PKxmZQUZuSXHPWuttSJtscjZIOPl7VSv5rUfKlwiBRyoqxoUcEjgwXasc8gd/agCbULSUr/osyLxj526fWqEU1zYsN0kEqZ5wc49a1tWt44kLFDtI5GTWLLb2oiDQW5Z884PWgDr9OmTUbQgRkK47DArHl0N7e6YPKnlsdwGeaueFp5ioVz5SkAbTzWjrEtgkLSTyL5q8hiccUAc5JcDT4ysqMRz94Zrg/Hfiaw/sqe2jDBmGMAVr+L/ABTai1dI7uNpOQAOcV4tefbdXvSkavKXbaABmgDn5cO7YzgknFQZGRwcg/rXQ614dvdEWM337tpBwrdSKzrSCOXJkBZc9BQA7S7RtRu1STPljuPSvd/hNZ2Ok6qtyVZUtvvF1A/WvH7W9isVCxLtk57Utz4p1KSEWyXZELcEDg4oA9I+LPxTuPEusWmkWZEWlxXsQkK9XIkXn6UV45coY8T5y6yKfodwooA6b4d+KbjRNQidZmERPzIGwCK+qPD+uWOraXFdRujFvcGvi7T4N0ignbkd67vwr4guvDUy/LK1sx5Hb680AfRWo3yvMBECDnjHArKlju5ZPlht3X/poay/D3iO21uBXjnjzjlCckVJezrJIYQHA6Fs96AG3sLFwsrIrAjcFNV7mGySH5ixdh8uRVq10fy2Mv2gOD/CTmpUsIribfPEzt14OPwoAgt7OOS2yygHHHFZF9ZW5Y5mkXHoeK6fVrA29uGijZYcZO6uRvYHMm2QF1bHTigCDSrSyXUhvEzMSMEjINdNq1pYy24fawlQcEDvWPbyrYTRJHCc7gR8ua7LTGJ3NcBQjdFx7UAZ/heIXkTq7co2AG9K6W3sPsrYkEeMcAHNcpexJaXjS26suW5FdCZbRLUSs58wr13UAT3kazKxmcRp6g4ryH4ja4bVJLOzupnVuCSc8VueJdeUwtDaFvNJ2n5j3/GvNbjR9Qurt3mVmQNk9enrzQBztlbi5uw0hkG4557mu8jhit4FjhAYcA56/SsiKOC0creo4x6HBNQKBcXIMEcxG47RuJzQBo+IrW3SzgnEj78ncAO3+cV6h+zx4e/059dUyeUsbRLuUjcSB0rkNB8KLdSRSa1dRrbrysRchj619E+Dl06HR4bbTEVYYwBjrmgDf57HnHFfJviKKSHxLqq34drpbmQnzOM8+/WvrL6V5L8f/CsV9of9u2gWO/tSqSEf8tEJx+YzQB4VdS3LMWQhQeQAaSza3kIju3AkHHJGRUTi4SHbJ8+wnIWqplBPyJtc+o5oA9D+HGnjUPEdtb2plMiSb8gdADnk19O147+zsLWPS71WAGoO2T/ue1exUAcH8VPByeJbK3uY1UXVo245/iTB4r5k8ZXJtrkRW8Sx+VkNgdDX2pIMxOMZ+U8evFfFfj/Un/4SnUI5YQq+aQVK4NADNI1PWxAZLZfOj4zvb2qnq1tdarmWWNYmB52nvTtHmhRhsWUqxycdDW2t1YxuUMFycg/dHHPagDjDoV4oyASn96l0Oz1RtXgtNLjlmu5X2pGhxk9ck9ABySTwAM13U3lz2wjgjaNBnG9cZr16z0HQvBvwvv8AVrGaO81DULX7Ob1AcnzPl2p3UDJPYnbz2AAPCvDvjia1kzeD7p27gDXqGgeNtF+xH9+zTlT8rKf89683uNAtJtojRoiOfmGKr6hEmnw7IeST0U0Adbq2o2mpyedFK0Rz90Dj8au+FvEFpYPIZgAoPHt/jXG6L4Vur/wdrfiV5HjttPESREHiSVpUBH0Csc+5X3qtZ6nLHDh4t5OcErQB7T/b+n3sZLXHykf54rlNR16xsMm2uXc7uh9K82vdVuWmxcb1BXoOO38qyrm8uHGYzmM/3u9AHp9x4ucoGhndQh7HH0rmNY8YTXSskk5IwBzzn8arfEjw9eeEvEE2mXTS+WVEtvIR96NumfccqfcGsTw34c1LxNqsVjp0eS55duij3NAFrQtKvPF3iGLT9NWRppDyQOFXuTX0v4R+GmjeBtElvtTl+0TwoZJJZBwuPStTwb4d8P8Awv8ADKm5mgS4IzNcvje5PYe1eLfHL4pv4gj/ALH0SYx2CtukdeDJ7H2oA86+JHiQeJPEM88WBbKxWFRjpXJpI0ZwGxz+FOY8jIwO2KYil2IXOfpQAu8s43ENn1NSiB2kGwYqS0snadQ6/KT2rafSbaGLzGuXBHIHrQBmXdsw02Z3BHTr9RRTtTaL+zmWGVnYsq4J6nIooAqmeNHDoxkI6g8V9KfCOy8OeOPC7WV3axi4iHzoPvDPGRXyqCQRnqa6Dwdreq6LrtrPokkxu2dUWKLJMpJwF2jrnOMUAex+KPhT4n8P+IYj4Oil1CyuXwjIygJ7MTwB7msjTvFH2bVLi1v76OXyJCjPES0bkHBKnuM96+h/DXjvw7f2UenG6s7XUYgsFxYxOCIZCuWRSAAwByCV4yCK+dPjX8O4/Dupm/0Uu2n3GX2jnyz6cdqAO+s/E9jPDGsAVmOAR6Guo0G4jmJk3DcB9wd6+TrG+vLZv3TNx/eNdRpfjfWNNQhGRjjHzUAfR3iaWWS2CxTFBg8CuA8q7e58uaV8gBsnvXmk3jLW7+VfMl+gHAFWode1Teu8AsRjIyaAPSYY501EPcudoxjPFaV54hgiLBMMVHTPSvJpNQvZJGMkr5HJGa09N8y5tpZLktwM5Xk0AdHqviiZ1dY4TyeDnnFTaTfztEz3Id48HIPaubsvEFjHIbcQlpScZdOn+TWrdSxeSrox5+bA6GgCS6dJpT9ltQT7HpTbHT9TlDxm4khVgeMVWW6kuDshARsck8ZqrqV9qGlxRzDDKDljnJoA1ZfDKRqZdYvA6AZyR29Kwr3WtN0+JodPtl35IDg+1c/qXjK4umCPlgBjpxSaVpcuqqGKMqserDGc0AV7XWbjUtdtVvLuQQtIqnPIAzX2Z4V0y107Sbb7K25XjDbvWvj678O/2XqNu7sShcZ9q+pvDmv2q+GrI27rhYxxwKAOzkLYIQ4c9Cea8w+LesG3kjsL26WOykQMV29Wz3Nbmn+Mo5DL9pAXaTjnBxXl3xSd/ExLwsGkjOQM44oA4bxToNwltJqGk3m+05yq+lYnhW0ub15bi5jeSKIbjnoea7LwvfRQWbafqIPzDbtIzWqPD9tDpV00Fw8QkAxtIGaAOq+A+L7Vb67W38tLdDCGz15Fe1V8xfC7xHd+Fbu8jjRJoWc7wx6+lekQfFyJQRdWBJJwCrYoA9V3YPOetfIHxj06S9+IWrvCm1TLhR68V9F6d46tL2EySoIEHPLV4X8XfFmm6nqfl6QA1wCd0irjJ/rQB5zElzpCZdM7exFRL4iuA2Y4tpXqRzXVaR4em1KwaS9lYKegznNZepeDzF81vMxPcEYoAveDL5vEGqNDqU/2ewgjM1zLxkRqecf7RJCj3IrodQv0vNVnmF/GkUrArCn3ERBtRAPRV49fzrzmfQbu0iEi539sH9adbDUIQJXt8IvegDpdduZrwCOKcKy4G8DH5Vl6hompW6Rl7kSBjziul01o5bIPLEqsAFHb6VbtbTzULXM5EYBCjI5oA9Mvbrw6fg3BoGmTvavcQRvGs8eHkKzje7YyOWRu9ea3gstEtCWRZmUZVR1x61N4omQamIbCUT2trDFbRMCNrBFALD2Lbm/GsJY5ZJ997FvC8bSc5FAHJXFxdapdMzQPs3Y9vap721nW3jVIyMN1PY+9ejR6dbvb4tI1T5eQi96jhsJHISWHdgkkE0AdP+0D4i8M+I/DemTWEk8939okjt7hYiqHbt8xGLYI+8hHB/WvMtE8cjwnaGPSYMXb/elbmuh8VaYreBtSUhFktbiK9jAbs2Y3x9SYvyryCNWkkO1NwB9aANzxL4o1TxLcedqV28gxwOgH4Vzk3DHDBu5q/dxoioANsncetQx2zEqzRfLQBXhQyEDBPHatiwt4IxmRcDvUsZtUg3KoWQZ+lZ9zeKc4OT055xQBsTXNrCjC2cbhyMnNc/d3bzFw56+tVZXycqeP60mflY4+b9KAI5cLsZunmJnnp8wopl5jyeOPmUD35FFAFiO3M4LKnTpj0rc0PUY/Dun3U1nG512YmKK6ONtrEQMtH3808jd/CM45OV52HUJEPyjAHvViGfJ/enj0oAZFcTWsoeJ2Vwc5Dd/Wu80b4n6otmbHVG+2Wp/hcZPT1rkfIimXPQ1UuLMxPzxxkUAaupzrdTSS2iiGNiTis9ZpI25kG4VJpd1H5rJKm7j8qmvdMbDSwr8o7d6AGC/kAC5y3rivQfC8Ey6Z50wI3nglfX0z+Fef6LE1zqEcTxhucYzXrMEtvaWYjMmXVR8mcgH/AAoAytJtLmPxBa3plVXtplmTPTKkED9K9t8T+DbezRdb0OPOmTqJpIF6RBhncv8As89O306eMAzXd6REDEmc5U9R6V6NYeIru+sI9B1K6C2LRCGF87drg/IWYdQfunPAHPagDlNV0iwnnLgLGc5Jx/hVdbGG0hITMyA8bWzUWpSmNpIp98M0LeW8R7MOCDS2+qwx221LZTIBgjNAFiwjaUs7wNtA+UDnHNY/iN7+Zhaxf6o8fd6D61s2XiSCT9wQFlwAOP5VJPaT3Cnk88biAcUAclo3hdI3Et0plJwRjoPrXb20kkVsvzRQIpwBtwaRYJNOtVVWM7EZOab9nlZA0kfzHJA6dOnNAGbqkFzfoU3hQTn5xjPpWTaajquiSIjeZ9nB59MV0VjLcLcgPAHjHXccD8as6vC18YyYf3a9PQUAKHuNSiimWYJHt+cE8Amnz2iWo3I5O4DOD69K5aL7ZZXvlySkQNz5ZJx+NalpeneEvEAjJyHLcD6CgDJuXlh1LbIjMMn5gOD716Pe6Cs3hmK5ZWIWPPBPWuX1G2WbYLUBwpJDA969Mitrqf4czRtEYmWDBIOSKAPLdG0xYpWJfdGW6d8VuahZWUFsHiyshYY3HNZGioPtOxrjzJOflNXbmXeG+3whFHAJOeKAMjxhf7NIEVoWMpJBxyT2rk/BmhC+vzcakkuxGGSeM108Np9p1lzDma3jwwbHGMfzrXW5WCMxrF5iMQSo4xQBa86yh3R2zhCvAyeKrrFJdys87o6BcfKOQazNTtxKwaPMS9WxSR217BGi28rMmPmAGMUASvDbsylEII42k8YpkdzuDwiBRt/2Bmr8EaGNfNjUzZHbOTUN1blZQ0ExiJGdoGc0Ac34hs5prNmQqjAg7QcGsjQ7C71NGiecKMk/M+APwrq725trrMbMJZQcN2P0qvFbQFQYFMbjqMZwaAKlrpk1o4TeWZeRuPArTmgE43O6+ZgdOlZVxqBt7iMXchMC+vpWu32W8jjbT5VYEcr1AzQBIkM6Rh/NXPpnrTpLiYW22Ulic/MnUD1pIbW4+zsTC7PtO0k4BNS28Uloz5G6NiOnb86AM/VIFk0aQThi5XA5z3ri7XTVt0lnkJHPp1Fdxq2r2ixSQBPm9PeuUvbtp0aOOQBVGAoH3qAOWvF8+UqhA57mpZcw25G5S31pb2SBYmVUKSdzn9axmYlgNxPPHegB0jtvJLHPscVGc4JB9ue9PGBx6+3amgjd1Oe1AB8vf9etKBwQMZpvOSpPPtUgOOQBg0AV7g7YVIIPzqPrzRSXpK2xYdnUjn3ooAojqPX2qRGYE4PJ9TUK/lTgMD3oAtQTHcNxIx6GtW2uoVUb/n9d3b3rCz9SM04EkZ7f1oA27iIOPMtio/QmizkuUJWQnZWTG8iH7xGODV6LUDjDjIJoA0tOcWepRz4O0NnAr0zT1trxRcD7zAZx1OPWvLkljdcxYDduetXLHWbq0YKJCI+pAPFAHpU1oQ5+zty56k8e2ferMOnKku7UJ+W6qr9K5/TPE1rdYDvtf0PPOO1aMlpNfKZgcns+DjJoAsavqf2q/ZQWlnlwWdwMkgAA+/Tr+eaibToZwPNdldhkbOgpv2NbQxSzOHfocjNXdtqU82Ng0hG3Zn9aAK9r4egjcyKzhwRk56VuZ/0NwSd4AwetUbWSR3dJG8tWxjIzx71akCxSKI7lSD1GP88UANRI4LcSqZpJiAcD5hilvbzfChEbhx1BHtU8N5b2rZMyAPyTjioPtca3G+OZJoyfujtQBHZSosWGDk4xk9h71et5Uiw22RuMjOTj/PpUDOrRFtpBJyF9z2qSCeSO3+SMhwePyoAp6xbrfRb4vlZRznj8Kp6bDbXFuY2ZgynnI5zWvK48rdsbeRkjP8/8965q986w1BJHjdYmAJJ6c0AX7TzLbUljgYtGSFxuzX0Ro9iJfCCR8FpYO9eHaXbCC4inETtFn5mB4Ar37QL+zn0WBopY9iRgMM9KAPmbWbW903xi0SgZJJUD+QrN8Uajf2hji+R1cAgkHvXdeO7eS68UNeQgmCJmXIHSvNtUvXvdZEcpGxR90jAGDQB0/heeK104y3BkExHOORitKLVhdmZI4Y8LgA45plmkFvGkd1alwwxnP4Z//VUtx9hjX/RUEQTg57j3/GgCCK5njLoIY5Du5yOo/wA/yqx/aNyCvkQRAjggjpSok11EHtriM4OCP73402GCKKDfcSqHHJz0I9KAEnuZvNDNAgPU4BwO+aqarfWqWxkTeZeuNveob3xDFFGUtH3nJ6dag01pGH2y4ZSrfNgjBoAi0QwozTSw/P8AwjZ+laE7QOS8KbJs/dA4NTXN9CG8wW7OT/d6Gqjs11uOCu0HG7g0AZ91aC7LpNCoGOo5pbHRZLeORbZmwSOAcYxWnD9qjtw5+YAAMVGO9VLjVRbKzIyoQejc80ASxHyInea6l+XIwckYrE1jxkkBaKFfMB4OR3rJ1TxBPqAaED73BwMYqhDY28TCSaRTjnk9qAJ4r1b9WmuAFfGSQM1m395DAWW3yHHQgU2/1OMEx2qAD1xWJNIZcs2AB3oASSQu+T0qMg7jxgnpSkHjAz7UEHgqe3rk0AAHHbOeppuPT15yKcwBbPGCKaR3+lAACS2TtHNOH+zy3Tr1pOxxzSkLwccEYNAFa/4tiDwdy/zopdR5sv8Aga/zooAzgfXk+vpS9AOOlJxx6fSl70AOHJ56dCcUqcfUelNzkk4FO5/DFAD1OCB68UoIx/Km9x6+lAOOwx1z60ATxu6jg4xVm3udnEgDDHWqQPGffpU2AwGB8x7UAaC3giUbFG4c8Ct3SvF95bgRFVKYwSeeK5IcZBB/nT1mbZtIB/woA9Ut9csb2GIyysJTywxgZ9Pyrp9O+w3yL5R28Y6Yya8Mt5jCA+evbNaK+ILtEAjkIHpQB7e9nHBMcFSBzkt0zUaQm4k3LGoz6j/PpXkkHiy4X/WlnyMEZ/Wtqz8bSIybkYDqCeQM/wD1qAO5utMudRLxrFGijgHOD+VcVrenX+iSGRJWdA2G+birUfjNy5J79xS6p4ojexaEYYueS3PbFADNA8YwNGsGoEh89cZrtrSWK6hEsM6lDyMnmvDZ4lMzuT8pPUHBq3YzXEBLW0rIB6mgD2KSSYurKEZF5bnvVDUreXUnjXzAihh/F2rhU8Q3S2jRPIdp5OT0qvc+IZyhEe4E9TQB6frF9a6TZIi3jttGCA2axLX4i3FuPs9mo2EevX34rzSee4uHZ5pC+eTg1JpbhbhdyttHXFAHoB8fZkaO5JUlvmIJ5qIWmlapqAuorxo3YZ27cCuJ1CC3Fx8uctz171FGCiAxltwxhRQB63GtykaqWDIvKsX5Ppx9KiW+sVimSd23sSPu8V5dHrN/C+xJWAB5zzVtfENw0RSfBOOoFAHfyeI9N02AsHZnB4UDvXn2v+KLvUp2KuyJkjA44qo93DJnejk9c+tV5Ps7Ae3PP+etAG34O1K1t74tqTb1zjkZr0v+0tHugPs8o2kcjbgD0rxoNHGd23r6VYj1Bgu1C6hvXtQB65PNBDld4CsMhj2NRS61p8UGPNDTAnOR2rySbVr5kMbuxRaqNLJIxO5ic8jPWgDvdT8ZMFMMCrHxjKk5rjJLu6uLoyyzFgT69faqLsSoTPP60igt1+VvXNAGjKJQTJbvt7fLVBp5QSGY+mD601hImMuefTmkVHZSVzkHke1ADSzE89T70Z9Tz7U+PlsbVKnjBpTlCBjOCOOuKAIznjoO1N9u/WpDz2x7UgGc+g4OeDQA1l45AoK8HPIHTNOAII656gVFIhljYI2wn7pHQHrz7dqAHYB7cD0p3PfpntSJkorMpQkcr/dqREJ5U8elAFPUgRakc43Lj86KXVAfsuMEZZevPeigDMfhlx6Uv8ePf+lFFADh99qD/SiigBydf+Bf0pU6rRRQBJHyjZ5wafF/7KaKKAB+v40J0aiigBT0NSKBhOByaKKAJV/1lW+6jtnpRRQBKPl+7x16VESS4BORn+hoooAsTKu0DAxj0+tNXgcelFFAEdv98jtSD/VH6miigCX+AfWpdO/4+GHbniiigCXUwB5OOMgZpqkrnaSMqM4+lFFADNo89+B92opwBKcccGiigBUGY1zzzTXUBEIAzzRRQAxfvGrH8S0UUANm++P941B/G1FFAEMn3yfSkPQ/Q0UUAEfJwem2nQsd7jJ+7RRQAqgeZHx6fzpzcYxx1/nRRQAOAC2AKhbh2x2oooAlH3R9D/WoFJ2nk/dFFFAEn8SfWnnv/umiigCjqxP2Fjk53Dn8aKKKAP/Z);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Contrast-enhanced CT scan in bilateral acute pyelonephritis showing triangular hypodense streaks spreading from the pelvis to the renal cortex (arrows).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Alain Meyrier, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_25_13712=[""].join("\n");
var outline_f13_25_13712=null;
var title_f13_25_13713="Aphthous ulcers";
var content_f13_25_13713=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F63475&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F63475&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Aphthous ulcers",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Round, yellow-gray ulcers are present on the oral mucosa.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_25_13713=[""].join("\n");
var outline_f13_25_13713=null;
var title_f13_25_13714="Primary stabbing headache";
var content_f13_25_13714=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Primary stabbing headache",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?13/25/13714/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/25/13714/contributors\">",
"     F Michael Cutrer, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?13/25/13714/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/25/13714/contributors\">",
"     Jerry W Swanson, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?13/25/13714/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/25/13714/contributors\">",
"     John F Dashe, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?13/25/13714/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 29, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Stabbing headache is one of several relatively uncommon headache syndromes that may occur either as a primary headache or as a headache secondary to potentially malignant processes. Careful evaluation for underlying causes is important for these uncommon types of headache.",
"   </p>",
"   <p>",
"    This topic will review primary stabbing headache. Other types of uncommon primary headache disorders are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/37/22101?source=see_link\">",
"     \"Primary cough headache\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/20/44356?source=see_link\">",
"     \"Primary exertional headache\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/43/16054?source=see_link\">",
"     \"Primary headache associated with sexual activity\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/36/5700?source=see_link\">",
"     \"Hypnic headache\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/19/12601?source=see_link\">",
"     \"Thunderclap headache\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/55/16243?source=see_link\">",
"     \"Nummular headache\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     TERMINOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the past, primary (or idiopathic) stabbing headache has been known by several terms, including ice-pick headache, ophthalmodynia periodica, and jabs and jolts syndrome.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     CLINICAL FEATURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Primary stabbing headache is characterized by transient, sharp jabbing pains that occur within a small, localized area of the scalp. The pains tend to occur exclusively or predominantly at variable locations within the first division of the trigeminal nerve and frequently cause the patient to wince. They appear suddenly either as single stabs or in volleys of intense stabbing pain.",
"   </p>",
"   <p>",
"    The stabs last from 1 to 10 seconds and occur at irregular intervals from rarely to many times each day [",
"    <a class=\"abstract\" href=\"UTD.htm?13/25/13714/abstract/1\">",
"     1",
"    </a>",
"    ]. There is a single report of a prolonged paroxysm lasting one week [",
"    <a class=\"abstract\" href=\"UTD.htm?13/25/13714/abstract/2\">",
"     2",
"    </a>",
"    ]. Primary stabbing headache has been described in both children and adults [",
"    <a class=\"abstract\" href=\"UTD.htm?13/25/13714/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The stabbing pains occur in the absence of organic disease of the cranial nerves or underlying cephalic structures [",
"    <a class=\"abstract\" href=\"UTD.htm?13/25/13714/abstract/4\">",
"     4",
"    </a>",
"    ]. However, a structural abnormality must be excluded if the pain is invariably localized at one site or is side-locked.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Differential diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The differential diagnosis of primary stabbing headache includes SUNCT syndrome (short lasting unilateral neuralgiform headache), occipital or other cephalic neuralgias, trigeminal neuralgia, nummular headache, and traumatic scalp injury. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/62/28648?source=see_link\">",
"     \"SUNCT and SUNA headache syndromes: Clinical features and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/49/31509?source=see_link\">",
"     \"Occipital neuralgia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/3/34873?source=see_link\">",
"     \"Trigeminal neuralgia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/55/16243?source=see_link\">",
"     \"Nummular headache\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     PATHOPHYSIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The pathophysiology is not understood. Most patients with primary stabbing headache also have another coexisting primary headache disorder, such as migraine or cluster headache [",
"    <a class=\"abstract\" href=\"UTD.htm?13/25/13714/abstract/1\">",
"     1",
"    </a>",
"    ]. In those cases, the stabbing usually occurs in areas of the head that are involved in the coexisting headache. This implies that the stabbing pain might result from spontaneous firing in individual nerve fibers sensitized by recurrent activation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Uncontrolled series have reported a therapeutic response to melatonin (3 to 12 mg daily) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/25/13714/abstract/5\">",
"     5",
"    </a>",
"    ] and indomethacin (75 to 150 mg daily) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/25/13714/abstract/6\">",
"     6",
"    </a>",
"    ]. No therapies have been evaluated in controlled trials.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Primary stabbing headache is characterized by transient, sharp jabbing pains that occur within a small, localized area of the scalp, exclusively or predominantly at variable locations within the first division of the trigeminal nerve. The stabs last from 1 to 10 seconds and occur at irregular intervals from once to many times each day. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Clinical features'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A structural abnormality must be excluded if the pain is invariably localized at one site. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Clinical features'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Primary stabbing headache may respond to melatonin (3 to 12 mg daily) and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/50/36649?source=see_link\">",
"       indomethacin",
"      </a>",
"      (75 to 150 mg daily). (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/25/13714/abstract/1\">",
"      Pareja JA, Ruiz J, de Isla C, et al. Idiopathic stabbing headache (jabs and jolts syndrome). Cephalalgia 1996; 16:93.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/25/13714/abstract/2\">",
"      Martins IP, Parreira E, Costa I. Extratrigeminal ice-pick status. Headache 1995; 35:107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/25/13714/abstract/3\">",
"      Soriani S, Battistella PA, Arnaldi C, et al. Juvenile idiopathic stabbing headache. Headache 1996; 36:565.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/25/13714/abstract/4\">",
"      Headache Classification Subcommittee of the International Headache Society. The International Classification of Headache Disorders: 2nd edition. Cephalalgia 2004; 24 Suppl 1:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/25/13714/abstract/5\">",
"      Rozen TD. Melatonin as treatment for idiopathic stabbing headache. Neurology 2003; 61:865.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/25/13714/abstract/6\">",
"      Fuh JL, Kuo KH, Wang SJ. Primary stabbing headache in a headache clinic. Cephalalgia 2007; 27:1005.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3327 Version 3.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0602-221.179.173.170-312020EB49-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_25_13714=[""].join("\n");
var outline_f13_25_13714=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H7\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      TERMINOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      CLINICAL FEATURES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Differential diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      PATHOPHYSIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/36/5700?source=related_link\">",
"      Hypnic headache",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/55/16243?source=related_link\">",
"      Nummular headache",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/49/31509?source=related_link\">",
"      Occipital neuralgia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/37/22101?source=related_link\">",
"      Primary cough headache",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/20/44356?source=related_link\">",
"      Primary exertional headache",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/43/16054?source=related_link\">",
"      Primary headache associated with sexual activity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/62/28648?source=related_link\">",
"      SUNCT and SUNA headache syndromes: Clinical features and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/19/12601?source=related_link\">",
"      Thunderclap headache",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/3/34873?source=related_link\">",
"      Trigeminal neuralgia",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f13_25_13715="Height velocity response to growth hormone treatment";
var content_f13_25_13715=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F76882&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F76882&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 615px\">",
"   <div class=\"ttl\">",
"    Response to growth hormone treatment in prepubertal children with growth hormone deficiency",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 595px; height: 639px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Height velocity patterns during the first (A, C) and second (B, D) years of growth hormone therapy related to age at treatment onset (centered mean age of the patient during the year of therapy). Separate curves are shown for children with severe growth hormone deficiency (A, B) and those with less-severe growth hormone deficiency (C, D). Dotted lines show mean height velocity before growth hormone therapy. Solid lines show percentile (P) curves.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Ranke MB, Lindberg A. Observed and predicted growth responses in prepubertal children with growth disorders: Guidance of growth hormone treatment by empirical variables. J Clin Endocrinol Metab 2010; 95:1229. Copyright &copy; 2010 The Endocrine Society.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_25_13715=[""].join("\n");
var outline_f13_25_13715=null;
var title_f13_25_13716="Iohexol: Patient drug information";
var content_f13_25_13716=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Iohexol: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/14/30949?source=see_link\">",
"     see \"Iohexol: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F183891\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Omnipaque&trade; 140 [DSC];",
"     </li>",
"     <li>",
"      Omnipaque&trade; 180;",
"     </li>",
"     <li>",
"      Omnipaque&trade; 240;",
"     </li>",
"     <li>",
"      Omnipaque&trade; 300;",
"     </li>",
"     <li>",
"      Omnipaque&trade; 350",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F9617644\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Omnipaque&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10025927\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691287",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used before an x-ray or an alike test.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10025926\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702318",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to iohexol or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697128",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have a contrast dye allergy, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703164",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an iodine allergy, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10025930\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697197",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have high blood sugar (diabetes), talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697258",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have heart disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697282",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have kidney disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697340",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have seizures, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697341",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have sickle cell disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697343",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have thyroid disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10025931\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698277",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Neck pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698249",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Muscle pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698261",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698189",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Irritation where the shot is given.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698328",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Unsafe allergic effects may rarely happen.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10025933\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698655",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       A fast heartbeat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699023",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad dizziness or passing out.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698640",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Trouble breathing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698619",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in strength on 1 side is greater than the other, trouble speaking or thinking, change in balance, or blurred eyesight.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699104",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not able to pass urine.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10025929\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696097",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug will be given to you by a doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694818",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Drink lots of noncaffeine liquids unless told to drink less liquid by your doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10025934\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699596",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug will be given to you in a hospital or doctor's office. You will not store it at home.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10025935\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12214 Version 35.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-89.32.226.102-49496BE7AC-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_25_13716=[""].join("\n");
var outline_f13_25_13716=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F183891\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9617644\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025927\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025926\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025930\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025931\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025933\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025929\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025934\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025935\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?30/14/30949?source=related_link\">",
"      Iohexol: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f13_25_13717="Metronidazole (topical): Drug information";
var content_f13_25_13717=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Metronidazole (topical): Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?0/5/95?source=see_link\">",
"    see \"Metronidazole (topical): Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?22/45/23252?source=see_link\">",
"    see \"Metronidazole (topical): Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F8770975\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      MetroCream&reg;;",
"     </li>",
"     <li>",
"      MetroGel-Vaginal&reg;;",
"     </li>",
"     <li>",
"      MetroGel&reg;;",
"     </li>",
"     <li>",
"      MetroLotion&reg;;",
"     </li>",
"     <li>",
"      Noritate&reg;;",
"     </li>",
"     <li>",
"      Rosadan&reg;;",
"     </li>",
"     <li>",
"      Vandazole&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F8770976\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      MetroCream&reg;;",
"     </li>",
"     <li>",
"      Metrogel&reg;;",
"     </li>",
"     <li>",
"      MetroLotion&reg;;",
"     </li>",
"     <li>",
"      Nidagel&trade;;",
"     </li>",
"     <li>",
"      Noritate&reg;;",
"     </li>",
"     <li>",
"      Rosasol&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F8771007\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antibiotic, Topical",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F8771178\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Acne rosacea:",
"     </b>",
"     Topical:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     0.75%: Apply and rub a thin film twice daily, morning and evening, to entire affected areas after washing.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     1%: Apply thin film to affected area once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Bacterial vaginosis or vaginitis due to",
"     </b>",
"     <b>",
"      <i>",
"       Gardnerella",
"      </i>",
"     </b>",
"     ,",
"     <b>",
"      <i>",
"       Mobiluncus",
"      </i>",
"     </b>",
"     : Vaginal: One applicatorful (~37.5 mg metronidazole) intravaginally once or twice daily for 5 days; apply once in morning and evening if using twice daily, if daily, use at bedtime",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F8771179\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use the lower end of the dosing recommendations for adults",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F8771215\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cream, topical: 0.75% (45 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     MetroCream&reg;: 0.75% (45 g) [contains benzyl alcohol]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Noritate&reg;: 1% (60 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Rosadan&reg;: 0.75% (45 g) [contains benzyl alcohol]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gel, topical: 0.75% (45 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     MetroGel&reg;: 1% (55 g, 60 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Rosadan&reg;: 0.75% (45 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gel, vaginal: 0.75% (70 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     MetroGel-Vaginal&reg;: 0.75% (70 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Vandazole&reg;: 0.75% (70 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Lotion, topical: 0.75% (59 mL, 60 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     MetroLotion&reg;: 0.75% (59 mL) [contains benzyl alcohol]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F8770978\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F8771200\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;margin-left:0em;text-align:justify;display:inline\">",
"     No disulfiram-like reactions have been reported after",
"     <b>",
"      topical",
"     </b>",
"     application, although metronidazole can be detected in the blood. Apply to clean, dry skin. Cosmetics may be used after application (wait at least 5 minutes after using lotion).",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F8771026\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Topical: Treatment of inflammatory lesions and erythema of rosacea",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Vaginal gel: Bacterial vaginosis",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F8771049\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      Topical:",
"     </b>",
"     Frequency not defined:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Hypertension",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Headache",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Acne, burning, contact dermatitis, dryness, erythema, irritation, pruritus, rash",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Nausea, unusual/metallic taste, xerostomia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Local: Allergic reaction",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Peripheral neuropathy, tingling/numbness of extremities",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ocular: Eye irritation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Flu-like syndrome",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Vaginal:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &gt;10%: Genitourinary: Vaginal discharge (12%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Headache (5%), dizziness (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Gastrointestinal discomfort (7%), nausea and/or vomiting (4%), unusual/metallic taste (2%), appetite decreased (1%), cramping (1%), diarrhea (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Genitourinary:",
"     <i>",
"      Candida",
"     </i>",
"     cervicitis/vaginitis (10%), vulva/vaginal irritation (9%), pelvic discomfort (3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;1%: Abdominal bloating, abdominal gas, darkened urine, depression, fatigue, itching, rash, thirst, xerostomia",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F8771034\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to metronidazole, nitroimidazole derivatives, or any component of the formulation",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F8771035\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Carcinogenic: Possibly carcinogenic based on animal data.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; CNS effects: Aseptic meningitis, encephalopathy, seizures, and neuropathies (peripheral and optic) have been reported with systemic metronidazole, especially with increased doses and chronic treatment; peripheral neuropathy has also been reported with topical products; monitor and consider discontinuation of therapy if signs/symptoms occur. Use with caution in patients with CNS disease.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Eye irritation: May cause tearing of the eye; avoid contact with the eyes. In the event of accidental contact, wash out immediately.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Use with caution in patients with severe liver impairment due to potential accumulation.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Superinfection: Prolonged use may result in fungal or bacterial superinfection. Approximately 10% of women treated with the vaginal gel developed",
"     <i>",
"      Candida",
"     </i>",
"     vaginitis during or immediately after treatment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Blood dyscrasias: Use with caution in patients with or history of blood dyscrasias.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Dosage form related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:2em;text-align:justify;\">",
"     &bull; Vaginal gel: Disulfiram-like reaction to ethanol has been reported with systemic metronidazole and may occur with the vaginal gel; consider avoidance of alcoholic beverages during therapy with vaginal gel. Do not administer the vaginal gel to patients who have taken disulfiram within the past 2 weeks.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F8771053\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F8771054\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alcohol (Ethyl): MetroNIDAZOLE (Topical) may enhance the adverse/toxic effect of Alcohol (Ethyl). A disulfiram-like reaction may occur.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BCG: Antibiotics may diminish the therapeutic effect of BCG.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Disulfiram: MetroNIDAZOLE (Topical) may enhance the adverse/toxic effect of Disulfiram.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mebendazole: May enhance the adverse/toxic effect of MetroNIDAZOLE (Topical). Particularly the risk for Stevens-Johnson Syndrome or Toxic Epidermal Necrolysis may be increased.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ritonavir: MetroNIDAZOLE (Topical) may enhance the adverse/toxic effect of Ritonavir. A disulfiram-like reaction could occur due to the alcohol contained in Kaletra (lopinavir/ritonavir) oral solution.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Picosulfate: Antibiotics may diminish the therapeutic effect of Sodium Picosulfate.  Management: Consider using an alternative product for bowel cleansing prior to a colonoscopy in patients who have recently used or are concurrently using an antibiotic.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tipranavir: MetroNIDAZOLE (Topical) may enhance the adverse/toxic effect of Tipranavir.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F8771029\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     B (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F8771030\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events were not observed in animal reproduction studies. Metronidazole crosses the placenta and rapidly distributes into the fetal circulation following oral administration. Although there have been a few reports of facial anomalies after",
"     <i>",
"      in utero",
"     </i>",
"     exposure, most studies with systemic metronidazole have not found an increased risk adverse fetal or neonatal outcomes. Refer to the Metronidazole (Systemic) monograph for details. The amount of metronidazole available systemically following topical application is less in comparison to oral doses. Oral metronidazole is preferred for the treatment of symptomatic bacterial vaginosis in pregnant patients (consult current CDC guidelines).",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F8771032\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Enters breast milk/not recommended (AAP rates &ldquo;of concern&rdquo;; AAP 2001 update pending)",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F9773196\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Following oral administration, metronidazole and its active metabolite are measurable in the maternal plasma, breast milk, and infant plasma. The amount of metronidazole available systemically following topical application is less in comparison to oral doses. Because of tumorigenicity observed in animal studies, the decision to continue or discontinue breast-feeding during therapy should take into account the risk of exposure to the infant and the benefits of treatment to the mother (per manufacturer).",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F8771217\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Cream",
"     </b>",
"     (MetroCream External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.75% (45 g): $511.98",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Cream",
"     </b>",
"     (MetroNIDAZOLE External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.75% (45 g): $315.00",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Cream",
"     </b>",
"     (Noritate External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1% (60 g): $265.40",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Cream",
"     </b>",
"     (Rosadan External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.75% (45 g): $203.12",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Gel",
"     </b>",
"     (Metrogel External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1% (55 g): $295.74",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Gel",
"     </b>",
"     (MetroGel-Vaginal Vaginal)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.75% (70 g): $55.98",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Gel",
"     </b>",
"     (MetroNIDAZOLE External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.75% (45 g): $170.85",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Gel",
"     </b>",
"     (MetroNIDAZOLE Vaginal)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.75% (70 g): $33.71",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Gel",
"     </b>",
"     (Rosadan External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.75% (45 g): $201.13",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Gel",
"     </b>",
"     (Vandazole Vaginal)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.75% (70 g): $33.71",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Lotion",
"     </b>",
"     (MetroLotion External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.75% (59 mL): $534.96",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Lotion",
"     </b>",
"     (MetroNIDAZOLE External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.75% (59 mL): $247.14",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F14190112\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Acea Gel (GB, IE);",
"     </li>",
"     <li>",
"      Geloderm (CN);",
"     </li>",
"     <li>",
"      Li Fu (CL);",
"     </li>",
"     <li>",
"      Metroderme (PT);",
"     </li>",
"     <li>",
"      Metrogel (CR, DE, DO, GB, GT, HN, NI, PA, SV, TW);",
"     </li>",
"     <li>",
"      Metrogyl Gel (TH);",
"     </li>",
"     <li>",
"      Metrosa (EE);",
"     </li>",
"     <li>",
"      Nidazea (BE);",
"     </li>",
"     <li>",
"      Robaz (GR, PH, TH);",
"     </li>",
"     <li>",
"      Rosaced gel (BE, FR);",
"     </li>",
"     <li>",
"      Rosiced (PT);",
"     </li>",
"     <li>",
"      Roza (TR);",
"     </li>",
"     <li>",
"      Rozacreme (FR);",
"     </li>",
"     <li>",
"      Rozagel (FR);",
"     </li>",
"     <li>",
"      Rozex (AR, AT, AU, BE, BR, CH, CO, CZ, DK, EE, FI, FR, GB, HK, IE, IL, IT, KP, MY, NL, NO, NZ, PE, PL, PY, SE, SG, UY, VE, ZA);",
"     </li>",
"     <li>",
"      Zidoval (IL)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F8771139\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     After diffusing into the organism, interacts with DNA to cause a loss of helical DNA structure and strand breakage resulting in inhibition of protein synthesis and cell death in susceptible organisms",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F8771141\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;\">",
"     Absorption:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Topical: Concentrations achieved systemically after application of the 1 g topical gel and cream are &lt;1% of those obtained after a 250 mg oral dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Vaginal gel:  ~50% of oral dose",
"    </p>",
"    <p style=\"text-indent:0em;text-align:justify;\">",
"     Time to peak, serum:",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:2em;text-align:justify;\">",
"     Topical cream: 8-12 hours",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:2em;text-align:justify;\">",
"     Topical gel: 6-10 hours",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:2em;text-align:justify;\">",
"     Vaginal gel: 6-12 hours",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      American Academy of Pediatrics Committee on Drugs, \"Transfer of Drugs and Other Chemicals Into Human Milk,\"",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2001, 108(3):776-89.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?13/25/13717/abstract-text/11533352/pubmed\" id=\"11533352\" target=\"_blank\">",
"        11533352",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention (CDC), \"Sexually Transmitted Diseases Treatment Guidelines, 2010,\"",
"      <i>",
"       MMWR Recomm Rep",
"      </i>",
"      , 2010, 59(RR-12):1-110.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?13/25/13717/abstract-text/21160459/pubmed\" id=\"21160459\" target=\"_blank\">",
"        21160459",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9590 Version 35.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-190.81.197.98-C80C007BE0-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_25_13717=[""].join("\n");
var outline_f13_25_13717=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8770975\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8770976\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8771007\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8771178\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8771179\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8771215\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8770978\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8771200\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8771026\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8771049\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8771034\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8771035\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8771053\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8771054\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8771029\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8771030\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8771032\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9773196\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8771217\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14190112\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8771139\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8771141\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9590\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9590|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?34/7/34936?source=related_link\">",
"      Metronidazole (systemic): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?18/48/19205?source=related_link\">",
"      Metronidazole (systemic): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?19/48/20231?source=related_link\">",
"      Metronidazole (systemic): Pediatric drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?0/5/95?source=related_link\">",
"      Metronidazole (topical): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?22/45/23252?source=related_link\">",
"      Metronidazole (topical): Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f13_25_13718="Chlorpheniramine and pseudoephedrine: Drug information";
var content_f13_25_13718=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Chlorpheniramine and pseudoephedrine: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?16/14/16613?source=see_link\">",
"    see \"Chlorpheniramine and pseudoephedrine: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F150160\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Dicel&reg; Chewable [OTC];",
"     </li>",
"     <li>",
"      LoHist-D [OTC];",
"     </li>",
"     <li>",
"      Maxichlor PSE [OTC];",
"     </li>",
"     <li>",
"      Neutrahist Pediatric [OTC];",
"     </li>",
"     <li>",
"      SudoGest&trade; Sinus &amp; Allergy [OTC]",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F150161\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Triaminic&reg; Cold &amp; Allergy",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F150175\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Alkylamine Derivative;",
"     </li>",
"     <li>",
"      Alpha-/Beta- Agonist;",
"     </li>",
"     <li>",
"      Decongestant;",
"     </li>",
"     <li>",
"      Histamine H;",
"      <sub>",
"       1",
"      </sub>",
"      Antagonist",
"     </li>",
"     <li>",
"      Histamine H",
"      <sub>",
"       1",
"      </sub>",
"      Antagonist, First Generation",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F150164\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Rhinitis/decongestant:",
"     </b>",
"     Oral:",
"     <b>",
"      Note:",
"     </b>",
"     All dosing is presented in terms of chlorpheniramine maleate and pseudoephedrine hydrochloride.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Liquid: Chlorpheniramine 2 mg and pseudoephedrine 30 mg per 5 mL: 10 mL every 4-6 hours (maximum: 60 mL/24hours)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Chlorpheniramine 2 mg and pseudoephedrine 30 mg: Two tablets every 4-6 hours (maximum: 8 tablets/24 hours)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Chlorpheniramine 4 mg and pseudoephedrine 60 mg: One tablet every 4-6 hours (maximum: 4 tablets/24 hours)",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F150171\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Rhinitis/decongestant:",
"     </b>",
"     Oral:",
"     <b>",
"      Note:",
"     </b>",
"     All dosing is presented in terms of chlorpheniramine maleate and pseudoephedrine hydrochloride.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Children: 6-11 years:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Liquid:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Chlorpheniramine 0.8 mg and pseudoephedrine 9 mg per 1 mL: 2 mL every 4-6 hours (maximum: 8 mL/24 hours)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Chlorpheniramine 2 mg and pseudoephedrine 30 mg per 5 mL: 5 mL every 4-6 hours (maximum: 30 mL/24 hours)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Tablet:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Chlorpheniramine 2 mg and pseudoephedrine 30 mg: One tablet every 4-6 hours (maximum: 4 tablets/24 hours)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Chlorpheniramine 4 mg and pseudoephedrine 60 mg: One-half tablet every 4-6 hours (maximum: 2 tablets/24 hours)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Children &ge;12 years: Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F150165\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F150144\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling. [DSC] = Discontinued product",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Liquid, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     LoHist-D: Chlorpheniramine maleate 2 mg and pseudoephedrine hydrochloride 30 mg per 5 mL (473 mL) [dye free, ethanol free, sugar free; cherry flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Liquid, oral [drops]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neutrahist Pediatric: Chlorpheniramine maleate 0.8 mg and pseudoephedrine hydrochloride 9 mg per 1 mL (30 mL) [ethanol free, sugar free; contains propylene glycol; cherry flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral: Chlorpheniramine maleate 4 mg and pseudoephedrine hydrochloride 60 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Maxichlor PSE: Chlorpheniramine maleate 4 mg and pseudoephedrine hydrochloride 60 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     SudoGest&trade; Sinus &amp; Allergy: Chlorpheniramine maleate 4 mg and pseudoephedrine hydrochloride 60 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, chewable, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dicel&reg; Chewables: Chlorpheniramine maleate 2 mg and pseudoephedrine hydrochloride 30 mg [ethanol free; contains sodium 17 mg/tablet, soy lecithin; strawberry-banana cream flavor]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F150132\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F150146\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Relief of nasal congestion associated with the common cold, hay fever, allergic rhinitis, and other allergies",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F150181\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Chlor-Trimeton&reg; may be confused with Chloromycetin&reg;",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Sudafed&reg; may be confused with Sufenta&reg;",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F150173\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     See individual agents.",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F150150\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to chlorpheniramine, pseudoephedrine, or any component of the formulation; use with or within 2 weeks of discontinuing MAO inhibitor",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Additional contraindications per some manufacturers: Severe hypertension, severe cardiovascular disease; narrow-angle glaucoma; urinary retention; peptic ulcer disease; breast-feeding",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F150136\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; CNS depression: May cause CNS depression, which may impair physical or mental abilities; patients must be cautioned about performing tasks which require mental alertness (eg, operating machinery or driving).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cardiovascular disease: Use with caution in patients with cardiovascular disease (including hypertension and ischemic heart disease); contraindicated with severe disease.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Diabetes: Use with caution in patients with diabetes mellitus.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Increased intraocular pressure: Use with caution in patients with increased intraocular pressure.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Prostatic hyperplasia/urinary obstruction: Use with caution in patients with prostatic hyperplasia and/or GU obstruction.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pyloroduodenal obstruction: Use with caution in patients with pyloroduodenal obstruction (including stenotic peptic ulcer).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Respiratory disease: Use with caution in patients with asthma or other chronic breathing disorders.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Thyroid dysfunction: Use with caution in patients with thyroid dysfunction.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Sedatives: Effects may be potentiated when used with other sedative drugs or ethanol.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: Use with caution in the elderly; may be more sensitive to adverse effects.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pediatrics: Antihistamines may cause excitation in young children. Do not exceed pediatric dosing recommendations. If no recommendations exist on OTC labeling for patient&rsquo;s age, the product should",
"     <b>",
"      not",
"     </b>",
"     be administered without the guidance of a physician.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Self-medication (OTC use): When used for self medication (OTC), notify healthcare provider if symptoms do not improve within 7 days or are accompanied by fever. Discontinue and contact healthcare provider if nervousness, dizziness or sleeplessness occur.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F150172\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to individual components.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F150140\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Abiraterone Acetate: May increase the serum concentration of CYP2D6 Substrates. Management: Avoid concurrent use of abiraterone with CYP2D6 substrates that have a narrow therapeutic index whenever possible.  When concurrent use is not avoidable, monitor patients closely for signs/symptoms of toxicity.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Acetylcholinesterase Inhibitors (Central): Anticholinergics may diminish the therapeutic effect of Acetylcholinesterase Inhibitors (Central). Acetylcholinesterase Inhibitors (Central) may diminish the therapeutic effect of Anticholinergics. If the anticholinergic action is a side effect of the agent, the result may be beneficial.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aclidinium: May enhance the anticholinergic effect of Anticholinergics.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alcohol (Ethyl): CNS Depressants may enhance the CNS depressant effect of Alcohol (Ethyl).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alpha1-Blockers: May diminish the hypertensive effect of Alpha-/Beta-Agonists. Similarly, Alpha-/Beta-Agonists may antagonize hypotensive effects of Alpha1-Blockers. Alpha1-Blockers may diminish the vasoconstricting effect of Alpha-/Beta-Agonists. Similarly, Alpha-/Beta-Agonists may antagonize Alpha1-Blocker vasodilation.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amphetamines: May diminish the sedative effect of Antihistamines.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antacids: May decrease the excretion of Alpha-/Beta-Agonists.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Aluminum Hydroxide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anticholinergics: May enhance the adverse/toxic effect of other Anticholinergics.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levocabastine (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP2D6 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     AtoMOXetine: May enhance the hypertensive effect of Sympathomimetics. AtoMOXetine may enhance the tachycardic effect of Sympathomimetics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Azelastine (Nasal): CNS Depressants may enhance the CNS depressant effect of Azelastine (Nasal).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Benzylpenicilloyl Polylysine: Antihistamines may diminish the diagnostic effect of Benzylpenicilloyl Polylysine.  Management: Suspend systemic H1 antagonists for benzylpenicilloyl-polylysine skin testing and delay testing until systemic antihistaminic effects have dissipated. A histamine skin test may be used to assess persistent antihistaminic effects.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Benzylpenicilloyl Polylysine: Alpha-/Beta-Agonists may diminish the diagnostic effect of Benzylpenicilloyl Polylysine.  Management: Consider use of a histamine skin test as a positive control to assess a patient's ability to mount a wheal and flare response.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Betahistine: Antihistamines may diminish the therapeutic effect of Betahistine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bromocriptine: Alpha-/Beta-Agonists may enhance the adverse/toxic effect of Bromocriptine. Including increased blood pressure, ventricular arrhythmias, and seizure.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Buprenorphine: CNS Depressants may enhance the CNS depressant effect of Buprenorphine.  Management: Consider reduced doses of CNS depressants used in combination with buprenorphine.  Consider avoiding other CNS depressants in patients thought to be at high risk of buprenorphine overuse or self-injection.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cannabinoids: May enhance the tachycardic effect of Sympathomimetics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Carbonic Anhydrase Inhibitors: May decrease the excretion of Alpha-/Beta-Agonists.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Brinzolamide; Dorzolamide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CNS Depressants: May enhance the adverse/toxic effect of other CNS Depressants.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levocabastine (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2D6 Inhibitors (Moderate): May decrease the metabolism of CYP2D6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2D6 Inhibitors (Strong): May decrease the metabolism of CYP2D6 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Darunavir: May increase the serum concentration of CYP2D6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Droperidol: May enhance the CNS depressant effect of CNS Depressants. Management: Consider dose reductions of droperidol or of other CNS agents (e.g., opioids, barbiturates) with concomitant use.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ergot Derivatives: May enhance the hypertensive effect of Alpha-/Beta-Agonists. Ergot Derivatives may enhance the vasoconstricting effect of Alpha-/Beta-Agonists.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Ergoloid Mesylates.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     FentaNYL: Alpha-/Beta-Agonists (Indirect-Acting) may decrease the serum concentration of FentaNYL. Specifically, fentanyl nasal spray serum concentrations may decrease and onset of effect may be delayed.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hyaluronidase: Antihistamines may diminish the therapeutic effect of Hyaluronidase.  Management: Patients receiving antihistamines (particularly at larger doses) may not experience the desired clinical response to standard doses of hyaluronidase.  Larger doses of hyaluronidase may be required.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     HydrOXYzine: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Iobenguane I 123: Sympathomimetics may diminish the therapeutic effect of Iobenguane I 123.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ipratropium (Oral Inhalation): May enhance the anticholinergic effect of Anticholinergics.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Magnesium Sulfate: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the hypertensive effect of Alpha-/Beta-Agonists (Indirect-Acting).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metyrosine: CNS Depressants may enhance the sedative effect of Metyrosine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mirtazapine: CNS Depressants may enhance the CNS depressant effect of Mirtazapine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Paraldehyde: CNS Depressants may enhance the CNS depressant effect of Paraldehyde.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Peginterferon Alfa-2b: May decrease the serum concentration of CYP2D6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Perampanel: May enhance the CNS depressant effect of CNS Depressants. Management: Patients taking perampanel with any other drug that has CNS depressant activities should avoid complex and high-risk activities, particularly those such as driving that require alertness and coordination, until they have experience using the combination.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pramipexole: CNS Depressants may enhance the sedative effect of Pramipexole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pramlintide: May enhance the anticholinergic effect of Anticholinergics. These effects are specific to the GI tract.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ROPINIRole: CNS Depressants may enhance the sedative effect of ROPINIRole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rotigotine: CNS Depressants may enhance the sedative effect of Rotigotine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selective Serotonin Reuptake Inhibitors: CNS Depressants may enhance the adverse/toxic effect of Selective Serotonin Reuptake Inhibitors. Specifically, the risk of psychomotor impairment may be enhanced.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Serotonin/Norepinephrine Reuptake Inhibitors: May enhance the tachycardic effect of Alpha-/Beta-Agonists. Serotonin/Norepinephrine Reuptake Inhibitors may enhance the vasopressor effect of Alpha-/Beta-Agonists.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Oxybate: May enhance the CNS depressant effect of CNS Depressants. Management: Consider alternatives to combined use. When combined use is needed, consider minimizing doses of one or more drugs. Use of sodium oxybate with alcohol or sedative hypnotics is contraindicated.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Spironolactone: May diminish the vasoconstricting effect of Alpha-/Beta-Agonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sympathomimetics: May enhance the adverse/toxic effect of other Sympathomimetics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tiotropium: Anticholinergics may enhance the anticholinergic effect of Tiotropium.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zolpidem: CNS Depressants may enhance the CNS depressant effect of Zolpidem.  Management: Reduce the Intermezzo brand sublingual zolpidem dose to 1.75 mg for men who are also receiving other CNS depressants.  No such dose change is recommended for women.  Avoid use with other CNS depressants at bedtime; avoid use with alcohol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F150158\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Ethanol: May increase CNS depression.  Management: Monitor for increased effects with coadministration; caution patients about effects.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F14464797\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F150153\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Reproduction studies have not been conducted with this combination product. See individual agents.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F14464799\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Contraindicated",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F150154\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use of some products is contraindicated by the manufacturer in breast-feeding women. See individual agents.",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F7716283\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Some products may contain sodium.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16323062\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Chewable",
"     </b>",
"     (Dicel Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2-30 mg (20): $30.00",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Liquid",
"     </b>",
"     (LoHist-D Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2-30 mg/5 mL (473 mL): $41.68",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (SudoGest Sinus/Allergy Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     4-60 mg (24): $2.10",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F150156\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Alergical SF (PE);",
"     </li>",
"     <li>",
"      Bodrexin Pilek Alergi (ID);",
"     </li>",
"     <li>",
"      Coriminic (IN);",
"     </li>",
"     <li>",
"      Demazin 6 Hour Relief (AU);",
"     </li>",
"     <li>",
"      Fenfedrin (HK, SG);",
"     </li>",
"     <li>",
"      Nafarin (ID);",
"     </li>",
"     <li>",
"      Nasaler Plus CL (PE);",
"     </li>",
"     <li>",
"      Nastizol (EC);",
"     </li>",
"     <li>",
"      Sinarest-AF (IN)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F150135\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Chlorpheniramine competes with histamine for H",
"     <sub>",
"      1",
"     </sub>",
"     -receptor sites on effector cells in the gastrointestinal tract, blood vessels, and respiratory tract.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Pseudoephedrine is a sympathomimetic amine and isomer of ephedrine; acts as a decongestant in respiratory tract mucous membranes with less vasoconstrictor action than ephedrine in normotensive individuals.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F150149\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     See individual agents.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      American Academy of Pediatrics Committee on Drugs, \"Transfer of Drugs and Other Chemicals Into Human Milk,\"",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2001, 108(3):776-89.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?13/25/13718/abstract-text/11533352 /pubmed\" id=\"11533352 \" target=\"_blank\">",
"        11533352",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8864 Version 45.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-61.234.146.186-543E46505B-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_25_13718=[""].join("\n");
var outline_f13_25_13718=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F150160\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F150161\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F150175\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F150164\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F150171\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F150165\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F150144\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F150132\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F150146\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F150181\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F150173\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F150150\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F150136\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F150172\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F150140\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F150158\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14464797\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F150153\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14464799\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F150154\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7716283\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16323062\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F150156\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F150135\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F150149\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8864\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8864|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?16/14/16613?source=related_link\">",
"      Chlorpheniramine and pseudoephedrine: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f13_25_13719="Epidemiology, pathogenesis, and clinical manifestations of lymphatic filariasis";
var content_f13_25_13719=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Epidemiology, pathogenesis, and clinical manifestations of lymphatic filariasis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?13/25/13719/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/25/13719/contributors\">",
"     Karin Leder, MBBS, FRACP, PhD, MPH, DTMH",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/25/13719/contributors\">",
"     Peter F Weller, MD, FACP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?13/25/13719/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/25/13719/contributors\">",
"     Peter F Weller, MD, FACP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?13/25/13719/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/25/13719/contributors\">",
"     Elinor L Baron, MD, DTMH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?13/25/13719/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 1, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Filariasis is caused by nematodes (roundworms) that inhabit the lymphatics and subcutaneous tissues. Three filarial species cause lymphatic filariasis: Wuchereria bancrofti, Brugia malayi, and Brugia timori. Infections are transmitted by mosquito vectors; humans are definitive hosts. Lymphatic filariasis is a major cause of disfigurement and disability in endemic areas, leading to significant economic and psychosocial impact.",
"   </p>",
"   <p>",
"    The epidemiology, pathogenesis, and clinical features of lymphatic filariasis will be reviewed here. The diagnosis, treatment, and prevention of lymphatic filariasis and other filarial infections, including onchocerciasis, loiasis, and mansonellosis, are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/56/15241?source=see_link\">",
"     \"Diagnosis, treatment, and prevention of lymphatic filariasis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/30/20970?source=see_link\">",
"     \"Onchocerciasis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/26/36263?source=see_link\">",
"     \"Loiasis (Loa loa infection)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;W. bancrofti occurs in sub-Saharan Africa, Southeast Asia, the Indian subcontinent, many of the Pacific islands, and focal areas of Latin America. B. malayi occurs mainly in China, India, Malaysia, the Philippines, Indonesia, and various Pacific islands. B. timori occurs on the Timor Island of Indonesia (",
"    <a class=\"graphic graphic_figure graphicRef81417 \" href=\"UTD.htm?30/55/31606\">",
"     figure 1",
"    </a>",
"    ). Overall, approximately two-thirds of individuals infected with lymphatic filariasis are in Asia.",
"   </p>",
"   <p>",
"    It is estimated that more than 120 million people worldwide are infected. More than 90 percent of these infections are due to W. bancrofti;, while the remainder are due largely to B. malayi. Estimates suggest that more than 40 million infected individuals are seriously incapacitated and disfigured by lymphatic filariasis [",
"    <a class=\"abstract\" href=\"UTD.htm?13/25/13719/abstract/1\">",
"     1",
"    </a>",
"    ]. A study from India (India accounts for 40 percent of the global prevalence of infection) estimated that more than $840 million is lost each year due to treatment costs and missed working days [",
"    <a class=\"abstract\" href=\"UTD.htm?13/25/13719/abstract/2\">",
"     2",
"    </a>",
"    ]. Another study in India noted that patients with chronic filariasis lose around 29 days of work per year due to complications of infection, highlighting the considerable burden the disease places on individuals and on the community [",
"    <a class=\"abstract\" href=\"UTD.htm?13/25/13719/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The prevalence of microfilaremia in endemic communities increases with age. In endemic areas, most individuals have been exposed by the third or fourth decade of life. The burden of infection with adult worms increases with exposure over time. The adult worm does not replicate within the human host. Therefore if an individual leaves an endemic area, the adult worm burden cannot increase, since exposure to infective larvae has ceased. Mosquito vectors are relatively inefficient transmission vectors of filariasis; therefore a relatively prolonged stay in an endemic area is usually required for acquisition of infection.",
"   </p>",
"   <p>",
"    The mosquito vectors for filariasis vary geographically. Mosquito vectors for Wuchereria include Culex, Anopheles, Aedes, Mansonia, and Coquillettidia; vectors for Brugia are typically Mansonia and Aedes. Both urban and rural transmission of disease occurs. In many tropical and subtropical areas, the prevalence of infection is increasing due to progressive urbanization and increased breeding sites for mosquito vectors.",
"   </p>",
"   <p>",
"    Humans are the only hosts for Bancroftian filariasis; this is an important epidemiologic distinction for goals to suppress and eradicate lymphatic filariasis. In contrast, Brugian filariasis infects humans as well as domestic and wild animals.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Life cycle",
"    </span>",
"    &nbsp;&mdash;&nbsp;The life cycle of filariasis begins with introduction of third-stage filarial larvae onto human skin by a mosquito during a blood meal; subsequently, larvae enter the bite wound and enter local lymphatic vessels. Over a period of approximately nine months, these larvae develop into mature adult worms (",
"    <a class=\"graphic graphic_figure graphicRef74534 \" href=\"UTD.htm?30/48/31495\">",
"     figure 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef52000 \" href=\"UTD.htm?20/24/20871\">",
"     figure 3",
"    </a>",
"    ).&nbsp;Female Wuchereria worms measure 80 to 100 mm in length and 0.24 to 0.30 mm in diameter, and the males measure about 40 mm by .1 mm.&nbsp;Female Brugia worms measure 43 to 55 mm in length by 130 to 170 &mu;m in width, and males measure 13 to 23 mm in length by 70 to 80 &mu;m in width.",
"   </p>",
"   <p>",
"    The adults survive for approximately five years (occasionally up to 12 to 15 years). Male and females worms mate and produce sheathed microfilariae.&nbsp;Wuchereria microfilariae are 244 to 296 microns by 7.5 to 10 microns; Brugia microfilariae are 177 to 230 microns in length and 5 to 7 microns in width. The microfilariae migrate into lymph and enter the blood stream.&nbsp;A mosquito ingests the microfilariae during a blood meal. In the mosquito the microfilariae develop into third-stage larvae, which can infect another human when the mosquito takes a blood meal, completing the life cycle.",
"   </p>",
"   <p>",
"    In most of the world, microfilariae are present in the bloodstream in largest numbers during the evening hours (&ldquo;nocturnal periodicity&rdquo;). In the South Pacific, W. bancrofti microfilariae are &ldquo;subperiodic&rdquo; and do not exhibit increases in numbers circulating at night. &nbsp;",
"   </p>",
"   <p>",
"    The interval between acquisition of infective larvae from a mosquito bite and detection of microfilariae in the blood is the prepatent period. In general, this interval is approximately 12 months in duration.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The pathogenesis and clinical progression of filarial disease is likely influenced by a number of factors, including the extent and duration of exposure to infective insect bites, the quantity of accumulating adult worm antigen in the lymphatics, the host immune response, and the number of secondary bacterial and fungal infections [",
"    <a class=\"abstract\" href=\"UTD.htm?13/25/13719/abstract/4-6\">",
"     4-6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6728515\">",
"    <span class=\"h2\">",
"     Host immune response",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinical presentations among exposed individuals can be variable depending on the host immune response. Some filariasis symptoms arise from immune reactions to dying adult worms in the lymphatics. Other immune responses likely vary over the course of infection. Early in infection, filarial antigens provoke Th2-type immune responses, leading to production of cytokines, including IL-5, and resulting in increased levels of IgE and IgG4. Later in infection, immunoregulatory responses predominate, leading to suppression of Th1 and Th2 immune responses and likely contributing to the chronicity of infection [",
"    <a class=\"abstract\" href=\"UTD.htm?13/25/13719/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In general, patients with a robust immune response to microfilariae clear antigens from the bloodstream and do not have detectable microfilaremia. Frequently these patients have heightened immune responses to adult parasite antigens, with severe lymphatic inflammation and fibrosis. Thus, paradoxically, clinical symptoms of lymphedema can be severe among individuals without detectable microfilaremia, whereas asymptomatic infected individuals frequently have detectable circulating microfilariae [",
"    <a class=\"abstract\" href=\"UTD.htm?13/25/13719/abstract/7,8\">",
"     7,8",
"    </a>",
"    ]. These patients generally do not have sufficient immune response to clear parasite antigens from the blood, but have few clinical symptoms. The worms in the lymphatics can cause mechanical pathology but do not induce an inflammatory response [",
"    <a class=\"abstract\" href=\"UTD.htm?13/25/13719/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Individuals chronically infected with lymphatic filariasis generally have an impaired lymphocyte proliferation response to filarial antigens [",
"    <a class=\"abstract\" href=\"UTD.htm?13/25/13719/abstract/5\">",
"     5",
"    </a>",
"    ]. Different life cycle stages of filarial parasites each have their own mechanism of modulating responses so that potentially inflammatory IFN-gamma responses are downregulated [",
"    <a class=\"abstract\" href=\"UTD.htm?13/25/13719/abstract/10,11\">",
"     10,11",
"    </a>",
"    ]. Defects in antigen-presenting cell (APC) function appear to participate in this acquired immune hyporesponsiveness, although the mechanisms as to how this occurs are poorly understood. Specifically, T cell responses to parasitic antigens of patients with microfilaremia are down-regulated. Evidence suggests this down-regulation involves both Th1 and Th2 cytokines [",
"    <a class=\"abstract\" href=\"UTD.htm?13/25/13719/abstract/12\">",
"     12",
"    </a>",
"    ], governed at the transcriptional level by a complex interplay of inhibitory mediators. This results in diminished production of IFN-gamma, TNF-alpha, IL-4, IL-5, and IL-10 in infected patients [",
"    <a class=\"abstract\" href=\"UTD.htm?13/25/13719/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a study conducted at two time points 17 years apart on an island where Bancroftian filariasis is endemic, persistently microfilaremic patients had the lowest lymphocyte responses. Patients whose microfilaremia cleared had lower lymphocyte responses to parasitic antigens than patients who were uninfected at both time points [",
"    <a class=\"abstract\" href=\"UTD.htm?13/25/13719/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Individual variations in immune responses relate to a number of host and parasite factors, including the timing of first exposure to parasites, the specific filarial pathogen involved, the intensity of exposure to infected mosquitoes, and other as yet uncharacterized host characteristics [",
"    <a class=\"abstract\" href=\"UTD.htm?13/25/13719/abstract/15\">",
"     15",
"    </a>",
"    ]. Genetic factors likely influence lymphedema susceptibility; lymphedema tends to cluster in families [",
"    <a class=\"abstract\" href=\"UTD.htm?13/25/13719/abstract/16,17\">",
"     16,17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Prenatal exposure appears to be an important factor leading to greater immune tolerance to parasite antigens [",
"    <a class=\"abstract\" href=\"UTD.htm?13/25/13719/abstract/9\">",
"     9",
"    </a>",
"    ]. Early exposure also skews filaria-specific immunity toward a Th2-type cytokine response [",
"    <a class=\"abstract\" href=\"UTD.htm?13/25/13719/abstract/18\">",
"     18",
"    </a>",
"    ]. Thus, individuals from endemic areas are often asymptomatic until late in disease when the worm burden is high, whereas nonimmune expatriates tend to have brisk immune responses and more severe early clinical symptoms, even in light infections.",
"   </p>",
"   <p>",
"    Lymphatic filariasis is likely first acquired in childhood; it has been suggested that as many as one-third of children are asymptomatically infected before age five [",
"    <a class=\"abstract\" href=\"UTD.htm?13/25/13719/abstract/19\">",
"     19",
"    </a>",
"    ]. The risk of infection in childhood may be related to the maternal immune response during pregnancy. In one study of 159 Kenyan pregnant women with active Wuchereria infection, neonates lacking filarial-specific T cell responses in cord blood at birth had a 13-fold increased risk of developing childhood infection (compared with uninfected controls) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/25/13719/abstract/20\">",
"     20",
"    </a>",
"    ]. Neonates with evidence of T-cell specific immunity in cord blood lymphocytes had a five-fold increased risk of developing childhood infection (compared to uninfected controls).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6728508\">",
"    <span class=\"h2\">",
"     Wolbachia",
"    </span>",
"    &nbsp;&mdash;&nbsp;It has been recognized that the lymphatic filarial parasites contain endosymbiotic bacteria, Wolbachia [",
"    <a class=\"abstract\" href=\"UTD.htm?13/25/13719/abstract/21\">",
"     21",
"    </a>",
"    ]. These are rickettsia-like organisms that appear to be required for homeostasis of the host parasite.",
"   </p>",
"   <p>",
"    Some of the inflammatory manifestations of lymphatic filariasis that result in progression of clinical disease are likely attributable to Wolbachia organisms [",
"    <a class=\"abstract\" href=\"UTD.htm?13/25/13719/abstract/16,22,23\">",
"     16,22,23",
"    </a>",
"    ]. Soluble extracts of many filarial species stimulate innate inflammatory responses which are absent or reduced if the bacteria are absent or have been cleared with antibiotics [",
"    <a class=\"abstract\" href=\"UTD.htm?13/25/13719/abstract/24\">",
"     24",
"    </a>",
"    ]. In addition, acute and severe inflammatory responses have been observed in individuals with Brugia malayi infection when Wolbachia are released into the blood following death or damage of the worms after antifilarial chemotherapy [",
"    <a class=\"abstract\" href=\"UTD.htm?13/25/13719/abstract/25,26\">",
"     25,26",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most individuals with filariasis in endemic areas are asymptomatic; development of symptoms correlates with cumulative acquisition of worms. Asymptomatic infected individuals have subclinical abnormalities in lymphatic drainage, even in the absence of clinical symptoms. In endemic areas clinical symptoms usually manifest at adolescence or adulthood. Estimates suggest that about one-third of infected individuals have clinical manifestations [",
"    <a class=\"abstract\" href=\"UTD.htm?13/25/13719/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The clinical course of lymphatic filariasis includes three phases: asymptomatic microfilaremia, episodes of acute adenolymphangitis (ADL), and chronic disease (irreversible lymphedema). Recurrent episodes of ADL may be superimposed upon chronic lymphedema.",
"   </p>",
"   <p>",
"    Eosinophilia is common and may exceed",
"    <span class=\"nowrap\">",
"     3000/microL.",
"    </span>",
"    The frequency of eosinophilia due to filariasis is difficult to determine since other helminth infections frequently coexist among individuals in endemic areas [",
"    <a class=\"abstract\" href=\"UTD.htm?13/25/13719/abstract/27\">",
"     27",
"    </a>",
"    ]. Other nonspecific laboratory findings include microscopic hematuria and proteinuria; these may be present in individuals with renal system involvement. (See",
"    <a class=\"local\" href=\"#H12\">",
"     'Renal involvement'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    No difference in clinical manifestations have been noted among HIV-infected individuals, and no quantitative differences in circulating filarial antigen levels between HIV-positive and HIV-negative patients have been observed [",
"    <a class=\"abstract\" href=\"UTD.htm?13/25/13719/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19882465\">",
"    <span class=\"h2\">",
"     Individuals in endemic areas",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Acute manifestations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute manifestations of lymphatic filariasis include acute adenolymphangitis (ADL), filarial fever, and tropical pulmonary eosinophilia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h4\">",
"     Acute adenolymphangitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute adenolymphangitis (ADL) characteristically presents with sudden onset of fever and painful lymphadenopathy. Retrograde lymphangitis (spread of inflammation distally from the lymph node) is frequently observed. ADL is believed to occur because of immune-mediated responses to dying adult worms.",
"   </p>",
"   <p>",
"    A variety of anatomic sites may be involved; the inguinal lymph nodes and lower extremities are commonly involved sites. In general acute inflammation tends to resolve after four to seven days. Recurrences typically occur one to four times per year; the number of recurrent events increases with increasing severity of lymphedema [",
"    <a class=\"abstract\" href=\"UTD.htm?13/25/13719/abstract/29,30\">",
"     29,30",
"    </a>",
"    ]. Secondary bacterial infection can also occur due to the breakdown of skin barriers in edematous skin or overlying intensely inflamed lymph nodes.",
"   </p>",
"   <p>",
"    Acute lymphatic disease can also involve the genitalia; this is the most common manifestation in males with Bancroftian filariasis. Typical symptoms include painful epididymitis associated with fever and malaise.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h4\">",
"     Filarial fever",
"    </span>",
"    &nbsp;&mdash;&nbsp;Filarial fever is characterized by acute, self-limited episodes of fever, often in the absence of lymphangitis or lymphadenopathy. Filarial fever may be confused with other causes of fever in the tropics, such as malaria.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h4\">",
"     Tropical pulmonary eosinophilia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tropical pulmonary eosinophilia is caused by an immune hyperresponsiveness to microfilariae trapped in the lungs and is characterized by nocturnal wheezing. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/30/2532?source=see_link\">",
"     \"Tropical filarial pulmonary eosinophilia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Chronic manifestations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chronic manifestations of lymphatic filariasis include lymphedema, renal involvement, and secondary infection.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h4\">",
"     Lymphedema",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lymphedema refers to limb swelling related to chronic inflammation of the lymphatic vessels; it is a common late sequela of filarial infection (",
"    <a class=\"graphic graphic_picture graphicRef79016 \" href=\"UTD.htm?39/46/40679\">",
"     picture 1",
"    </a>",
"    ). Involvement of inguinal lymph vessels leads to swelling of the lower limb(s). Involvement of axillary lymph nodes leads to swelling of the upper limb(s); in women involvement of the breast can also occur. Early in the course of disease, pitting edema develops. Chronic inflammation leads to brawny nonpitting edema and hardening of the tissues, resulting in hyperpigmentation and hyperkeratosis. Severe lymphedema is sometimes called referred to as elephantiasis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/52/1866?source=see_link\">",
"     \"Clinical manifestations and diagnosis of lymphedema\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Another cause of tropical lymphedema that must be distinguished from lymphatic filariasis is podoconiosis; it is found at altitudes higher than those at which mosquitoes can transmit filarial infection (a maximum of about 1500 m or 4920 feet) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/25/13719/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Chronic lymphatic disease can also involve the genitalia, resulting in the development of unilateral or bilateral hydrocele(s). Hydroceles can be large (up to or greater than 30 cm in diameter); they are usually painless unless complicated by bacterial infection. Localization of adult worms in the lymphatics of the spermatic cord can lead to palpable thickening of the cord. Lymphatic filariasis of the ovary and mesosalpinx has also been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?13/25/13719/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h4\">",
"     Renal involvement",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intestinal lymph may be intermittently discharged into the renal pelvis, causing lymph fluid to be passed in the urine. This is known as chyluria, and it results in a milky appearance to the urine [",
"    <a class=\"abstract\" href=\"UTD.htm?13/25/13719/abstract/33\">",
"     33",
"    </a>",
"    ]&nbsp;(",
"    <a class=\"graphic graphic_picture graphicRef60451 \" href=\"UTD.htm?4/47/4849\">",
"     picture 2",
"    </a>",
"    ). Since large amounts of fat and protein can be lost in the urine in individuals with chyluria, this condition can lead to nutritional deficiencies, including anemia and hypoproteinemia.",
"   </p>",
"   <p>",
"    Individuals with Bancroftian filariasis, especially those who have detectable microfilaremia, can also develop hematuria and proteinuria [",
"    <a class=\"abstract\" href=\"UTD.htm?13/25/13719/abstract/34\">",
"     34",
"    </a>",
"    ]. The underlying etiology and long term significance of this finding remain unclear. It may be caused by an immune complex nephritis, but this has not been confirmed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h4\">",
"     Secondary infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Secondary bacterial",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    fungal infections are common sequelae of lymphatic filariasis and contribute significantly to the progression of severe disease. Redundant skin folds and skin tears due to edema serve as entry points for secondary pathogens, with resultant local",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    systemic infection.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Travelers and expatriates",
"    </span>",
"    &nbsp;&mdash;&nbsp;Travelers and expatriates usually have insufficient exposure to filariasis to develop the chronic complications of infection observed with high worm burdens. However, these individuals may demonstrate a hypersensitivity reaction to developing larvae which rarely occurs among individuals in endemic areas. This is characterized by a local eosinophilic infiltrate with lymphangitis and lymphadenitis, urticaria, rash, and a peripheral eosinophilia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8154366\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Filariasis is caused by nematodes (roundworms) that inhabit the lymphatics and subcutaneous tissues. Three species cause lymphatic filariasis: Wuchereria bancrofti, Brugia malayi, and Brugia timori. Infection is transmitted by mosquito vectors; humans are definitive hosts. Lymphatic filariasis is a major cause of disfigurement and disability in endemic areas, leading to significant economic and psychosocial impact (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.).",
"     </li>",
"     <li>",
"      W. bancrofti occurs in sub-Saharan Africa, Southeast Asia, the Indian subcontinent, many of the Pacific islands, and focal areas of Latin America. B. malayi occurs mainly in China, India, Malaysia, the Philippines, Indonesia, and various Pacific islands. B. timori occurs on the Timor Island of Indonesia. It is estimated that more than 120 million people worldwide are infected. More than 90 percent of these infections are due to W. bancrofti, while most of the remainder are due to B. malayi. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The life cycle of filariasis begins with introduction of larvae onto human skin by a mosquito during a blood meal; these gain entry via the bite wound and enter local lymphatic vessels (",
"      <a class=\"graphic graphic_figure graphicRef74534 \" href=\"UTD.htm?30/48/31495\">",
"       figure 2",
"      </a>",
"      and",
"      <a class=\"graphic graphic_figure graphicRef52000 \" href=\"UTD.htm?20/24/20871\">",
"       figure 3",
"      </a>",
"      ). The larvae develop into mature adult worms which mate and produce sheathed microfilariae with nocturnal periodicity. A mosquito ingests the microfilariae during a blood meal; these develop into larvae which can infect another human when the mosquito takes a subsequent blood meal, completing the life cycle. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Life cycle'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The pathogenesis and clinical progression of filarial disease is likely influenced by a number of factors including the extent and duration of exposure to infective insect bites, the quantity of accumulating adult worm antigen in the lymphatics, the host immune response, and the number of secondary bacterial and fungal infections. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Pathogenesis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The development of clinical symptoms correlates with cumulative acquisition of worms. In endemic areas acute manifestations of lymphatic filariasis include acute adenolymphangitis, filarial fever, and tropical pulmonary eosinophilia. Chronic manifestations of lymphatic filariasis include lymphedema, renal involvement, and secondary infection. (See",
"      <a class=\"local\" href=\"#H19882465\">",
"       'Individuals in endemic areas'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Travelers and expatriates usually have insufficient exposure to filariasis to develop the chronic complications of infection observed with high worm burdens. However, these individuals may demonstrate a hypersensitivity reaction to developing larvae which rarely occurs among individuals in endemic areas. This is characterized by a local eosinophilic infiltrate with lymphangitis and lymphadenitis, urticaria, rash, and a peripheral eosinophilia. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Travelers and expatriates'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/25/13719/abstract/1\">",
"      Global Programme to eliminate lymphatic filariasis: progress report on mass drug administration, 2010. Wkly Epidemiol Rec 2011; 86:377.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/25/13719/abstract/2\">",
"      Ramaiah KD, Das PK, Michael E, Guyatt H. The economic burden of lymphatic filariasis in India. Parasitol Today 2000; 16:251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/25/13719/abstract/3\">",
"      Babu BV, Swain BK, Rath K. Impact of chronic lymphatic filariasis on quantity and quality of productive work among weavers in an endemic village from India. Trop Med Int Health 2006; 11:712.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/25/13719/abstract/4\">",
"      Baird JB, Charles JL, Streit TG, et al. Reactivity to bacterial, fungal, and parasite antigens in patients with lymphedema and elephantiasis. Am J Trop Med Hyg 2002; 66:163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/25/13719/abstract/5\">",
"      King CL. Transmission intensity and human immune responses to lymphatic filariasis. Parasite Immunol 2001; 23:363.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/25/13719/abstract/6\">",
"      Lamb TJ, Le Goff L, Kurniawan A, et al. Most of the response elicited against Wolbachia surface protein in filarial nematode infection is due to the infective larval stage. J Infect Dis 2004; 189:120.",
"     </a>",
"    </li>",
"    <li>",
"     Nutman TB, Kazura J. Lymphatic Filariasis. In: Tropical Infectious Diseases: Principles, Pathogens, and Practice, 2nd ed, Guerrant R, Walker DH, Weller PF (Eds), Churchill Livingstone, Philadelphia 2011. Vol 3, p.729.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/25/13719/abstract/8\">",
"      Dissanayake S. In Wuchereria bancrofti filariasis, asymptomatic microfilaraemia does not progress to amicrofilaraemic lymphatic disease. Int J Epidemiol 2001; 30:394.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/25/13719/abstract/9\">",
"      Ottesen EA. The Wellcome Trust Lecture. Infection and disease in lymphatic filariasis: an immunological perspective. Parasitology 1992; 104 Suppl:S71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/25/13719/abstract/10\">",
"      Lawrence RA, Devaney E. Lymphatic filariasis: parallels between the immunology of infection in humans and mice. Parasite Immunol 2001; 23:353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/25/13719/abstract/11\">",
"      Babu S, Blauvelt CP, Kumaraswami V, Nutman TB. Cutting edge: diminished T cell TLR expression and function modulates the immune response in human filarial infection. J Immunol 2006; 176:3885.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/25/13719/abstract/12\">",
"      Hoerauf A, Satoguina J, Saeftel M, Specht S. Immunomodulation by filarial nematodes. Parasite Immunol 2005; 27:417.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/25/13719/abstract/13\">",
"      Babu S, Blauvelt CP, Kumaraswami V, Nutman TB. Regulatory networks induced by live parasites impair both Th1 and Th2 pathways in patent lymphatic filariasis: implications for parasite persistence. J Immunol 2006; 176:3248.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/25/13719/abstract/14\">",
"      Steel C, Ottesen EA. Evolution of immunologic responsiveness of persons living in an area of endemic bancroftian filariasis: a 17-year follow-up. J Infect Dis 2001; 184:73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/25/13719/abstract/15\">",
"      Lymphatic filariasis: diagnosis and pathogenesis. WHO expert committee on filariasis. Bull World Health Organ 1993; 71:135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/25/13719/abstract/16\">",
"      Lammie PJ, Cuenco KT, Punkosdy GA. The pathogenesis of filarial lymphedema: is it the worm or is it the host? Ann N Y Acad Sci 2002; 979:131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/25/13719/abstract/17\">",
"      Choi EH, Nutman TB, Chanock SJ. Genetic variation in immune function and susceptibility to human filariasis. Expert Rev Mol Diagn 2003; 3:367.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/25/13719/abstract/18\">",
"      Malhotra I, Ouma JH, Wamachi A, et al. Influence of maternal filariasis on childhood infection and immunity to Wuchereria bancrofti in Kenya. Infect Immun 2003; 71:5231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/25/13719/abstract/19\">",
"      Witt C, Ottesen EA. Lymphatic filariasis: an infection of childhood. Trop Med Int Health 2001; 6:582.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/25/13719/abstract/20\">",
"      Malhotra I, Mungai PL, Wamachi AN, et al. Prenatal T cell immunity to Wuchereria bancrofti and its effect on filarial immunity and infection susceptibility during childhood. J Infect Dis 2006; 193:1005.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/25/13719/abstract/21\">",
"      Grobusch MP, Kombila M, Autenrieth I, et al. No evidence of Wolbachia endosymbiosis with Loa loa and Mansonella perstans. Parasitol Res 2003; 90:405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/25/13719/abstract/22\">",
"      Taylor MJ, Hoerauf A. Wolbachia bacteria of filarial nematodes. Parasitol Today 1999; 15:437.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/25/13719/abstract/23\">",
"      Punkosdy GA, Addiss DG, Lammie PJ. Characterization of antibody responses to Wolbachia surface protein in humans with lymphatic filariasis. Infect Immun 2003; 71:5104.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/25/13719/abstract/24\">",
"      Taylor MJ. Wolbachia in the inflammatory pathogenesis of human filariasis. Ann N Y Acad Sci 2003; 990:444.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/25/13719/abstract/25\">",
"      Taylor MJ, Cross HF, Ford L, et al. Wolbachia bacteria in filarial immunity and disease. Parasite Immunol 2001; 23:401.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/25/13719/abstract/26\">",
"      Taylor MJ. A new insight into the pathogenesis of filarial disease. Curr Mol Med 2002; 2:299.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/25/13719/abstract/27\">",
"      Ottesen EA, Weller PF. Eosinophilia following treatment of patients with schistosomiasis mansoni and Bancroft's filariasis. J Infect Dis 1979; 139:343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/25/13719/abstract/28\">",
"      Talaat KR, Kumarasamy N, Swaminathan S, et al. Filarial/human immunodeficiency virus coinfection in urban southern India. Am J Trop Med Hyg 2008; 79:558.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/25/13719/abstract/29\">",
"      Pani SP, Srividya A. Clinical manifestations of bancroftian filariasis with special reference to lymphoedema grading. Indian J Med Res 1995; 102:114.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/25/13719/abstract/30\">",
"      Pani SP, Yuvaraj J, Vanamail P, et al. Episodic adenolymphangitis and lymphoedema in patients with bancroftian filariasis. Trans R Soc Trop Med Hyg 1995; 89:72.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/25/13719/abstract/31\">",
"      Tekola Ayele F, Adeyemo A, Finan C, et al. HLA class II locus and susceptibility to podoconiosis. N Engl J Med 2012; 366:1200.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/25/13719/abstract/32\">",
"      Sethi S, Misra K, Singh UR, Kumar D. Lymphatic filariasis of the ovary and mesosalpinx. J Obstet Gynaecol Res 2001; 27:285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/25/13719/abstract/33\">",
"      Franco-Paredes C, Hidron A, Steinberg J. A woman from British Guyana with recurrent back pain and fever. Chyluria associated with infection due to Wuchereria bancrofti. Clin Infect Dis 2006; 42:1297, 1340.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/25/13719/abstract/34\">",
"      Dreyer G, Ottesen EA, Galdino E, et al. Renal abnormalities in microfilaremic patients with Bancroftian filariasis. Am J Trop Med Hyg 1992; 46:745.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5675 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-190.102.30.19-F4418191A5-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_25_13719=[""].join("\n");
var outline_f13_25_13719=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H8154366\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Life cycle",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6728515\">",
"      Host immune response",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6728508\">",
"      Wolbachia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19882465\">",
"      Individuals in endemic areas",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Acute manifestations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Acute adenolymphangitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Filarial fever",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Tropical pulmonary eosinophilia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Chronic manifestations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Lymphedema",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Renal involvement",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Secondary infection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Travelers and expatriates",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8154366\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/5675\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/5675|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?30/55/31606\" title=\"figure 1\">",
"      Lymphatic filariasis map",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?30/48/31495\" title=\"figure 2\">",
"      Wuchereria life cycle",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?20/24/20871\" title=\"figure 3\">",
"      Brugia life cycle",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/5675|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?39/46/40679\" title=\"picture 1\">",
"      Leg with filariasis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?4/47/4849\" title=\"picture 2\">",
"      Urine sample with chyluria",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/52/1866?source=related_link\">",
"      Clinical manifestations and diagnosis of lymphedema",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/56/15241?source=related_link\">",
"      Diagnosis, treatment, and prevention of lymphatic filariasis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/26/36263?source=related_link\">",
"      Loiasis (Loa loa infection)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/30/20970?source=related_link\">",
"      Onchocerciasis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/30/2532?source=related_link\">",
"      Tropical filarial pulmonary eosinophilia",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f13_25_13720="Chapter 2B: Renin-angiotensin system";
var content_f13_25_13720=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Chapter 2B: Renin-angiotensin system",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?13/25/13720/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/25/13720/contributors\">",
"     Burton D Rose, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/25/13720/contributors\">",
"     Theodore W Post, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?13/25/13720/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/25/13720/contributors\">",
"     Burton D Rose, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?13/25/13720/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/25/13720/contributors\">",
"     Theodore W Post, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?13/25/13720/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 26, 2004.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although the physiology of those hormones that importantly affect renal function is discussed in Chap. 6, angiotensin II plays such a central role in the regulation of the glomerular filtration rate that it is useful to review the renin-angiotensin system at this time.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     RENIN RELEASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The afferent arteriole of each glomerulus contains specialized cells, called the juxtaglomerular cells (",
"    <a class=\"graphic graphic_figure graphicRef69949 \" href=\"UTD.htm?31/9/31889\">",
"     figure 1",
"    </a>",
"    ). These cells synthesize the precursor prorenin, which is cleaved into the active proteolytic enzyme renin. Active renin is then stored in and released from secretory granules&dagger; [",
"    <a class=\"abstract\" href=\"UTD.htm?13/25/13720/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. More proximal cells in the interlobular artery can also be recruited for renin release when the stimulus is prolonged [",
"    <a class=\"abstract\" href=\"UTD.htm?13/25/13720/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    &dagger;Prorenin is also secreted into the systemic circulation, accounting for 50 to 90 percent of circulating renin [",
"    <a class=\"abstract\" href=\"UTD.htm?13/25/13720/abstract/2\">",
"     2",
"    </a>",
"    ]. The physiological role of prorenin is unclear, since it has no direct effect on systemic hemodynamics and does not appear to be converted into active renin in the systemic circulation [",
"    <a class=\"abstract\" href=\"UTD.htm?13/25/13720/abstract/4\">",
"     4",
"    </a>",
"    ]. There is evidence, however, that the uterus also secretes renin and prorenin, and that the latter may play a local role in the regulation of uterine function, particularly during pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?13/25/13720/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Renal hypoperfusion, produced by hypotension or volume depletion, and increased sympathetic activity are the major physiologic stimuli to renin secretion (",
"    <a class=\"graphic graphic_figure graphicRef65116 \" href=\"UTD.htm?14/19/14654\">",
"     figure 2",
"    </a>",
"    ). There is a gradient of response according to the location of the glomeruli: renin release is most prominent in the outer cortical (or superficial) glomeruli, with a lesser response being seen in the midcortex and very little renin being secreted in the juxtamedullary glomeruli [",
"    <a class=\"abstract\" href=\"UTD.htm?13/25/13720/abstract/6\">",
"     6",
"    </a>",
"    ]. This pattern may reflect changes in glomerular perfusion pressure: the juxtamedullary glomeruli are closest to the interlobular artery (",
"    <a class=\"graphic graphic_figure graphicRef65665 \" href=\"UTD.htm?12/63/13296\">",
"     figure 3",
"    </a>",
"    ), whereas the outer cortical glomeruli are furthest away and perfused at a lower pressure. The physiologic significance of these observations is unclear.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     ANGIOTENSIN CONVERTING ENZYME",
"    </span>",
"    &nbsp;&mdash;&nbsp;Renin initiates a sequence of steps that begins with cleavage of a decapeptide angiotensin I from renin substrate (angiotensinogen), an alpha-2-globulin produced in the liver (and other organs including the kidney) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/25/13720/abstract/7,8\">",
"     7,8",
"    </a>",
"    ]. Angiotensin I is then converted into the octapeptide angiotensin II. This reaction is catalyzed by an enzyme called angiotensin converting enzyme (ACE), which is located in the lung, the luminal membrane of vascular endothelial cells, the glomerulus itself, and other organs.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Local renin-angiotensin systems",
"    </span>",
"    &nbsp;&mdash;&nbsp;The concentration of ACE is highest in the lung and it had been thought that most angiotensin II formation occurred in the pulmonary circulation. It is now clear, however, that there are",
"    <strong>",
"     extrarenal",
"    </strong>",
"    renin-angiotensin systems and that angiotensin II can be synthesized at a variety of sites, including the kidney, vascular endothelium, adrenal gland, and brain [",
"    <a class=\"abstract\" href=\"UTD.htm?13/25/13720/abstract/7,9-11\">",
"     7,9-11",
"    </a>",
"    ]. These extrarenal systems may account for the persistent, although low, plasma levels of angiotensin II in anephric subjects [",
"    <a class=\"abstract\" href=\"UTD.htm?13/25/13720/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    It is presumed that local angiotensin II production is important for the regulation of local processes. Volume depletion, for example, leads to an increase in renal messenger RNA expression for both renin (in the glomerulus) and angiotensinogen (in the proximal tubule) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/25/13720/abstract/13\">",
"     13",
"    </a>",
"    ]. Activation of the local renin system may be mediated by local factors such prostaglandins, nitric oxide, and endothelin [",
"    <a class=\"abstract\" href=\"UTD.htm?13/25/13720/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The proximal tubule also contains ACE and angiotensin II receptors, suggesting that local angiotensin II formation can occur and stimulate Na+ reabsorption [",
"    <a class=\"abstract\" href=\"UTD.htm?13/25/13720/abstract/14\">",
"     14",
"    </a>",
"    ]. The observation that the concentration of angiotensin II in the peritubular capillary and proximal tubule is approximately",
"    <strong>",
"     1000 times",
"    </strong>",
"    higher than that in the systemic circulation is consistent with the possibility of a local effect [",
"    <a class=\"abstract\" href=\"UTD.htm?13/25/13720/abstract/15\">",
"     15",
"    </a>",
"    ]. This can be achieved without releasing enough renin into the circulation to induce systemic vasoconstriction.",
"   </p>",
"   <p>",
"    One clinical consequence of these observations is that measurement of the plasma renin activity or angiotensin II concentration may be a misleading estimate of the tissue activity of this system. In some patients with essential hypertension, for example, angiotensin II appears to be responsible for persistent renal vasoconstriction and sodium retention, even though the plasma levels of renin and angiotensin II are similar to those in hypertensives with normal renal perfusion [",
"    <a class=\"abstract\" href=\"UTD.htm?13/25/13720/abstract/16\">",
"     16",
"    </a>",
"    ]. These findings suggest a selective increase in the activity of the intrarenal renin-angiotensin system; the mechanism by which this occurs is not known. A similar selective activation of the intrarenal renin-angiotensin system may occur in stable congestive heart failure [",
"    <a class=\"abstract\" href=\"UTD.htm?13/25/13720/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Local generation of angiotensin II also can occur in vascular endothelium, where it may play an important role in the regulation of vascular tone and possibly in the development of hypertension [",
"    <a class=\"abstract\" href=\"UTD.htm?13/25/13720/abstract/7,17,18\">",
"     7,17,18",
"    </a>",
"    ]. Volume depletion increases angiotensinogen mRNA levels in aortic smooth muscle. If this results in enhanced release of angiotensinogen, then either locally produced or systemic renin could initiate the sequential formation of angiotensin I and, via endothelial converting enzyme, angiotensin II.",
"   </p>",
"   <p>",
"    These local effects could explain why angiotensin converting enzyme inhibitors are very useful antihypertensive agents, even in patients with low plasma renin activity and low circulating levels of angiotensin II [",
"    <a class=\"abstract\" href=\"UTD.htm?13/25/13720/abstract/10,19\">",
"     10,19",
"    </a>",
"    ]. Although the findings in human are only indirect, the potential importance of local renin-angiotensin systems in the genesis of hypertension has been more convincingly demonstrated in experiments in which a mouse renin gene was inserted into rats. The presence of this extra gene for renin led to severe hypertension that was largely corrected by an angiotensin converting enzyme inhibitor or an angiotensin II receptor antagonist [",
"    <a class=\"abstract\" href=\"UTD.htm?13/25/13720/abstract/20\">",
"     20",
"    </a>",
"    ]. Despite this evidence for angiotensin-mediated hypertension, the plasma renin activity, plasma angiotensin II level, and renal renin content were all below normal, while adrenal renin content and vascular angiotensin generation were markedly elevated [",
"    <a class=\"abstract\" href=\"UTD.htm?13/25/13720/abstract/20,21\">",
"     20,21",
"    </a>",
"    ]. Thus, the elevation in blood pressure in this low (plasma) renin form of hypertension was mediated by local renin release, in the adrenal gland and perhaps vascular endothelium.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Angiotensin converting enzyme 2",
"    </span>",
"    &nbsp;&mdash;&nbsp;A related enzyme to ACE has been identified and called angiotensin converting enzyme 2 (ACE2) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/25/13720/abstract/22-24\">",
"     22-24",
"    </a>",
"    ]. ACE2 is predominantly expressed in the endothelium of the coronary and intrarenal vessels and the epithelium of the renal tubules [",
"    <a class=\"abstract\" href=\"UTD.htm?13/25/13720/abstract/22\">",
"     22",
"    </a>",
"    ]. The gene for ACE2 maps to the X chromosome in humans [",
"    <a class=\"abstract\" href=\"UTD.htm?13/25/13720/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Like ACE, ACE2 acts on angiotensin I. However, the reaction with ACE2 generates angiotensin 1-9 rather than the octapeptide angiotensin II (angiotensin 1-8) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/25/13720/abstract/22\">",
"     22",
"    </a>",
"    ]. Angiotensin 1-9 has no known vascular activity but can be cleaved by ACE to angiotensin 1-7, a vasodilator, and smaller peptides. In contrast to ACE, ACE2 is not inhibited by ACE inhibitors and does not metabolize bradykinin [",
"    <a class=\"abstract\" href=\"UTD.htm?13/25/13720/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The physiologic importance of ACE2 is not completely understood. Disruption of the ACE2 gene in mice results in markedly reduced cardiac contractility and upregulation of hypoxia-induced genes in the heart, suggesting a role in the response to cardiac ischemia [",
"    <a class=\"abstract\" href=\"UTD.htm?13/25/13720/abstract/23\">",
"     23",
"    </a>",
"    ]. Disruption of ACE2 did not interfere with blood pressure regulation.",
"   </p>",
"   <p>",
"    The cardiac changes in mice with disruption of the ACE2 gene were associated with increased plasma angiotensin II and were completely reversed by ablation of the ACE genes [",
"    <a class=\"abstract\" href=\"UTD.htm?13/25/13720/abstract/23\">",
"     23",
"    </a>",
"    ]. These observations, plus the demonstration that angiotensin 1-7 is a vasodilator, suggest that ACE2 and ACE have counterbalancing effects.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     ACTIONS OF ANGIOTENSIN II",
"    </span>",
"    &nbsp;&mdash;&nbsp;Angiotensin II has two major systemic effects: systemic vasoconstriction and sodium and water retention. Both of these actions will tend to reverse the hypovolemia or hypotension that is usually responsible for the stimulation of renin secretion (",
"    <a class=\"graphic graphic_figure graphicRef65116 \" href=\"UTD.htm?14/19/14654\">",
"     figure 2",
"    </a>",
"    ) and (see",
"    <a class=\"local\" href=\"#H10\">",
"     'Control of renin secretion'",
"    </a>",
"    below)&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?13/25/13720/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The effects of angiotensin II are mediated by binding to specific angiotensin II receptors: AT1 and AT2 [",
"    <a class=\"abstract\" href=\"UTD.htm?13/25/13720/abstract/26\">",
"     26",
"    </a>",
"    ]. The vascular and renal tubular actions are primarily mediated by the AT1 receptors [",
"    <a class=\"abstract\" href=\"UTD.htm?13/25/13720/abstract/26,27\">",
"     26,27",
"    </a>",
"    ]. The effects of the AT2 receptors are less well understood; they may contribute to the tubular actions of angiotensin II and to the regulation of cell proliferation in the arterial wall [",
"    <a class=\"abstract\" href=\"UTD.htm?13/25/13720/abstract/26,28,29\">",
"     26,28,29",
"    </a>",
"    ]",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Renal sodium and water reabsorption",
"    </span>",
"    &nbsp;&mdash;&nbsp;Angiotensin II &nbsp;promotes renal NaCl and H2O reabsorption and therefore expansion of the plasma volume. This occurs by at least two mechanisms: direct stimulation of Na+ reabsorption in the early proximal tubule [",
"    <a class=\"abstract\" href=\"UTD.htm?13/25/13720/abstract/25,30,31\">",
"     25,30,31",
"    </a>",
"    ]; and by increased secretion of aldosterone from the adrenal cortex, which enhances Na+ transport in the cortical collecting tubule. Both systemic angiotensin II and angiotensin II generated within the adrenal gland contribute to the stimulation of aldosterone release (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/20/2376?source=see_link\">",
"     \"Chapter 6C: Aldosterone\"",
"    </a>",
"    ). [",
"    <a class=\"abstract\" href=\"UTD.htm?13/25/13720/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The proximal effect of angiotensin II appears to result at least in part from activation of the Na+-H+ antiporter in the luminal membrane [",
"    <a class=\"abstract\" href=\"UTD.htm?13/25/13720/abstract/32-34\">",
"     32-34",
"    </a>",
"    ]. This enhancement of Na+-H+ exchange appears to be mediated by two angiotensin II-dependent pathways: stimulation of an inhibitory G protein that decreases cyclic AMP generation, thereby minimizing the normally suppressive effect of cyclic AMP on Na+-H+ exchange [",
"    <a class=\"abstract\" href=\"UTD.htm?13/25/13720/abstract/32\">",
"     32",
"    </a>",
"    ]; and, to a lesser degree, stimulation of phosphatidylinositol turnover, resulting in the generation of protein kinase C [",
"    <a class=\"abstract\" href=\"UTD.htm?13/25/13720/abstract/33\">",
"     33",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/33/19988?source=see_link\">",
"     \"Chapter 6A: Mechanisms of hormone action\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Studies using a highly specific AT1 receptor antagonist suggest that angiotensin II may be responsible for as much as 40 to 50 percent of Na+ and H2O reabsorption in the initial S1 segment of the proximal tubule [",
"    <a class=\"abstract\" href=\"UTD.htm?13/25/13720/abstract/28,35\">",
"     28,35",
"    </a>",
"    ]. The AT2 receptors also appear to contribute to this response [",
"    <a class=\"abstract\" href=\"UTD.htm?13/25/13720/abstract/28\">",
"     28",
"    </a>",
"    ]. There is a much lesser effect in the more distal part of the proximal tubule where there are fewer angiotensin II receptors.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Systemic vasoconstriction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Angiotensin II &nbsp;produces arteriolar vasoconstriction which, by elevating systemic vascular resistance, increases the systemic blood pressure. In addition to a direct action of angiotensin II on vascular smooth muscle (which appears to be mediated primarily by protein kinase C generation [",
"    <a class=\"abstract\" href=\"UTD.htm?13/25/13720/abstract/36\">",
"     36",
"    </a>",
"    ]), experimental observations suggest that enhanced sensitivity to and facilitated release of norepinephrine may also play a contributory role [",
"    <a class=\"abstract\" href=\"UTD.htm?13/25/13720/abstract/37,38\">",
"     37,38",
"    </a>",
"    ]. However, the applicability of the angiotensin II-norepinephrine relationship to humans is uncertain; it may be that only high angiotensin II levels, such as those seen with advanced congestive heart failure, are sufficient to stimulate norepinephrine release [",
"    <a class=\"abstract\" href=\"UTD.htm?13/25/13720/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The net effect is that angiotensin II plays an important role in the maintenance of blood pressure in all circumstances in which renin secretion is enhanced and circulating angiotensin II levels are high. This is true in the hypertension associated with renal artery stenosis (in which renal ischemia stimulates renin release) as well as in normotensive states associated with effective circulating volume depletion&dagger;, such as true volume depletion, heart failure, and hepatic cirrhosis [",
"    <a class=\"abstract\" href=\"UTD.htm?13/25/13720/abstract/40-42\">",
"     40-42",
"    </a>",
"    ]. As an example, the administration of an angiotensin II inhibitor to a normotensive patient with hepatic cirrhosis can lower the blood pressure by as much as 25 mmHg, possibly leading to symptomatic hypotension [",
"    <a class=\"abstract\" href=\"UTD.htm?13/25/13720/abstract/42\">",
"     42",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    &dagger; (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/45/7893?source=see_link\">",
"     \"Chapter 8A: Effective circulating volume and the steady state\"",
"    </a>",
"    )",
"   </p>",
"   <p>",
"    The vascular action of angiotensin II involves enhanced phosphatidylinositol turnover, rather than the generation of cyclic AMP as in the proximal tubule [",
"    <a class=\"abstract\" href=\"UTD.htm?13/25/13720/abstract/43\">",
"     43",
"    </a>",
"    ]. The ensuing formation of diacylglycerol leads to the release of arachidonic acid, which can then be converted into prostaglandins or, via the lipoxygenase pathway, into metabolites of hydroxyeicosatetraenoic acid [",
"    <a class=\"abstract\" href=\"UTD.htm?13/25/13720/abstract/44\">",
"     44",
"    </a>",
"    ]. The latter compounds partially mediate angiotensin II-induced vasoconstriction (as well as aldosterone release) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/25/13720/abstract/44\">",
"     44",
"    </a>",
"    ], whereas vasodilator prostaglandins tend to minimize the increase in vascular resistance.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Regulation of GFR",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to influencing systemic hemodynamics, angiotensin II plays an important role in the regulation of glomerular filtration rate (GFR) and renal blood flow [",
"    <a class=\"abstract\" href=\"UTD.htm?13/25/13720/abstract/25\">",
"     25",
"    </a>",
"    ]. Although the clinical implications of these effects will be discussed below, it is helpful to review them briefly at this time. Angiotensin II can affect renal blood flow and the GFR by constricting the efferent and afferent glomerular arterioles, and the interlobular artery [",
"    <a class=\"abstract\" href=\"UTD.htm?13/25/13720/abstract/45-47\">",
"     45-47",
"    </a>",
"    ]. These responses may be mediated at least in part by the local generation of the vasoconstrictor thromboxane A2 [",
"    <a class=\"abstract\" href=\"UTD.htm?13/25/13720/abstract/48\">",
"     48",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although both afferent and efferent arterioles are constricted, the efferent arteriole has a smaller basal diameter; as a result, the increase in efferent resistance may be as much as three times greater as that at the afferent arteriole&dagger; [",
"    <a class=\"abstract\" href=\"UTD.htm?13/25/13720/abstract/49\">",
"     49",
"    </a>",
"    ]. The net effect is a reduction in renal blood flow (due to the increase in renal vascular resistance) and an elevation in the hydraulic pressure in the glomerular capillary (Pgc), which tends to maintain the GFR when the renin-angiotensin system is activated by a fall in systemic pressure.",
"   </p>",
"   <p>",
"    &dagger; The disparate afferent and efferent effects of angiotensin II may also be in part related to different mechanisms of constriction. Calcium channel blockers abolish the afferent response, while having little or no effect on the increase in efferent tone [",
"    <a class=\"abstract\" href=\"UTD.htm?13/25/13720/abstract/50\">",
"     50",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The likelihood of excessive renal vasoconstriction is minimized because angiotensin II also stimulates the release of vasodilator prostaglandins from the glomeruli [",
"    <a class=\"abstract\" href=\"UTD.htm?13/25/13720/abstract/51\">",
"     51",
"    </a>",
"    ]. The importance of this response can be illustrated by blocking the increase in prostaglandin synthesis with a nonsteroidal antiinflammatory drug. In this setting, a low sodium diet leads to more marked renal ischemia and, due to the decline in perfusion, a substantial reduction in GFR [",
"    <a class=\"abstract\" href=\"UTD.htm?13/25/13720/abstract/52\">",
"     52",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/60/966?source=see_link\">",
"     \"Chapter 6E: Prostaglandins and the kidney\"",
"    </a>",
"    .) Similarly, the degree of systemic vasoconstriction may also be minimized by the local angiotensin II-induced release of prostacyclin [",
"    <a class=\"abstract\" href=\"UTD.htm?13/25/13720/abstract/53\">",
"     53",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Angiotensin II has two other effects that can influence the GFR. First, it constricts the glomerular mesangium at higher concentrations, thereby lowering the surface area available for filtration. Second, angiotensin II sensitizes the afferent arteriole to the constricting signal of tubuloglomerular feedback [",
"    <a class=\"abstract\" href=\"UTD.htm?13/25/13720/abstract/25\">",
"     25",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/46/10985?source=see_link\">",
"     \"Chapter 2D: Regulation of GFR and renal plasma flow\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The net result is that angiotensin II has counteracting effects on the regulation of GFR: the increase in Pgc will tend to increase filtration, while the reduction in renal blood flow and mesangial contraction will tend to reduce filtration. The result is variable in different conditions, although how this occurs is incompletely understood. When renal perfusion pressure is reduced as in renal artery stenosis, angiotensin II acts to maintain the GFR and the administration of an ACE inhibitor can cause acute renal failure. In comparison, the GFR may be reduced by angiotensin II in hypertension and congestive heart failure [",
"    <a class=\"abstract\" href=\"UTD.htm?13/25/13720/abstract/25,54\">",
"     25,54",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     CONTROL OF RENIN SECRETION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The factors that regulate renin secretion are directly related to the major actions of angiotensin II: increased Na+ and water reabsorption; and systemic vasoconstriction.",
"   </p>",
"   <p>",
"    In normal subjects, the major determinant of renin secretion is Na+ intake: a high intake expands the extracellular volume and decreases renin release whereas a low intake (or fluid loss from any site) leads to a reduction in extracellular volume and stimulation of renin secretion. Acute increases in renin secretion, as with volume depletion, primarily reflect the release of preformed renin from secretory granules [",
"    <a class=\"abstract\" href=\"UTD.htm?13/25/13720/abstract/2\">",
"     2",
"    </a>",
"    ]. More chronic stimuli lead to increased synthesis of new prorenin and renin [",
"    <a class=\"abstract\" href=\"UTD.htm?13/25/13720/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The associated changes in angiotensin II and aldosterone production induced by renin then allow Na+ to be excreted with volume expansion or retained with volume depletion. Intrarenally formed angiotensin II probably plays at least a contributory role in this response as illustrated by the rise in messenger RNA for both renin and angiotensin substrate in the renal cortex following a low sodium diet [",
"    <a class=\"abstract\" href=\"UTD.htm?13/25/13720/abstract/55\">",
"     55",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    These changes in volume are primarily sensed at one or more of three sites, leading to the activation of effectors which govern the release of renin (",
"    <a class=\"graphic graphic_figure graphicRef65116 \" href=\"UTD.htm?14/19/14654\">",
"     figure 2",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?13/25/13720/abstract/1\">",
"     1",
"    </a>",
"    ]: (1) baroreceptors (or stretch receptors) in the wall of the afferent arteriole [",
"    <a class=\"abstract\" href=\"UTD.htm?13/25/13720/abstract/56\">",
"     56",
"    </a>",
"    ]; (2) the cardiac and arterial baroreceptors, which regulate sympathetic neural activity and the level of circulating catecholamines, both of which enhance renin secretion via the &szlig;1-adrenergic receptors [",
"    <a class=\"abstract\" href=\"UTD.htm?13/25/13720/abstract/57,58\">",
"     57,58",
"    </a>",
"    ]; and (3) the cells of the macula densa in the early distal tubule (",
"    <a class=\"graphic graphic_figure graphicRef69949 \" href=\"UTD.htm?31/9/31889\">",
"     figure 1",
"    </a>",
"    ), which appear to be stimulated by a reduction in chloride delivery, particularly in the Cl- concentration in the fluid delivered to this site [",
"    <a class=\"abstract\" href=\"UTD.htm?13/25/13720/abstract/59,60\">",
"     59,60",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Baroreceptors",
"    </span>",
"    &nbsp;&mdash;&nbsp;The baroreceptors respond to changes in stretch in the afferent arteriolar wall. The ensuing alterations in renin release appear to be mediated by enhanced calcium entry into the cells when renal perfusion pressure is increased [",
"    <a class=\"abstract\" href=\"UTD.htm?13/25/13720/abstract/61\">",
"     61",
"    </a>",
"    ] and by the local release of prostanoids, particularly prostacyclin, when renal perfusion pressure is reduced [",
"    <a class=\"abstract\" href=\"UTD.htm?13/25/13720/abstract/57,62,63\">",
"     57,62,63",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Macula densa",
"    </span>",
"    &nbsp;&mdash;&nbsp;The macula densa dependence upon Cl- is related to the characteristics of the Na+-K+-2Cl- cotransporter in the luminal membrane of the thick ascending limb and macula densa that promotes the entry of these ions into the cell (",
"    <a class=\"graphic graphic_figure graphicRef75301 \" href=\"UTD.htm?30/62/31725\">",
"     figure 4",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?13/25/13720/abstract/59,64,65\">",
"     59,64,65",
"    </a>",
"    ]. The activity of this transporter is maximally stimulated at low concentrations of Na+ and K+, but is regulated within the physiologic range by alterations in the concentration of Cl- (",
"    <a class=\"graphic graphic_figure graphicRef54349 \" href=\"UTD.htm?0/56/909\">",
"     figure 5",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?13/25/13720/abstract/59\">",
"     59",
"    </a>",
"    ]. As an example, the decrease in proximal NaCl reabsorption that is seen with volume expansion will enhance the Cl- concentration at the macula densa, thereby reducing renin secretion. In comparison, the administration of Na+ with other anions (bicarbonate, acetate) has little effect, since the tubular fluid Cl- concentration will not rise [",
"    <a class=\"abstract\" href=\"UTD.htm?13/25/13720/abstract/59,60\">",
"     59,60",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The importance of Na+-K+-2Cl- cotransport in the macula densa may explain the ability of loop diuretics to specifically enhance renin release. Although any diuretic can increase renin release by inducing volume depletion, the loop diuretics directly inhibit the Na+-K+-2Cl- transporter (see Chap. 15); as a result, less Cl- is reabsorbed, thereby stimulating renin secretion [",
"    <a class=\"abstract\" href=\"UTD.htm?13/25/13720/abstract/59,66\">",
"     59,66",
"    </a>",
"    ]. The thiazide-type diuretics, on the other hand, inhibit Na+-Cl- cotransport primarily in the distal tubule and connecting segment; they do not directly affect the macula densa or renin release [",
"    <a class=\"abstract\" href=\"UTD.htm?13/25/13720/abstract/66\">",
"     66",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Two factors may contribute to the mechanism by which the macula densa affects renin secretion: adenosine and PGE2 [",
"    <a class=\"abstract\" href=\"UTD.htm?13/25/13720/abstract/57,62,67,68\">",
"     57,62,67,68",
"    </a>",
"    ]. As an example, adenosine may mediate at least part of the suppression of renin secretion when NaCl delivery to the macula densa is increased [",
"    <a class=\"abstract\" href=\"UTD.htm?13/25/13720/abstract/67,68\">",
"     67,68",
"    </a>",
"    ]. The adenosine required to mediate this response may be derived from the breakdown of ATP that occurs as the increase in delivery leads to enhanced local NaCl reabsorption. On the other hand, the rise in renin release seen when NaCl delivery is reduced (as in hypovolemic states) may be mediated by increased production of PGE2 and PGI2, effects mediated by cyclooxygenase-2 [",
"    <a class=\"abstract\" href=\"UTD.htm?13/25/13720/abstract/62,69-72\">",
"     62,69-72",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The interaction between the renin-angiotensin system and prostaglandins may seem confusing, since each stimulates the secretion of the other [",
"    <a class=\"abstract\" href=\"UTD.htm?13/25/13720/abstract/51,52,57,63\">",
"     51,52,57,63",
"    </a>",
"    ] and they induce opposing vascular actions &mdash; vasoconstriction with angiotensin II and vasodilation with most prostaglandins. However, angiotensin II is a systemic vasoconstrictor, whereas the prostaglandins act locally, because they are rapidly metabolized when they enter the systemic circulation. Thus, the net effect of simultaneous renal secretion of angiotensin II and prostaglandins is that angiotensin II can cause systemic vasoconstriction and raise the blood pressure, while the prostaglandins minimize the degree of renal vasoconstriction, thereby maintaining renal blood flow and GFR [",
"    <a class=\"abstract\" href=\"UTD.htm?13/25/13720/abstract/52\">",
"     52",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The contributions of the three major factors governing renin release can be appreciated from the response to hypovolemia. The decrease in volume initially lowers the blood pressure, which diminishes the stretch in the afferent arteriole, increases sympathetic activity, and reduces NaCl delivery to the macula densa (in part by enhancing proximal reabsorption) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/25/13720/abstract/59\">",
"     59",
"    </a>",
"    ]. Each of these changes then promotes renin secretion. This response can be largely abolished by inhibiting its mediators with a combination of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/50/36649?source=see_link\">",
"     indomethacin",
"    </a>",
"    (which inhibits prostaglandin synthesis) and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/49/8986?source=see_link\">",
"     propranolol",
"    </a>",
"    (a &szlig;-adrenergic blocker) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/25/13720/abstract/73\">",
"     73",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    On the other hand, renin release is diminished by volume expansion (as with a high Na+ intake). In addition to reversal of the above sequence, atrial natriuretic peptide also may contribute by directly impairing the secretion of both renin and aldosterone [",
"    <a class=\"abstract\" href=\"UTD.htm?13/25/13720/abstract/74\">",
"     74",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/20/36163?source=see_link\">",
"     \"Chapter 2C: Determinants of GFR\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    (From Rose, BD, Post, TW, Clinical Physiology of Acid-Base and Electrolyte Disorders, 5th ed, McGraw-Hill, New York, 2001.)",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/25/13720/abstract/1\">",
"      Sk&oslash;tt O, Jensen BL. Cellular and intrarenal control of renin secretion. Clin Sci (Lond) 1993; 84:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/25/13720/abstract/2\">",
"      Toffelmire EB, Slater K, Corvol P, et al. Response of plasma prorenin and active renin to chronic and acute alterations of renin secretion in normal humans. Studies using a direct immunoradiometric assay. J Clin Invest 1989; 83:679.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/25/13720/abstract/3\">",
"      Gomez RA, Chevalier RL, Everett AD, et al. Recruitment of renin gene-expressing cells in adult rat kidneys. Am J Physiol 1990; 259:F660.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/25/13720/abstract/4\">",
"      Hosoi M, Kim S, Takada T, et al. Effects of prorenin on blood pressure and plasma renin concentrations in stroke-prone spontaneously hypertensive rats. Am J Physiol 1992; 262:E234.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/25/13720/abstract/5\">",
"      Shaw KJ, Do YS, Kjos S, et al. Human decidua is a major source of renin. J Clin Invest 1989; 83:2085.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/25/13720/abstract/6\">",
"      Nushiro N, Ito S, Carretero OA. Renin release from microdissected superficial, midcortical, and juxtamedullary afferent arterioles in rabbits. Kidney Int 1990; 38:426.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/25/13720/abstract/7\">",
"      Naftilan AJ, Zuo WM, Inglefinger J, et al. Localization and differential regulation of angiotensinogen mRNA expression in the vessel wall. J Clin Invest 1991; 87:1300.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/25/13720/abstract/8\">",
"      Schunkert H, Ingelfinger JR, Hirsch AT, et al. Evidence for tissue-specific activation of renal angiotensinogen mRNA expression in chronic stable experimental heart failure. J Clin Invest 1992; 90:1523.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/25/13720/abstract/9\">",
"      Wagner, C, Jensen, BL, Kramer, BK, Kurtz, A. Control of the renal renin system by local factors. Kidney Int 1998; 54 (Suppl 67):S78.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/25/13720/abstract/10\">",
"      Dzau VJ. Tissue renin-angiotensin system in myocardial hypertrophy and failure. Arch Intern Med 1993; 153:937.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/25/13720/abstract/11\">",
"      Kifor I, Moore TJ, Fallo F, et al. Potassium-stimulated angiotensin release from superfused adrenal capsules and enzymatically dispersed cells of the zona glomerulosa. Endocrinology 1991; 129:823.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/25/13720/abstract/12\">",
"      Wilkes BM, Mento PF, Pearl AR, et al. Plasma angiotensins in anephric humans: evidence for an extrarenal angiotensin system. J Cardiovasc Pharmacol 1991; 17:419.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/25/13720/abstract/13\">",
"      Ingelfinger JR, Zuo WM, Fon EA, et al. In situ hybridization evidence for angiotensinogen messenger RNA in the rat proximal tubule. An hypothesis for the intrarenal renin angiotensin system. J Clin Invest 1990; 85:417.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/25/13720/abstract/14\">",
"      Yanagawa N. Potential role of local luminal angiotensin II in proximal tubule sodium transport. Kidney Int 1991; 39 (suppl 32):S-33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/25/13720/abstract/15\">",
"      Seikaly MG, Arant BS Jr, Seney FD Jr. Endogenous angiotensin concentrations in specific intrarenal fluid compartments of the rat. J Clin Invest 1990; 86:1352.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/25/13720/abstract/16\">",
"      Redgrave J, Rabinowe S, Hollenberg NK, Williams GH. Correction of abnormal renal blood flow response to angiotensin II by converting enzyme inhibition in essential hypertensives. J Clin Invest 1985; 75:1285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/25/13720/abstract/17\">",
"      Oliver JA, Sciacca RR. Local generation of angiotensin II as a mechanism of regulation of peripheral vascular tone in the rat. J Clin Invest 1984; 74:1247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/25/13720/abstract/18\">",
"      Kessler SP, deS Senanayake P, Scheidemantel TS, et al. Maintenance of normal blood pressure and renal functions are independent effects of angiotensin-converting enzyme. J Biol Chem 2003; 278:21105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/25/13720/abstract/19\">",
"      Wenting GJ, de Bruyn JH, Man in't Veld AJ, et al. Hemodynamic effects of captopril in essential hypertension, renovascular hypertension and cardiac failure: correlations with short- and long-term effects on plasma renin. Am J Cardiol 1982; 49:1453.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/25/13720/abstract/20\">",
"      Bader M, Zhao Y, Sander M, et al. Role of tissue renin in the pathophysiology of hypertension in TGR(mREN2)27 rats. Hypertension 1992; 19:681.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/25/13720/abstract/21\">",
"      Hilgers KF, Peters J, Veelken R, et al. Increased vascular angiotensin formation in female rats harboring the mouse Ren-2 gene. Hypertension 1992; 19:687.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/25/13720/abstract/22\">",
"      Donoghue M, Hsieh F, Baronas E, et al. A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1-9. Circ Res 2000; 87:E1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/25/13720/abstract/23\">",
"      Crackower MA, Sarao R, Oudit GY, et al. Angiotensin-converting enzyme 2 is an essential regulator of heart function. Nature 2002; 417:822.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/25/13720/abstract/24\">",
"      Boehm M, Nabel EG. Angiotensin-converting enzyme 2--a new cardiac regulator. N Engl J Med 2002; 347:1795.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/25/13720/abstract/25\">",
"      Ichikawi I, Harris RC. Angiotensin actions in the kidney: renewed insight into the old hormone. Kidney Int 1991; 40:583.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/25/13720/abstract/26\">",
"      Goodfriend TL, Elliott ME, Catt KJ. Angiotensin receptors and their antagonists. N Engl J Med 1996; 334:1649.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/25/13720/abstract/27\">",
"      Murphy TJ, Alexander RW, Griendling KK, et al. Isolation of a cDNA encoding the vascular type-1 angiotensin II receptor. Nature 1991; 351:233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/25/13720/abstract/28\">",
"      Quan A, Baum M. Effect of luminal angiotensin II receptor antagonists on proximal tubule transport. Am J Hypertens 1999; 12:499.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/25/13720/abstract/29\">",
"      Stoll M, Steckelings UM, Paul M, et al. The angiotensin AT2-receptor mediates inhibition of cell proliferation in coronary endothelial cells. J Clin Invest 1995; 95:651.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/25/13720/abstract/30\">",
"      Cogan MG. Angiotensin II: a powerful controller of sodium transport in the early proximal tubule. Hypertension 1990; 15:451.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/25/13720/abstract/31\">",
"      Quan A, Baum M. Regulation of proximal tubule transport by angiotensin II. Semin Nephrol 1997; 17:423.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/25/13720/abstract/32\">",
"      Liu FY, Cogan MG. Angiotensin II stimulates early proximal bicarbonate absorption in the rat by decreasing cyclic adenosine monophosphate. J Clin Invest 1989; 84:83.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/25/13720/abstract/33\">",
"      Liu FY, Cogan MG. Role of protein kinase C in proximal bicarbonate absorption and angiotensin signaling. Am J Physiol 1990; 258:F927.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/25/13720/abstract/34\">",
"      Geibel J, Giebisch G, Boron WF. Angiotensin II stimulates both Na(+)-H+ exchange and Na+/HCO3- cotransport in the rabbit proximal tubule. Proc Natl Acad Sci U S A 1990; 87:7917.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/25/13720/abstract/35\">",
"      Cogan MG, Xie MH, Liu FY, et al. Effects of DuP 753 on proximal nephron and renal transport. Am J Hypertens 1991; 4:315S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/25/13720/abstract/36\">",
"      Scholz H, Kurtz A. Role of protein kinase C in renal vasoconstriction caused by angiotensin II. Am J Physiol 1990; 259:C421.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/25/13720/abstract/37\">",
"      Zimmerman JB, Robertson D, Jackson EK. Angiotensin II-noradrenergic interactions in renovascular hypertensive rats. J Clin Invest 1987; 80:443.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/25/13720/abstract/38\">",
"      Purdy RE, Weber MA. Angiotensin II amplification of alpha-adrenergic vasoconstriction: role of receptor reserve. Circ Res 1988; 63:748.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/25/13720/abstract/39\">",
"      Clemson B, Gaul L, Gubin SS, et al. Prejunctional angiotensin II receptors. Facilitation of norepinephrine release in the human forearm. J Clin Invest 1994; 93:684.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/25/13720/abstract/40\">",
"      Watkins L Jr, Burton JA, Haber E, et al. The renin-angiotensin-aldosterone system in congestive failure in conscious dogs. J Clin Invest 1976; 57:1606.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/25/13720/abstract/41\">",
"      Dzau VJ. Renal and circulatory mechanisms in congestive heart failure. Kidney Int 1987; 31:1402.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/25/13720/abstract/42\">",
"      Schroeder ET, Anderson GH, Goldman SH, Streeten DH. Effect of blockade of angiotensin II on blood pressure, renin and aldosterone in cirrhosis. Kidney Int 1976; 9:511.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/25/13720/abstract/43\">",
"      Rasmussen H. The calcium messenger system (2). N Engl J Med 1986; 314:1164.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/25/13720/abstract/44\">",
"      Stern N, Golub M, Nozawa K, et al. Selective inhibition of angiotensin II-mediated vasoconstriction by lipoxygenase blockade. Am J Physiol 1989; 257:H434.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/25/13720/abstract/45\">",
"      Myers BD, Deen WM, Brenner BM. Effects of norepinephrine and angiotensin II on the determinants of glomerular ultrafiltration and proximal tubule fluid reabsorption in the rat. Circ Res 1975; 37:101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/25/13720/abstract/46\">",
"      Yuan BH, Robinette JB, Conger JD. Effect of angiotensin II and norepinephrine on isolated rat afferent and efferent arterioles. Am J Physiol 1990; 258:F741.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/25/13720/abstract/47\">",
"      Heyeraas KJ, Aukland K. Interlobular arterial resistance: influence of renal arterial pressure and angiotensin II. Kidney Int 1987; 31:1291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/25/13720/abstract/48\">",
"      Wilcox CS, Welch WJ, Snellen H. Thromboxane mediates renal hemodynamic response to infused angiotensin II. Kidney Int 1991; 40:1090.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/25/13720/abstract/49\">",
"      Denton KM, Fennessy PA, Alcorn D, Anderson WP. Morphometric analysis of the actions of angiotensin II on renal arterioles and glomeruli. Am J Physiol 1992; 262:F367.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/25/13720/abstract/50\">",
"      Carmines PK, Mitchell KD, Navar LG. Effect of calcium antagonists on renal hemodynamics and glomerular function. Kidney Int Suppl 1992; 36:S-43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/25/13720/abstract/51\">",
"      Stahl RA, Paravicini M, Schollmeyer P. Angiotensin II stimulation of prostaglandin E2 and 6-keto-F1 alpha formation by isolated human glomeruli. Kidney Int 1984; 26:30.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/25/13720/abstract/52\">",
"      Oliver JA, Pinto J, Sciacca RR, Cannon PJ. Increased renal secretion of norepinephrine and prostaglandin E2 during sodium depletion in the dog. J Clin Invest 1980; 66:748.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/25/13720/abstract/53\">",
"      Vallotton MB, Gerber-Wicht C, Dolci W, W&uuml;thrich RP. Interaction of vasopressin and angiotensin II in stimulation of prostacyclin synthesis in vascular smooth muscle cells. Am J Physiol 1989; 257:E617.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/25/13720/abstract/54\">",
"      Ichikawa I, Pfeffer JM, Pfeffer MA, et al. Role of angiotensin II in the altered renal function of congestive heart failure. Circ Res 1984; 55:669.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/25/13720/abstract/55\">",
"      Ingelfinger JR, Pratt RE, Ellison K, Dzau VJ. Sodium regulation of angiotensinogen mRNA expression in rat kidney cortex and medulla. J Clin Invest 1986; 78:1311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/25/13720/abstract/56\">",
"      Bock HA, Hermle M, Brunner FP, Thiel G. Pressure dependent modulation of renin release in isolated perfused glomeruli. Kidney Int 1992; 41:275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/25/13720/abstract/57\">",
"      Freeman RH, Davis JO, Villarreal D. Role of renal prostaglandins in the control of renin release. Circ Res 1984; 54:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/25/13720/abstract/58\">",
"      Kopp U, DiBona GF. Interaction of renal beta 1-adrenoceptors and prostaglandins in reflex renin release. Am J Physiol 1983; 244:F418.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/25/13720/abstract/59\">",
"      Lorenz JN, Weihprecht H, Schnermann J, et al. Renin release from isolated juxtaglomerular apparatus depends on macula densa chloride transport. Am J Physiol 1991; 260:F486.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/25/13720/abstract/60\">",
"      Kotchen TA, Luke RG, Ott CE, et al. Effect of chloride on renin and blood pressure responses to sodium chloride. Ann Intern Med 1983; 98:817.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/25/13720/abstract/61\">",
"      Jones-Dombi T, Churchill P. The baroreceptor mechanism for controlling renin secretion: effect of calcium channel blockers. J Pharmacol Exp Ther 1993; 266:274.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/25/13720/abstract/62\">",
"      Ito S, Carretero OA, Abe K, et al. Effect of prostanoids on renin release from rabbit afferent arterioles with and without macula densa. Kidney Int 1989; 35:1138.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/25/13720/abstract/63\">",
"      Data JL, Gerber JG, Crump WJ, et al. The prostaglandin system. A role in canine baroreceptor control of renin release. Circ Res 1978; 42:454.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/25/13720/abstract/64\">",
"      Lapointe JY, Bell PD, Cardinal J. Direct evidence for apical Na+:2Cl-:K+ cotransport in macula densa cells. Am J Physiol 1990; 258:F1466.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/25/13720/abstract/65\">",
"      Schlatter E, Salomonsson M, Persson AE, Greger R. Macula densa cells sense luminal NaCl concentration via furosemide sensitive Na+2Cl-K+ cotransport. Pflugers Arch 1989; 414:286.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/25/13720/abstract/66\">",
"      Mart&iacute;nez-Maldonado M, Gely R, Tapia E, Benabe JE. Role of macula densa in diuretics-induced renin release. Hypertension 1990; 16:261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/25/13720/abstract/67\">",
"      Spielman WS, Arend LJ. Adenosine receptors and signaling in the kidney. Hypertension 1991; 17:117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/25/13720/abstract/68\">",
"      Weihprecht H, Lorenz JN, Schnermann J, et al. Effect of adenosine1-receptor blockade on renin release from rabbit isolated perfused juxtaglomerular apparatus. J Clin Invest 1990; 85:1622.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/25/13720/abstract/69\">",
"      Greenberg SG, Lorenz JN, He XR, et al. Effect of prostaglandin synthesis inhibition on macula densa-stimulated renin secretion. Am J Physiol 1993; 265:F578.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/25/13720/abstract/70\">",
"      Peti-Peterdi J, Komlosi P, Fuson AL, et al. Luminal NaCl delivery regulates basolateral PGE2 release from macula densa cells. J Clin Invest 2003; 112:76.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/25/13720/abstract/71\">",
"      Traynor TR, Smart A, Briggs JP, Schnermann J. Inhibition of macula densa-stimulated renin secretion by pharmacological blockade of cyclooxygenase-2. Am J Physiol 1999; 277:F706.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/25/13720/abstract/72\">",
"      Fujino T, Nakagawa N, Yuhki K, et al. Decreased susceptibility to renovascular hypertension in mice lacking the prostaglandin I2 receptor IP. J Clin Invest 2004; 114:805.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/25/13720/abstract/73\">",
"      Henrich WL, Schrier RW, Berl T. Mechanisms of renin secretion during hemorrhage in the dog. J Clin Invest 1979; 64:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/25/13720/abstract/74\">",
"      Cuneo RC, Espiner EA, Nicholls MG, et al. Effect of physiological levels of atrial natriuretic peptide on hormone secretion: inhibition of angiotensin-induced aldosterone secretion and renin release in normal man. J Clin Endocrinol Metab 1987; 65:765.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7277 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-218.189.88.190-75239E8C8F-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_25_13720=[""].join("\n");
var outline_f13_25_13720=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      RENIN RELEASE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      ANGIOTENSIN CONVERTING ENZYME",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Local renin-angiotensin systems",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Angiotensin converting enzyme 2",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      ACTIONS OF ANGIOTENSIN II",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Renal sodium and water reabsorption",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Systemic vasoconstriction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Regulation of GFR",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      CONTROL OF RENIN SECRETION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Baroreceptors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Macula densa",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEPH/7277\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEPH/7277|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?31/9/31889\" title=\"figure 1\">",
"      Macula densa",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?14/19/14654\" title=\"figure 2\">",
"      Renin release",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?12/63/13296\" title=\"figure 3\">",
"      Renal circulation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?30/62/31725\" title=\"figure 4\">",
"      Loop of Henle transport",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?0/56/909\" title=\"figure 5\">",
"      Cl dependence of renin release",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/20/36163?source=related_link\">",
"      Chapter 2C: Determinants of GFR",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/46/10985?source=related_link\">",
"      Chapter 2D: Regulation of GFR and renal plasma flow",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/33/19988?source=related_link\">",
"      Chapter 6A: Mechanisms of hormone action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/20/2376?source=related_link\">",
"      Chapter 6C: Aldosterone",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/60/966?source=related_link\">",
"      Chapter 6E: Prostaglandins and the kidney",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/45/7893?source=related_link\">",
"      Chapter 8A: Effective circulating volume and the steady state",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f13_25_13721="Autoimmune pancreatitis patient with IgG4 immunostaining";
var content_f13_25_13721=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F76767&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F76767&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Autoimmune pancreatitis patient with IgG4 immunostaining",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 361px; height: 583px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Histological findings for the pancreas in an autoimmune pancreatitis patient showing (A) dense lymphoplasmacytic infiltration and storiform fibrosis (HE staining), and (B) abundant infiltration of IgG4-positive plasma cells (IgG4 immunostaining).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Takuma K, Kamisawa T, Igarashi Y. Autoimmune pancreatitis and IgG4-related sclerosing cholangitis. Curr Opinion Rheum 2011; 23:80. Copyright &copy; 2011 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_25_13721=[""].join("\n");
var outline_f13_25_13721=null;
var title_f13_25_13722="Epidemiology, clinical manifestations, and treatment of cytomegalovirus infection in immunocompetent hosts";
var content_f13_25_13722=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Epidemiology, clinical manifestations, and treatment of cytomegalovirus infection in immunocompetent hosts",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?13/25/13722/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/25/13722/contributors\">",
"     Timothy J Friel, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?13/25/13722/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/25/13722/contributors\">",
"     Martin S Hirsch, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?13/25/13722/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/25/13722/contributors\">",
"     Anna R Thorner, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?13/25/13722/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 5, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The spectrum of human illness caused by cytomegalovirus (CMV) is diverse and mostly dependent on the host. CMV infections in immunocompromised patients cause substantial morbidity and mortality, especially among transplant recipients and those infected with the human immunodeficiency virus (HIV). Infection in the immunocompetent host is generally asymptomatic or may present as a mononucleosis syndrome. However, occasionally primary CMV infection can lead to severe organ specific complications with significant morbidity and mortality [",
"    <a class=\"abstract\" href=\"UTD.htm?13/25/13722/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. Infection of pregnant women, even if asymptomatic, is occasionally associated with the syndrome of congenital CMV in newborns. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/21/12634?source=see_link\">",
"     \"Cytomegalovirus infection in pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The manifestations of CMV in the immunocompetent host will be reviewed here. The diagnosis and treatment of CMV infections in the immunocompetent host is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/25/8597?source=see_link\">",
"     \"Diagnosis of cytomegalovirus\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     INFECTION, LATENCY AND REACTIVATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Like other members of the Herpesvirus family, cytomegalovirus (CMV) establishes latent infection after the resolution of acute infection. Productive (lytic) infection leads to the synthesis of immediate-early, early, and late viral proteins [",
"    <a class=\"abstract\" href=\"UTD.htm?13/25/13722/abstract/3\">",
"     3",
"    </a>",
"    ]. Viral DNA has been detected in monocytes, dendritic cells, megakaryocytes, and myeloid progenitor cells in the bone marrow [",
"    <a class=\"abstract\" href=\"UTD.htm?13/25/13722/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Secondary, symptomatic disease may present later in the life of the host, reflecting one of two possibilities: reactivation of latent CMV or reinfection with a novel exogenous strain [",
"    <a class=\"abstract\" href=\"UTD.htm?13/25/13722/abstract/5\">",
"     5",
"    </a>",
"    ]. One prospective study of 205 postpartum seropositive wo`men found that approximately one-third of the participants had CMV reinfection over a mean of 35 months of follow-up [",
"    <a class=\"abstract\" href=\"UTD.htm?13/25/13722/abstract/5\">",
"     5",
"    </a>",
"    ]. In this study, reinfection was determined by the appearance of new antibodies with strain-specific binding to unique polymorphic determinants on the envelope glycoprotein of cytomegalovirus. A similar frequency of reinfection was noted in a study of healthy seropositive women over 30 months of follow-up; furthermore, CMV viremia and viruria were common, suggesting that naturally acquired immunity to CMV does not alter shedding patterns [",
"    <a class=\"abstract\" href=\"UTD.htm?13/25/13722/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Reactivation of CMV may occur at any time during the life of the human host, although the risk is higher in the setting of systemic immunosuppression, either iatrogenic or secondary to underlying medical conditions, such as the acquired immunodeficiency syndrome (AIDS).",
"   </p>",
"   <p>",
"    The bulk of CMV-related disease in immunocompetent hosts is related to primary infection. The differentiation between endogenous reactivation and exogenous reinfection is difficult in clinical practice.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     IMMUNOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;In immunocompetent hosts, T cells play an important role in controlling viral replication and disease, but do not eliminate the virus completely. High frequencies of specific cytomegalovirus (CMV) CD4+ and CD8+ T cell responses have been demonstrated in immunocompetent hosts [",
"    <a class=\"abstract\" href=\"UTD.htm?13/25/13722/abstract/7,8\">",
"     7,8",
"    </a>",
"    ]. Using cytokine flow cytometry and overlapping peptides comprising more than 200 CMV open reading frames, researchers have been able to demonstrate that 151 ORFs are immunogenic for CD4+ and CD8+ T cells [",
"    <a class=\"abstract\" href=\"UTD.htm?13/25/13722/abstract/8\">",
"     8",
"    </a>",
"    ]. Furthermore, T cell responses comprise approximately 10 percent of both the CD4+ and CD8+ memory compartments in peripheral blood [",
"    <a class=\"abstract\" href=\"UTD.htm?13/25/13722/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The proportion of humans with evidence of prior CMV infection varies throughout the world, with seroprevalence rates ranging between 40 to 100 percent of the adult population [",
"    <a class=\"abstract\" href=\"UTD.htm?13/25/13722/abstract/9\">",
"     9",
"    </a>",
"    ]. Seroprevalence generally correlates inversely with a country's socioeconomic development, with highest rates observed in developing countries throughout Africa and Asia [",
"    <a class=\"abstract\" href=\"UTD.htm?13/25/13722/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The prevalence of CMV-specific antibody increases with age [",
"    <a class=\"abstract\" href=\"UTD.htm?13/25/13722/abstract/11-14\">",
"     11-14",
"    </a>",
"    ]. As an example, in a study from Finland, the seroprevalence rates were 47 percent in 10 to 12 year olds, 68 percent in 15 to 35 year olds, and 81 percent among 36 to 60 year olds [",
"    <a class=\"abstract\" href=\"UTD.htm?13/25/13722/abstract/11\">",
"     11",
"    </a>",
"    ]. In a US-based study, CMV seroprevalence increased from 36 percent in 6 to 11 year olds to 91 percent in those aged &gt;80 years [",
"    <a class=\"abstract\" href=\"UTD.htm?13/25/13722/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    CMV seroprevalence also varies by race and ethnicity; in one US study among individuals aged 6 to 49 years, seroprevalence was 40 percent in non-Hispanic whites, 71 percent in non-Hispanic blacks, and 77 percent in Mexican Americans [",
"    <a class=\"abstract\" href=\"UTD.htm?13/25/13722/abstract/13\">",
"     13",
"    </a>",
"    ]. Another study demonstrated that the incidence of new CMV infections occurred at an earlier age among non-Hispanic blacks (16.3 years) and Mexican Americans (17.5 years) compared with non-Hispanic whites (29.3 years) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/25/13722/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the United States-based study mentioned above, other factors associated with CMV seropositivity included female sex, foreign birthplace, low household income, household crowding, and low household education [",
"    <a class=\"abstract\" href=\"UTD.htm?13/25/13722/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     TRANSMISSION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cytomegalovirus (CMV) has been cultured from multiple sites, including urine, blood, throat, cervix, semen, stool, tears, and breast milk [",
"    <a class=\"abstract\" href=\"UTD.htm?13/25/13722/abstract/16,17\">",
"     16,17",
"    </a>",
"    ]. Transmission can occur via multiple routes:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Sexual &mdash; Sexual modes of transmission are supported by evidence that seroprevalence rates are higher among patients with multiple sexual partners or a history of prior sexually transmitted diseases and that virus can be detected in the genital tract [",
"      <a class=\"abstract\" href=\"UTD.htm?13/25/13722/abstract/18\">",
"       18",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Close contacts &mdash; Seroconversion is well-described among family members [",
"      <a class=\"abstract\" href=\"UTD.htm?13/25/13722/abstract/19\">",
"       19",
"      </a>",
"      ] and children in daycare centers [",
"      <a class=\"abstract\" href=\"UTD.htm?13/25/13722/abstract/20\">",
"       20",
"      </a>",
"      ]. Contacts are probably exposed to virus shed from the upper respiratory tract and urine. Protracted viral shedding is much more common among children than immunocompetent adults.",
"     </li>",
"     <li>",
"      Blood or tissue exposure &mdash; Transmission of CMV following transfusion of blood products [",
"      <a class=\"abstract\" href=\"UTD.htm?13/25/13722/abstract/21,22\">",
"       21,22",
"      </a>",
"      ] and transplantation of organs from seropositive donors is well documented. In a study of more than 600 immunocompetent CMV-seronegative blood product recipients, CMV seroconversion was demonstrated in 0.9 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?13/25/13722/abstract/23\">",
"       23",
"      </a>",
"      ]. The estimated risk of transfusion per unit of blood was 0.38 percent. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?24/5/24665?source=see_link\">",
"       \"Leukoreduction to prevent complications of blood transfusion\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/2/29738?source=see_link\">",
"       \"Cytomegalovirus infection in renal transplant recipients\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Occupational &mdash; Susceptible workers in daycare centers and other facilities with many children are at risk of seroconversion [",
"      <a class=\"abstract\" href=\"UTD.htm?13/25/13722/abstract/20\">",
"       20",
"      </a>",
"      ]. Healthcare workers may also be exposed, but the actual risk of seroconversion among susceptible individuals appears to be low [",
"      <a class=\"abstract\" href=\"UTD.htm?13/25/13722/abstract/24\">",
"       24",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Perinatal &mdash; Neonates and infants may be infected with CMV in utero during maternal viremia, during exposure to secretions in the birth canal, or postnatally from breast milk. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?12/21/12634?source=see_link\">",
"       \"Cytomegalovirus infection in pregnancy\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    There is evidence that CMV can survive in saliva on environmental surfaces for variable periods, depending on the surface. In one study, CMV in filtered human saliva was applied to environmental surfaces and samples were evaluated by culture and real-time polymerase chain reaction [",
"    <a class=\"abstract\" href=\"UTD.htm?13/25/13722/abstract/25\">",
"     25",
"    </a>",
"    ]. CMV was found to be viable on metal and wood to one hour, on glass and plastic to three hours, and on rubber, cloth, and cracker to six hours. Dry surfaces were less likely to yield viable virus during environmental sampling than wet surfaces.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     CMV MONONUCLEOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;A syndrome resembling infectious mononucleosis is the most common presentation of symptomatic cytomegalovirus (CMV) infection in immunocompetent adults. Classic mononucleosis is an illness characterized by significant, often protracted fevers, and lassitude in the setting of absolute lymphocytosis and atypical lymphocytes [",
"    <a class=\"abstract\" href=\"UTD.htm?13/25/13722/abstract/16\">",
"     16",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H8\">",
"     'Laboratory abnormalities'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Infectious mononucleosis is most commonly caused by Epstein-Barr virus (EBV) and is diagnosed by the presence of heterophile antibody [",
"    <a class=\"abstract\" href=\"UTD.htm?13/25/13722/abstract/16\">",
"     16",
"    </a>",
"    ]. When the patient with symptoms and signs of classic infectious mononucleosis is heterophile-negative, then the most likely etiology is CMV infection and additional diagnostic testing should be pursued (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/25/8597?source=see_link\">",
"     \"Diagnosis of cytomegalovirus\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/18/31018?source=see_link\">",
"     \"Infectious mononucleosis in adults and adolescents\"",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    A landmark study of 494 patients with infectious mononucleosis was significant for the following results [",
"    <a class=\"abstract\" href=\"UTD.htm?13/25/13722/abstract/26\">",
"     26",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      79 percent of patients had infectious mononucleosis secondary to Epstein-Barr virus (EBV) as diagnosed by heterophile antibody.",
"     </li>",
"     <li>",
"      73 patients were heterophile antibody negative; almost half of these patients had CMV infection as defined by rising complement-fixing antibodies. It was concluded that CMV mononucleosis represented primary infection in previously seronegative patients.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    CMV mononucleosis can be accompanied by dermatologic manifestations in approximately one-third of patients including macular, papular, maculopapular, rubelliform, morbilliform, and scarlatiniform eruptions [",
"    <a class=\"abstract\" href=\"UTD.htm?13/25/13722/abstract/1\">",
"     1",
"    </a>",
"    ]. Exposure to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/51/13112?source=see_link\">",
"     ampicillin",
"    </a>",
"    or related beta-lactam antibiotics has also been associated with the development of a characteristic generalized maculopapular rash in patients with CMV mononucleosis, analogous to that seen with EBV [",
"    <a class=\"abstract\" href=\"UTD.htm?13/25/13722/abstract/27,28\">",
"     27,28",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Differences between EBV and CMV mononucleosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;While the syndromes caused by EBV and CMV are similar, several important distinctions warrant emphasis.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The mononucleosis syndrome associated with CMV infection has been described as \"typhoidal\" in presentation, since systemic symptoms and fever predominate and signs of enlarged cervical nodes and splenomegaly are not as commonly seen as they are in EBV [",
"      <a class=\"abstract\" href=\"UTD.htm?13/25/13722/abstract/26\">",
"       26",
"      </a>",
"      ]. As an example, in studies in Israel and the United States, cervical lymphadenopathy occurred in 13 to 17 percent of patients [",
"      <a class=\"abstract\" href=\"UTD.htm?13/25/13722/abstract/2,29\">",
"       2,29",
"      </a>",
"      ]. These observations contrast sharply with the finding of diffuse lymphadenopathy in more than 80 percent of patients with classic EBV-related mononucleosis [",
"      <a class=\"abstract\" href=\"UTD.htm?13/25/13722/abstract/16\">",
"       16",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      However, children with CMV are more likely than adults to present with cervical lymphadenopathy. In one age-based comparative study of CMV in patients without underlying immunosuppression, cervical lymphadenopathy was documented in 86 percent of children less than 12 years compared to only six percent in adults [",
"      <a class=\"abstract\" href=\"UTD.htm?13/25/13722/abstract/30\">",
"       30",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Unlike EBV, CMV uncommonly causes exudative tonsillopharyngitis [",
"      <a class=\"abstract\" href=\"UTD.htm?13/25/13722/abstract/26,31\">",
"       26,31",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Adults with CMV-related mononucleosis tend to be somewhat older than those with EBV infection at the time of clinical presentation [",
"      <a class=\"abstract\" href=\"UTD.htm?13/25/13722/abstract/16,26\">",
"       16,26",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Laboratory abnormalities",
"    </span>",
"    &nbsp;&mdash;&nbsp;Two cardinal hematologic abnormalities help to define the syndrome of mononucleosis: an absolute lymphocytosis with greater than 50 percent mononuclear cells and the presence of more than 10 percent atypical lymphocytes on peripheral blood smear [",
"    <a class=\"abstract\" href=\"UTD.htm?13/25/13722/abstract/1,2,16\">",
"     1,2,16",
"    </a>",
"    ]. These laboratory abnormalities do not differ significantly among patients with different etiologies of mononucleosis. Extreme elevations of the peripheral white blood cell (WBC) count are rare [",
"    <a class=\"abstract\" href=\"UTD.htm?13/25/13722/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    While the presence of atypical lymphocytes is required for the diagnosis, not all patients with active CMV infection have atypical cells at the time of presentation. In a review of 82 patients with CMV mononucleosis, 11 patients did not initially meet blood smear criteria for mononucleosis, but did so later in the course of their illness [",
"    <a class=\"abstract\" href=\"UTD.htm?13/25/13722/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    An absolute lymphocytosis may persist in patients for several months after the resolution of symptoms. In the first published series of patients with CMV mononucleosis, persistent lymphocytosis was documented in 8 of 18 patients (44 percent) and lasted between 2 to 11 months from the time of the original diagnosis [",
"    <a class=\"abstract\" href=\"UTD.htm?13/25/13722/abstract/32\">",
"     32",
"    </a>",
"    ]. The persistence of atypical lymphocytes did not correlate with the duration of clinical symptoms.",
"   </p>",
"   <p>",
"    In addition to the cardinal hematologic manifestations of mononucleosis, other abnormalities may also be seen including [",
"    <a class=\"abstract\" href=\"UTD.htm?13/25/13722/abstract/1,2,33-36\">",
"     1,2,33-36",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Mild-to-moderate anemia",
"     </li>",
"     <li>",
"      Reduced haptoglobin levels",
"     </li>",
"     <li>",
"      Cold agglutinins",
"     </li>",
"     <li>",
"      Elevated levels of rheumatoid factor",
"     </li>",
"     <li>",
"      Positive anti-nuclear antibodies (ANA)",
"     </li>",
"     <li>",
"      Thrombocytopenia",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     ORGAN-SPECIFIC COMPLICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Disease localized to a single organ has been described in immunocompetent hosts, even presenting as a fulminant, multisystem disorder. However, these cases are rare and limited to small series and case reports [",
"    <a class=\"abstract\" href=\"UTD.htm?13/25/13722/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Gastrointestinal manifestations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Gastrointestinal involvement with cytomegalovirus (CMV) is uncommon in immunocompetent hosts, but can cause significant morbidity and mortality [",
"    <a class=\"abstract\" href=\"UTD.htm?13/25/13722/abstract/38-40\">",
"     38-40",
"    </a>",
"    ]. While CMV colitis is almost always secondary to the reactivation of latent infection in immunosuppressed patients, CMV colitis in the immunocompetent host can occur in the setting of primary infection. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/62/22504?source=see_link\">",
"     \"AIDS-related cytomegalovirus gastrointestinal disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In one review of 15 cases of CMV colitis among patients without underlying immunosuppression, the following findings were noted [",
"    <a class=\"abstract\" href=\"UTD.htm?13/25/13722/abstract/41\">",
"     41",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Seven patients had probable primary CMV infection based upon seroconversion at time of diagnosis, detection of CMV-specific IgM antibody, or positive viral cultures in the absence of detectable antibodies.",
"     </li>",
"     <li>",
"      Diarrhea, fever, and abdominal pain were common presenting symptoms.",
"     </li>",
"     <li>",
"      Among patients reporting diarrhea, stool was described as grossly bloody in 53 percent and positive for occult blood in 20 percent.",
"     </li>",
"     <li>",
"      Profuse gastrointestinal hemorrhage was the presenting symptom in the two patients without prodromal diarrhea.",
"     </li>",
"     <li>",
"      Pathology findings supported the diagnosis of inflammatory colitis with Cowdry inclusions, typical of CMV disease.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The presence of abnormal mucosal surfaces prior to CMV infection may increase the risk of this infection. As an example, evidence of gastrointestinal CMV in patients with preexisting inflammatory bowel disease has been described [",
"    <a class=\"abstract\" href=\"UTD.htm?13/25/13722/abstract/42,43\">",
"     42,43",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    CMV colitis can be confused with ischemic colitis when an elderly patient presents with bloody diarrhea and abdominal pain [",
"    <a class=\"abstract\" href=\"UTD.htm?13/25/13722/abstract/38\">",
"     38",
"    </a>",
"    ]. CMV has also been implicated as a cause of symptomatic esophagitis [",
"    <a class=\"abstract\" href=\"UTD.htm?13/25/13722/abstract/44,45\">",
"     44,45",
"    </a>",
"    ], gastritis [",
"    <a class=\"abstract\" href=\"UTD.htm?13/25/13722/abstract/46,47\">",
"     46,47",
"    </a>",
"    ] and ileitis [",
"    <a class=\"abstract\" href=\"UTD.htm?13/25/13722/abstract/48\">",
"     48",
"    </a>",
"    ] in patients without underlying immunosuppression.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Hepatic manifestations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Liver function abnormalities are frequently encountered in patients with symptomatic CMV infection [",
"    <a class=\"abstract\" href=\"UTD.htm?13/25/13722/abstract/1\">",
"     1",
"    </a>",
"    ]. Subclinical transaminitis is the most common finding in immunocompetent patients; elevations of alkaline phosphatase and total bilirubin are less typical. Occasionally, patients will present with more significant laboratory abnormalities or signs of hepatic dysfunction. Portal vein thrombosis has also been described as a rare complication of acute CMV-associated hepatitis [",
"    <a class=\"abstract\" href=\"UTD.htm?13/25/13722/abstract/49,50\">",
"     49,50",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Though infrequent, CMV should also be included in the differential diagnosis of granulomatous hepatitis [",
"    <a class=\"abstract\" href=\"UTD.htm?13/25/13722/abstract/1,51,52\">",
"     1,51,52",
"    </a>",
"    ]. Prolonged, unexplained fever is the most common presentation. This condition is associated with the characteristic biopsy findings of multiple non-caseating epithelioid granulomas, portal triaditis, and focal necrosis [",
"    <a class=\"abstract\" href=\"UTD.htm?13/25/13722/abstract/51\">",
"     51",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/29/40406?source=see_link\">",
"     \"Hepatic granulomas\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Neurologic manifestations",
"    </span>",
"    &nbsp;&mdash;&nbsp;CMV infection has been associated with numerous neurologic sequelae in the immunocompetent host.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Encephalitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although rare, encephalitis is a serious potential complication of CMV infection and this entity should be considered in the differential diagnosis of unexplained encephalitis. In one study of ten cases of isolated CMV encephalitis, there were no fatalities, and only one patient had persistent neurologic deficits six months after diagnosis [",
"    <a class=\"abstract\" href=\"UTD.htm?13/25/13722/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Guillain-Barr&eacute; syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Guillain-Barr&eacute; syndrome (GBS) has been associated with a variety of infectious agents, including CMV and Campylobacter infections. This incidence of CMV-related GBS has been estimated to occur in approximately 0.6 to 2.2 cases per 1000 cases of primary CMV infection (versus 0.25 to 0.65 cases per 1000 cases of C. jejuni infection) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/25/13722/abstract/53\">",
"     53",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/6/40038?source=see_link&amp;anchor=H4#H4\">",
"     \"Pathogenesis of Guillain-Barr&eacute; syndrome in adults\", section on 'Antecedent events'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In a serologic study of patients with GBS, recent CMV infection was detected in 13 percent of patients by serology [",
"    <a class=\"abstract\" href=\"UTD.htm?13/25/13722/abstract/54\">",
"     54",
"    </a>",
"    ]. In a subsequent prospective study of 506 patients with GBS, 63 (12.4 percent) were found to have primary CMV infection, as detected by IgM detection with IgG avidity in combination with plasma CMV PCR [",
"    <a class=\"abstract\" href=\"UTD.htm?13/25/13722/abstract/53\">",
"     53",
"    </a>",
"    ]. In a series of 42 patients with GBS and serologic evidence of recent or past CMV infection, polymerase chain reaction (PCR) testing of the cerebrospinal fluid (CSF) demonstrated CMV DNA in approximately one-third of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?13/25/13722/abstract/55\">",
"     55",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients with CMV-related GBS are generally younger than those with Campylobacter-related and idiopathic forms of the syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?13/25/13722/abstract/53,56\">",
"     53,56",
"    </a>",
"    ]. The median age of patients with CMV-related GBS is 32 years, and 85 percent of patients are women [",
"    <a class=\"abstract\" href=\"UTD.htm?13/25/13722/abstract/53\">",
"     53",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In one study, patients with CMV-related GBS experienced more prominent sensory deficits, respiratory insufficiency, and cranial nerve impairments than those with Campylobacter-related and idiopathic forms of the syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?13/25/13722/abstract/56\">",
"     56",
"    </a>",
"    ]. However, in another study, facial palsy was the only clinical finding that was significantly more common in patients with CMV-related GBS compared with non-CMV-related GBS [",
"    <a class=\"abstract\" href=\"UTD.htm?13/25/13722/abstract/53\">",
"     53",
"    </a>",
"    ]. Studies on the long-term outcomes of CMV-related GBS have provided conflicting results. In one study, recovery from GBS appeared to be slower in patients in whom either CMV or Campylobacter infections were identified [",
"    <a class=\"abstract\" href=\"UTD.htm?13/25/13722/abstract/57\">",
"     57",
"    </a>",
"    ]. However, in another study, patients with CMV-related GBS were less likely to have severe long-term neurologic sequelae than patients with GBS that was not related to CMV [",
"    <a class=\"abstract\" href=\"UTD.htm?13/25/13722/abstract/53\">",
"     53",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    CMV-related GBS is typically associated with the development of antibodies to ganglioside GM2, although the exact role of these antibodies remains unresolved [",
"    <a class=\"abstract\" href=\"UTD.htm?13/25/13722/abstract/54,58\">",
"     54,58",
"    </a>",
"    ]. Importantly, anti-GM2 IgM antibodies are often detected not only in patients with CMV-related GBS, but also in patients with CMV infection who do not have GBS [",
"    <a class=\"abstract\" href=\"UTD.htm?13/25/13722/abstract/53\">",
"     53",
"    </a>",
"    ]. One group demonstrated that CMV-infected fibroblasts express surface epitopes capable of binding anti-GM2 antibodies [",
"    <a class=\"abstract\" href=\"UTD.htm?13/25/13722/abstract/59\">",
"     59",
"    </a>",
"    ]. This observation suggests that molecular mimicry between CMV-infected cells and GM2 may be important in disease pathogenesis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Other",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other focal neurologic deficits have been described in patients with CMV, including brachial plexus neuropathy [",
"    <a class=\"abstract\" href=\"UTD.htm?13/25/13722/abstract/60\">",
"     60",
"    </a>",
"    ], diffuse axonal peripheral neuropathy [",
"    <a class=\"abstract\" href=\"UTD.htm?13/25/13722/abstract/61\">",
"     61",
"    </a>",
"    ], transverse myelitis [",
"    <a class=\"abstract\" href=\"UTD.htm?13/25/13722/abstract/62,63\">",
"     62,63",
"    </a>",
"    ], Horner's syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?13/25/13722/abstract/2\">",
"     2",
"    </a>",
"    ], and cranial nerve palsies [",
"    <a class=\"abstract\" href=\"UTD.htm?13/25/13722/abstract/62\">",
"     62",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Pulmonary manifestations",
"    </span>",
"    &nbsp;&mdash;&nbsp;CMV pneumonia is rarely described in immunocompetent hosts. Although pulmonary complaints and radiologic abnormalities were cited in earlier reports of immunocompetent patients, proof that CMV is the actual cause of these abnormalities is generally lacking [",
"    <a class=\"abstract\" href=\"UTD.htm?13/25/13722/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Ocular manifestations",
"    </span>",
"    &nbsp;&mdash;&nbsp;CMV retinitis is a well-known occurrence in patients with advanced immunosuppression from HIV infection. However, CMV infection of the eye is uncommon among immunocompetent individuals and, until recently, had been limited to rare case reports [",
"    <a class=\"abstract\" href=\"UTD.htm?13/25/13722/abstract/61,64-66\">",
"     61,64-66",
"    </a>",
"    ]. With the development of the polymerase chain reaction (PCR), CMV infection has been identified with increasing frequency among immunocompetent patients presenting with anterior uveitis [",
"    <a class=\"abstract\" href=\"UTD.htm?13/25/13722/abstract/67-69\">",
"     67-69",
"    </a>",
"    ]. This was illustrated in a study in which immunocompetent patients presenting with anterior uveitis associated with elevated intraocular pressure (hypertensive anterior uveitis) underwent PCR analysis of anterior chamber aqueous fluid [",
"    <a class=\"abstract\" href=\"UTD.htm?13/25/13722/abstract/67\">",
"     67",
"    </a>",
"    ]. Among 105 samples, 24 (23 percent) had evidence of CMV DNA. In patients presenting with evidence of CMV-related anterior uveitis, CMV viral load within the aqueous fluid appears to correlate with the degree of corneal endothelial cell loss [",
"    <a class=\"abstract\" href=\"UTD.htm?13/25/13722/abstract/69\">",
"     69",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/51/37688?source=see_link\">",
"     \"Pathogenesis, clinical manifestations, and diagnosis of AIDS-related cytomegalovirus retinitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Cardiovascular manifestations",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10018016\">",
"    <span class=\"h3\">",
"     Pericarditis and myocarditis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pericarditis and myocarditis have been described in immunocompetent patients with acute CMV infection [",
"    <a class=\"abstract\" href=\"UTD.htm?13/25/13722/abstract/1,70-74\">",
"     1,70-74",
"    </a>",
"    ]. While CMV DNA has been detected by polymerase chain reaction (PCR) and in-situ hybridization in endomyocardial tissue from patients with isolated myocarditis and dilated cardiomyopathy, direct causality has not been clearly demonstrated [",
"    <a class=\"abstract\" href=\"UTD.htm?13/25/13722/abstract/74\">",
"     74",
"    </a>",
"    ]. Furthermore, in a study of 245 patients with dilated cardiomyopathy, viral genomes were isolated in 165 (67 percent); CMV DNA was isolated in only two patients [",
"    <a class=\"abstract\" href=\"UTD.htm?13/25/13722/abstract/75\">",
"     75",
"    </a>",
"    ]. However, in an autopsy study of 40 patients with fatal myocarditis, CMV DNA was isolated in 15 patients [",
"    <a class=\"abstract\" href=\"UTD.htm?13/25/13722/abstract/76\">",
"     76",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10018023\">",
"    <span class=\"h3\">",
"     Atherosclerosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several infectious agents have been implicated in the pathogenesis of atherosclerosis. Chlamydia pneumoniae and CMV have received the most attention. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/36/25160?source=see_link\">",
"     \"Chlamydophila (Chlamydia) pneumoniae infection as a potential etiologic factor in atherosclerosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    To date, a definitive causal relationship between infection with CMV and atheroma formation has not been clearly established. Several investigators have postulated that latent CMV infection of vascular endothelial cells promotes subsequent arterial smooth muscle cell proliferation, enhanced expression of scavenger receptors, and increased uptake of oxidized low-density lipoproteins, resulting in atherosclerosis [",
"    <a class=\"abstract\" href=\"UTD.htm?13/25/13722/abstract/77\">",
"     77",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Epidemiologic evidence has supported the association of CMV with accelerated atherosclerosis following cardiac transplantation [",
"    <a class=\"abstract\" href=\"UTD.htm?13/25/13722/abstract/78\">",
"     78",
"    </a>",
"    ]. Clinical studies have linked an increased risk of atherosclerotic coronary artery disease (CAD), restenosis of lesions following atherectomy, and post- angioplasty restenosis with serologic evidence of past CMV infection [",
"    <a class=\"abstract\" href=\"UTD.htm?13/25/13722/abstract/79-81\">",
"     79-81",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, not all studies have upheld the close seroepidemiologic association between viral infection and vascular plaque formation in carotid or coronary arteries [",
"    <a class=\"abstract\" href=\"UTD.htm?13/25/13722/abstract/82-85\">",
"     82-85",
"    </a>",
"    ]. Many pathologic studies have also failed to observe evidence of CMV in coronary plaques [",
"    <a class=\"abstract\" href=\"UTD.htm?13/25/13722/abstract/86,87\">",
"     86,87",
"    </a>",
"    ]. Thus, further prospective investigation into this proposed association will be necessary before firm conclusions can be reached.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10018030\">",
"    <span class=\"h3\">",
"     Venous thrombosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Venous thrombosis with or without associated pulmonary embolism has been reported in case reports and small case series of immunocompetent patients with acute CMV infection, often in the absence of known risk factors for hypercoagulability. While the development of lower extremity deep vein thrombosis may be related to prolonged stasis in hospitalized patients with severe CMV disease, the development of venous thrombosis at other sites such as the portal vein, internal jugular vein, ovarian vein, and mesenteric veins suggests that CMV may have a procoagulant effect [",
"    <a class=\"abstract\" href=\"UTD.htm?13/25/13722/abstract/49,50,88-91\">",
"     49,50,88-91",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     REACTIVATION IN CRITICALLY ILL PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cytomegalovirus (CMV) reactivation occurs commonly in critically ill patients [",
"    <a class=\"abstract\" href=\"UTD.htm?13/25/13722/abstract/92-98\">",
"     92-98",
"    </a>",
"    ]. Small observational studies and a systematic review have suggested that CMV reactivation in such patients is linked to increased length of hospital",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    intensive care unit (ICU) stay [",
"    <a class=\"abstract\" href=\"UTD.htm?13/25/13722/abstract/94,96-98\">",
"     94,96-98",
"    </a>",
"    ], duration of mechanical ventilation [",
"    <a class=\"abstract\" href=\"UTD.htm?13/25/13722/abstract/94,96\">",
"     94,96",
"    </a>",
"    ], severe sepsis [",
"    <a class=\"abstract\" href=\"UTD.htm?13/25/13722/abstract/98\">",
"     98",
"    </a>",
"    ], high disease severity [",
"    <a class=\"abstract\" href=\"UTD.htm?13/25/13722/abstract/98\">",
"     98",
"    </a>",
"    ], and mortality [",
"    <a class=\"abstract\" href=\"UTD.htm?13/25/13722/abstract/92,94,98\">",
"     92,94,98",
"    </a>",
"    ]. In a prospective blinded study of 120 critically ill immunocompetent patients who were CMV-seropositive, CMV reactivation was detected by real-time polymerase chain reaction (PCR) in 39 patients (33 percent) and was independently associated with continued hospitalization or death by 30 days after admission to the ICU [",
"    <a class=\"abstract\" href=\"UTD.htm?13/25/13722/abstract/97\">",
"     97",
"    </a>",
"    ]. Viremia was detected at a median of 12 days following ICU admission and persisted for 3 to 57 days (median 17 days).",
"   </p>",
"   <p>",
"    Further studies are necessary to determine whether antiviral prophylaxis of critically ill CMV-seropositive patients or treatment of reactivation in such patients will result in improved outcomes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10018037\">",
"    <span class=\"h1\">",
"     ASSOCIATION BETWEEN SEROPOSITIVITY AND OUTCOMES",
"    </span>",
"    &nbsp;&mdash;&nbsp;In a population-based study of 1468 Latino adults 60 years and older, all-cause mortality was 1.43 times higher among individuals with cytomegalovirus (CMV) IgG antibody titers in the highest quartile compared with lower quartiles (95% CI 1.14-1.79) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/25/13722/abstract/99\">",
"     99",
"    </a>",
"    ]. The hazard of cardiovascular mortality was also elevated in those with antibodies in the highest quartile (hazard ratio 1.35, 95% CI 1.01-1.80). Tumor necrosis factor and interleukin-6 levels mediated a substantial proportion of the association between high CMV antibody levels and both all-cause and cardiovascular mortality. This study suggests a link between CMV infection and mortality, potentially the result of the activation of inflammatory pathways. However, further studies are necessary to establish this possible association and, if validated, elucidate the biologic mechanisms underlying this association.",
"   </p>",
"   <p>",
"    In contrast to the study described above, in a retrospective study that evaluated the impact of CMV serostatus on outcomes in immunocompetent ICU patients, on multivariable analysis, there was no association between CMV seropositivity and ICU mortality which was the primary end point of the study [",
"    <a class=\"abstract\" href=\"UTD.htm?13/25/13722/abstract/100\">",
"     100",
"    </a>",
"    ]. There was also no association between CMV seropositivity and any of the secondary end points, which included in-hospital mortality, time to discharge from the ICU or hospital, time to wean from mechanical ventilation, and the need for renal replacement therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most cases of primary cytomegalovirus (CMV) infection in immunocompetent hosts are associated with minimal or no symptoms. Among patients with symptomatic CMV infection, especially the mononucleosis syndrome, the illness is generally self-limited, with complete recovery over a period of days to weeks. Antiviral therapy is not usually indicated.",
"   </p>",
"   <p>",
"    Currently, there are several agents available for the systemic therapy of CMV infection, including",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/30/33248?source=see_link\">",
"     ganciclovir",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/37/5718?source=see_link\">",
"     valganciclovir",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/56/29575?source=see_link\">",
"     foscarnet",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/2/20517?source=see_link\">",
"     cidofovir",
"    </a>",
"    . The efficacy and toxicities of these agents have been evaluated extensively only in immunocompromised patients. The clinical utility of these agents in the immunocompetent host remains unproven. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/25/17815?source=see_link\">",
"     \"Ganciclovir and valganciclovir: An overview\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/13/44244?source=see_link\">",
"     \"Foscarnet: An overview\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/47/37620?source=see_link\">",
"     \"Cidofovir: An overview\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Several case reports have documented successful therapy of previously healthy patients with severe manifestations of CMV infection. Patients with protracted CMV mononucleosis and many of the organ-specific complications of CMV have had successful clinical outcomes associated with the use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/30/33248?source=see_link\">",
"     ganciclovir",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?13/25/13722/abstract/37,70,101\">",
"     37,70,101",
"    </a>",
"    ],",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/37/5718?source=see_link\">",
"     valganciclovir",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?13/25/13722/abstract/68,102,103\">",
"     68,102,103",
"    </a>",
"    ], and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/56/29575?source=see_link\">",
"     foscarnet",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?13/25/13722/abstract/37,63,64,104\">",
"     37,63,64,104",
"    </a>",
"    ]. However, recurrence of CMV anterior uveitis following the discontinuation of antiviral therapy has also been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?13/25/13722/abstract/67\">",
"     67",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H17\">",
"     'Ocular manifestations'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Since the majority of immunocompetent patients with CMV disease recover without intervention, it is difficult to prove whether or not antiviral therapy has a significant impact on the clinical outcome. Doses of the drugs and the duration of therapy also have not been clarified for this group of patients. Since severe CMV infections in this population are rare, it is unlikely that a prospective randomized trial will ever be performed comparing antiviral therapy to placebo. Thus, the severity and potential morbidity of CMV disease must be balanced against the risk of medication toxicity in deciding whether or not to use antivirals in an individual immunocompetent patient.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    Basics topics (See",
"    <a class=\"medical medical_basics\" href=\"UTD.htm?19/10/19618?source=see_link\">",
"     \"Patient information: Cytomegalovirus (The Basics)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Although acute cytomegalovirus (CMV) infection is generally asymptomatic or produces only non-specific symptoms in the immunocompetent host, a broad variety of presentations have been described, ranging from a common form of infectious mononucleosis to marked systemic disease with significant morbidity. The illness is generally more innocuous in newly infected children than in adults.",
"     </li>",
"     <li>",
"      Transmission can occur via multiple routes including sexual transmission, close contact, as in day care centers, or blood and tissue exposure. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The most common syndrome related to primary CMV infection is CMV mononucleosis. Fever and systemic symptoms predominate in CMV related mononucleosis, while enlarged cervical lymph nodes and pharyngitis are much more commonly seen with EBV infection. Hematologic findings with both infections include an absolute lymphocytosis and atypical lymphocytes. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'CMV mononucleosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with CMV-related mononucleosis are heterophile antibody negative and require further diagnostic testing specifically for CMV. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?8/25/8597?source=see_link\">",
"       \"Diagnosis of cytomegalovirus\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      CMV infection has also been rarely associated with colitis, encephalitis, myocarditis, and other organ specific entities. &nbsp;(See",
"      <a class=\"local\" href=\"#H9\">",
"       'Organ-specific complications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      CMV reactivation is common in critically ill immunocompetent patients and is associated with increased length of hospital",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      intensive care unit stay, duration of mechanical ventilation, severe sepsis, high disease severity, and mortality. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Reactivation in critically ill patients'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Among patients with symptomatic CMV infection, especially the mononucleosis syndrome, the illness is generally self-limited, with complete recovery over a period of days to weeks. Antiviral therapy is not usually indicated. (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Therapy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/25/13722/abstract/1\">",
"      Cohen JI, Corey GR. Cytomegalovirus infection in the normal host. Medicine (Baltimore) 1985; 64:100.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/25/13722/abstract/2\">",
"      Horwitz CA, Henle W, Henle G, et al. Clinical and laboratory evaluation of cytomegalovirus-induced mononucleosis in previously healthy individuals. Report of 82 cases. Medicine (Baltimore) 1986; 65:124.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/25/13722/abstract/3\">",
"      Gandhi MK, Khanna R. Human cytomegalovirus: clinical aspects, immune regulation, and emerging treatments. Lancet Infect Dis 2004; 4:725.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/25/13722/abstract/4\">",
"      S&ouml;derberg-Naucl&eacute;r C, Fish KN, Nelson JA. Reactivation of latent human cytomegalovirus by allogeneic stimulation of blood cells from healthy donors. Cell 1997; 91:119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/25/13722/abstract/5\">",
"      Ross SA, Arora N, Novak Z, et al. Cytomegalovirus reinfections in healthy seroimmune women. J Infect Dis 2010; 201:386.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/25/13722/abstract/6\">",
"      Arora N, Novak Z, Fowler KB, et al. Cytomegalovirus viruria and DNAemia in healthy seropositive women. J Infect Dis 2010; 202:1800.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/25/13722/abstract/7\">",
"      Gillespie GM, Wills MR, Appay V, et al. Functional heterogeneity and high frequencies of cytomegalovirus-specific CD8(+) T lymphocytes in healthy seropositive donors. J Virol 2000; 74:8140.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/25/13722/abstract/8\">",
"      Sylwester AW, Mitchell BL, Edgar JB, et al. Broadly targeted human cytomegalovirus-specific CD4+ and CD8+ T cells dominate the memory compartments of exposed subjects. J Exp Med 2005; 202:673.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/25/13722/abstract/9\">",
"      Krech U. Complement-fixing antibodies against cytomegalovirus in different parts of the world. Bull World Health Organ 1973; 49:103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/25/13722/abstract/10\">",
"      Ho M. Epidemiology of cytomegalovirus infections. Rev Infect Dis 1990; 12 Suppl 7:S701.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/25/13722/abstract/11\">",
"      Klemola E, K&auml;&auml;ri&auml;inen L. Cytomegalovirus as a possible cause of a disease resembling infectious mononucleosis. Br Med J 1965; 2:1099.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/25/13722/abstract/12\">",
"      Staras SA, Dollard SC, Radford KW, et al. Seroprevalence of cytomegalovirus infection in the United States, 1988-1994. Clin Infect Dis 2006; 43:1143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/25/13722/abstract/13\">",
"      Bate SL, Dollard SC, Cannon MJ. Cytomegalovirus seroprevalence in the United States: the national health and nutrition examination surveys, 1988-2004. Clin Infect Dis 2010; 50:1439.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/25/13722/abstract/14\">",
"      Stadler LP, Bernstein DI, Callahan ST, et al. Seroprevalence of cytomegalovirus (CMV) and risk factors for infection in adolescent males. Clin Infect Dis 2010; 51:e76.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/25/13722/abstract/15\">",
"      Colugnati FA, Staras SA, Dollard SC, Cannon MJ. Incidence of cytomegalovirus infection among the general population and pregnant women in the United States. BMC Infect Dis 2007; 7:71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/25/13722/abstract/16\">",
"      Evans AS. Infectious mononucleosis and related syndromes. Am J Med Sci 1978; 276:325.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/25/13722/abstract/17\">",
"      Handsfield HH, Chandler SH, Caine VA, et al. Cytomegalovirus infection in sex partners: evidence for sexual transmission. J Infect Dis 1985; 151:344.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/25/13722/abstract/18\">",
"      Jordan MC, Rousseau WE, Noble GR, et al. Association of cervical cytomegaloviruses with venereal disease. N Engl J Med 1973; 288:932.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/25/13722/abstract/19\">",
"      Pass RF, Little EA, Stagno S, et al. Young children as a probable source of maternal and congenital cytomegalovirus infection. N Engl J Med 1987; 316:1366.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/25/13722/abstract/20\">",
"      Adler SP. Molecular epidemiology of cytomegalovirus: viral transmission among children attending a day care center, their parents, and caretakers. J Pediatr 1988; 112:366.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/25/13722/abstract/21\">",
"      Tolpin MD, Stewart JA, Warren D, et al. Transfusion transmission of cytomegalovirus confirmed by restriction endonuclease analysis. J Pediatr 1985; 107:953.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/25/13722/abstract/22\">",
"      Prince AM, Szmuness W, Millian SJ, David DS. A serologic study of cytomegalovirus infections associated with blood transfusions. N Engl J Med 1971; 284:1125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/25/13722/abstract/23\">",
"      Preiksaitis JK, Brown L, McKenzie M. The risk of cytomegalovirus infection in seronegative transfusion recipients not receiving exogenous immunosuppression. J Infect Dis 1988; 157:523.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/25/13722/abstract/24\">",
"      Blackman JA, Murph JR, Bale JF Jr. Risk of cytomegalovirus infection among educators and health care personnel serving disabled children. Pediatr Infect Dis J 1987; 6:725.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/25/13722/abstract/25\">",
"      Stowell JD, Forlin-Passoni D, Din E, et al. Cytomegalovirus survival on common environmental surfaces: opportunities for viral transmission. J Infect Dis 2012; 205:211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/25/13722/abstract/26\">",
"      Klemola E, Von Essen R, Henle G, Henle W. Infectious-mononucleosis-like disease with negative heterophil agglutination test. Clinical features in relation to Epstein-Barr virus and cytomegalovirus antibodies. J Infect Dis 1970; 121:608.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/25/13722/abstract/27\">",
"      Klemola E. Hypersensitivity reactions to ampicillin in cytomegalovirus mononucleosis. Scand J Infect Dis 1970; 2:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/25/13722/abstract/28\">",
"      Pullen H, Wright N, Murdoch JM. Hypersensitivity reactions to antibacterial drugs in infectious mononucleosis. Lancet 1967; 2:1176.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/25/13722/abstract/29\">",
"      Porath A, Schlaeffer F, Sarov I, Keynan A. Cytomegalovirus mononucleosis--a report of 70 cases in a community hospital. Isr J Med Sci 1987; 23:268.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/25/13722/abstract/30\">",
"      Pannuti CS, Vilas Boas LS, Angelo MJ, et al. Cytomegalovirus mononucleosis in children and adults: differences in clinical presentation. Scand J Infect Dis 1985; 17:153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/25/13722/abstract/31\">",
"      Begovac J, Soldo I, Presecki V. Cytomegalovirus mononucleosis in children compared with the infection in adults and with Epstein-Barr virus mononucleosis. J Infect 1988; 17:121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/25/13722/abstract/32\">",
"      Klemola E, von Essen R, Wager O, et al. Cytomegalovirus mononucleosis in previously healthy individuals. Five new cases and follow-up of 13 previously published cases. Ann Intern Med 1969; 71:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/25/13722/abstract/33\">",
"      Wright JG. Severe thrombocytopenia secondary to asymptomatic cytomegalovirus infection in an immunocompetent host. J Clin Pathol 1992; 45:1037.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/25/13722/abstract/34\">",
"      Horwitz CA, Moulds J, Henle W, et al. Cold agglutinins in infectious mononucleosis and heterophil-antibody-negative mononucleosis-like syndromes. Blood 1977; 50:195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/25/13722/abstract/35\">",
"      Crapnell K, Zanjani ED, Chaudhuri A, et al. In vitro infection of megakaryocytes and their precursors by human cytomegalovirus. Blood 2000; 95:487.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/25/13722/abstract/36\">",
"      van Spronsen DJ, Breed WP. Cytomegalovirus-induced thrombocytopenia and haemolysis in an immunocompetent adult. Br J Haematol 1996; 92:218.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/25/13722/abstract/37\">",
"      Eddleston M, Peacock S, Juniper M, Warrell DA. Severe cytomegalovirus infection in immunocompetent patients. Clin Infect Dis 1997; 24:52.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/25/13722/abstract/38\">",
"      Siegal DS, Hamid N, Cunha BA. Cytomegalovirus colitis mimicking ischemic colitis in an immunocompetent host. Heart Lung 2005; 34:291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/25/13722/abstract/39\">",
"      Patra S, Samal SC, Chacko A, et al. Cytomegalovirus infection of the human gastrointestinal tract. J Gastroenterol Hepatol 1999; 14:973.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/25/13722/abstract/40\">",
"      Goodgame RW. Gastrointestinal cytomegalovirus disease. Ann Intern Med 1993; 119:924.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/25/13722/abstract/41\">",
"      Klauber E, Briski LE, Khatib R. Cytomegalovirus colitis in the immunocompetent host: an overview. Scand J Infect Dis 1998; 30:559.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/25/13722/abstract/42\">",
"      Kaufman HS, Kahn AC, Iacobuzio-Donahue C, et al. Cytomegaloviral enterocolitis: clinical associations and outcome. Dis Colon Rectum 1999; 42:24.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/25/13722/abstract/43\">",
"      Papadakis KA, Tung JK, Binder SW, et al. Outcome of cytomegalovirus infections in patients with inflammatory bowel disease. Am J Gastroenterol 2001; 96:2137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/25/13722/abstract/44\">",
"      Venkataramani A, Schlueter AJ, Spech TJ, Greenberg E. Cytomegalovirus esophagitis in an immunocompetent host. Gastrointest Endosc 1994; 40:392.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/25/13722/abstract/45\">",
"      Villar LA, Massanari RM, Mitros FA. Cytomegalovirus infection with acute erosive esophagitis. Am J Med 1984; 76:924.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/25/13722/abstract/46\">",
"      Stam F, Kolkman JJ, Jiwa MM, Meuwissen SG. Cytomegalovirus gastritis in an immunocompetent patient. J Clin Gastroenterol 1996; 22:322.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/25/13722/abstract/47\">",
"      Himoto T, Goda F, Okuyama H, et al. Cytomegalovirus-associated acute gastric mucosal lesion in an immunocompetent host. Intern Med 2009; 48:1521.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/25/13722/abstract/48\">",
"      Taniwaki S, Kataoka M, Tanaka H, et al. Multiple ulcers of the ileum due to Cytomegalovirus infection in a patient who showed no evidence of an immunocompromised state. J Gastroenterol 1997; 32:548.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/25/13722/abstract/49\">",
"      Squizzato A, Ageno W, Cattaneo A, Brumana N. A case report and literature review of portal vein thrombosis associated with cytomegalovirus infection in immunocompetent patients. Clin Infect Dis 2007; 44:e13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/25/13722/abstract/50\">",
"      Spahr L, Cerny A, Morard I, et al. Acute partial Budd-Chiari syndrome and portal vein thrombosis in cytomegalovirus primary infection: a case report. BMC Gastroenterol 2006; 6:10.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/25/13722/abstract/51\">",
"      Clarke J, Craig RM, Saffro R, et al. Cytomegalovirus granulomatous hepatitis. Am J Med 1979; 66:264.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/25/13722/abstract/52\">",
"      Bonkowsky HL, Lee RV, Klatskin G. Acute granulomatous hepatitis. Occurrence in cytomegalovirus mononucleosis. JAMA 1975; 233:1284.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/25/13722/abstract/53\">",
"      Orlikowski D, Porcher R, Sivadon-Tardy V, et al. Guillain-Barr&eacute; syndrome following primary cytomegalovirus infection: a prospective cohort study. Clin Infect Dis 2011; 52:837.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/25/13722/abstract/54\">",
"      Jacobs BC, Rothbarth PH, van der Mech&eacute; FG, et al. The spectrum of antecedent infections in Guillain-Barr&eacute; syndrome: a case-control study. Neurology 1998; 51:1110.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/25/13722/abstract/55\">",
"      Steininger C, Popow-Kraupp T, Seiser A, et al. Presence of cytomegalovirus in cerebrospinal fluid of patients with Guillain-Barre syndrome. J Infect Dis 2004; 189:984.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/25/13722/abstract/56\">",
"      Visser LH, van der Mech&eacute; FG, Meulstee J, et al. Cytomegalovirus infection and Guillain-Barr&eacute; syndrome: the clinical, electrophysiologic, and prognostic features. Dutch Guillain-Barr&eacute; Study Group. Neurology 1996; 47:668.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/25/13722/abstract/57\">",
"      Visser LH, Schmitz PI, Meulstee J, et al. Prognostic factors of Guillain-Barr&eacute; syndrome after intravenous immunoglobulin or plasma exchange. Dutch Guillain-Barr&eacute; Study Group. Neurology 1999; 53:598.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/25/13722/abstract/58\">",
"      Khalili-Shirazi A, Gregson N, Gray I, et al. Antiganglioside antibodies in Guillain-Barr&eacute; syndrome after a recent cytomegalovirus infection. J Neurol Neurosurg Psychiatry 1999; 66:376.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/25/13722/abstract/59\">",
"      Ang CW, Jacobs BC, Brandenburg AH, et al. Cross-reactive antibodies against GM2 and CMV-infected fibroblasts in Guillain-Barr&eacute; syndrome. Neurology 2000; 54:1453.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/25/13722/abstract/60\">",
"      Duchowny M, Caplan L, Siber G. Cytomegalovirus infection of the adult nervous system. Ann Neurol 1979; 5:458.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/25/13722/abstract/61\">",
"      L&oacute;pez-Contreras J, Ris J, Domingo P, et al. Disseminated cytomegalovirus infection in an immunocompetent adult successfully treated with ganciclovir. Scand J Infect Dis 1995; 27:523.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/25/13722/abstract/62\">",
"      Tyler KL, Gross RA, Cascino GD. Unusual viral causes of transverse myelitis: hepatitis A virus and cytomegalovirus. Neurology 1986; 36:855.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/25/13722/abstract/63\">",
"      Giobbia M, Carniato A, Scotton PG, et al. Cytomegalovirus-associated transverse myelitis in a non-immunocompromised patient. Infection 1999; 27:228.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/25/13722/abstract/64\">",
"      Baglivo E, Leuenberger PM, Krause KH. Presumed bilateral cytomegalovirus-induced optic neuropathy in an immunocompetent person. A case report. J Neuroophthalmol 1996; 16:14.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/25/13722/abstract/65\">",
"      Chawla HB, Ford MJ, Munro JF, et al. Ocular involvement in cytomegalovirus infection in a previously healthy adult. Br Med J 1976; 2:281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/25/13722/abstract/66\">",
"      De Silva SR, Chohan G, Jones D, Hu M. Cytomegalovirus papillitis in an immunocompetent patient. J Neuroophthalmol 2008; 28:126.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/25/13722/abstract/67\">",
"      Chee SP, Bacsal K, Jap A, et al. Clinical features of cytomegalovirus anterior uveitis in immunocompetent patients. Am J Ophthalmol 2008; 145:834.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/25/13722/abstract/68\">",
"      van Boxtel LA, van der Lelij A, van der Meer J, Los LI. Cytomegalovirus as a cause of anterior uveitis in immunocompetent patients. Ophthalmology 2007; 114:1358.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/25/13722/abstract/69\">",
"      Miyanaga M, Sugita S, Shimizu N, et al. A significant association of viral loads with corneal endothelial cell damage in cytomegalovirus anterior uveitis. Br J Ophthalmol 2010; 94:336.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/25/13722/abstract/70\">",
"      Campbell PT, Li JS, Wall TC, et al. Cytomegalovirus pericarditis: a case series and review of the literature. Am J Med Sci 1995; 309:229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/25/13722/abstract/71\">",
"      McCormack JG, Bowler SD, Donnelly JE, Steadman C. Successful treatment of severe cytomegalovirus infection with ganciclovir in an immunocompetent host. Clin Infect Dis 1998; 26:1007.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/25/13722/abstract/72\">",
"      Waris E, R&auml;s&auml;nen O, Kreus KE, Kreus R. Fatal cytomegalovirus disease in a previously healthy adult. Scand J Infect Dis 1972; 4:61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/25/13722/abstract/73\">",
"      Tiula E, Leinikki P. Fatal cytomegalovirus infection in a previously healthy boy with myocarditis and consumption coagulopathy as presenting signs. Scand J Infect Dis 1972; 4:57.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/25/13722/abstract/74\">",
"      Sch&ouml;nian U, Crombach M, Maser S, Maisch B. Cytomegalovirus-associated heart muscle disease. Eur Heart J 1995; 16 Suppl O:46.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/25/13722/abstract/75\">",
"      K&uuml;hl U, Pauschinger M, Noutsias M, et al. High prevalence of viral genomes and multiple viral infections in the myocardium of adults with \"idiopathic\" left ventricular dysfunction. Circulation 2005; 111:887.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/25/13722/abstract/76\">",
"      Kyt&ouml; V, Vuorinen T, Saukko P, et al. Cytomegalovirus infection of the heart is common in patients with fatal myocarditis. Clin Infect Dis 2005; 40:683.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/25/13722/abstract/77\">",
"      High KP. Atherosclerosis and infection due to Chlamydia pneumoniae or cytomegalovirus: weighing the evidence. Clin Infect Dis 1999; 28:746.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/25/13722/abstract/78\">",
"      Danesh J, Collins R, Peto R. Chronic infections and coronary heart disease: is there a link? Lancet 1997; 350:430.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/25/13722/abstract/79\">",
"      Sorlie PD, Nieto FJ, Adam E, et al. A prospective study of cytomegalovirus, herpes simplex virus 1, and coronary heart disease: the atherosclerosis risk in communities (ARIC) study. Arch Intern Med 2000; 160:2027.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/25/13722/abstract/80\">",
"      Zhou YF, Leon MB, Waclawiw MA, et al. Association between prior cytomegalovirus infection and the risk of restenosis after coronary atherectomy. N Engl J Med 1996; 335:624.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/25/13722/abstract/81\">",
"      Blum A, Giladi M, Weinberg M, et al. High anti-cytomegalovirus (CMV) IgG antibody titer is associated with coronary artery disease and may predict post-coronary balloon angioplasty restenosis. Am J Cardiol 1998; 81:866.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/25/13722/abstract/82\">",
"      Sorlie PD, Adam E, Melnick SL, et al. Cytomegalovirus/herpesvirus and carotid atherosclerosis: the ARIC Study. J Med Virol 1994; 42:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/25/13722/abstract/83\">",
"      Adler SP, Hur JK, Wang JB, Vetrovec GW. Prior infection with cytomegalovirus is not a major risk factor for angiographically demonstrated coronary artery atherosclerosis. J Infect Dis 1998; 177:209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/25/13722/abstract/84\">",
"      Carlsson J, Miketic S, Brom J, et al. Prior cytomegalovirus, Chlamydia pneumoniae or Helicobacter pylori infection and the risk of restenosis after percutaneous transluminal coronary angioplasty. Int J Cardiol 2000; 73:165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/25/13722/abstract/85\">",
"      Manegold C, Alwazzeh M, Jablonowski H, et al. Prior cytomegalovirus infection and the risk of restenosis after percutaneous transluminal coronary balloon angioplasty. Circulation 1999; 99:1290.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/25/13722/abstract/86\">",
"      Daus H, Ozbek C, Saage D, et al. Lack of evidence for a pathogenic role of Chlamydia pneumoniae and cytomegalovirus infection in coronary atheroma formation. Cardiology 1998; 90:83.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/25/13722/abstract/87\">",
"      Sambiase NV, Higuchi ML, Nuovo G, et al. CMV and transplant-related coronary atherosclerosis: an immunohistochemical, in situ hybridization, and polymerase chain reaction in situ study. Mod Pathol 2000; 13:173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/25/13722/abstract/88\">",
"      Abgueguen P, Delbos V, Chennebault JM, et al. Vascular thrombosis and acute cytomegalovirus infection in immunocompetent patients: report of 2 cases and literature review. Clin Infect Dis 2003; 36:E134.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/25/13722/abstract/89\">",
"      Fridlender ZG, Khamaisi M, Leitersdorf E. Association between cytomegalovirus infection and venous thromboembolism. Am J Med Sci 2007; 334:111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/25/13722/abstract/90\">",
"      Ailani RK, Simms R, Caracioni AA, West BC. Extensive mesenteric inflammatory veno-occlusive disease of unknown etiology after primary cytomegalovirus infection: first case. Am J Gastroenterol 1997; 92:1216.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/25/13722/abstract/91\">",
"      Abquequen, P, Delbos, V, Ducancelle, A, et al. Venous thrombosis in immunocompetent patients with acute cytomegalovirus infection: A complication may be underestimated. Clin Microbiol Infect 2009; :.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/25/13722/abstract/92\">",
"      Cook CH, Yenchar JK, Kraner TO, et al. Occult herpes family viruses may increase mortality in critically ill surgical patients. Am J Surg 1998; 176:357.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/25/13722/abstract/93\">",
"      Heininger A, Jahn G, Engel C, et al. Human cytomegalovirus infections in nonimmunosuppressed critically ill patients. Crit Care Med 2001; 29:541.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/25/13722/abstract/94\">",
"      Jaber S, Chanques G, Borry J, et al. Cytomegalovirus infection in critically ill patients: associated factors and consequences. Chest 2005; 127:233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/25/13722/abstract/95\">",
"      Kutza AS, Muhl E, Hackstein H, et al. High incidence of active cytomegalovirus infection among septic patients. Clin Infect Dis 1998; 26:1076.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/25/13722/abstract/96\">",
"      von M&uuml;ller L, Klemm A, Weiss M, et al. Active cytomegalovirus infection in patients with septic shock. Emerg Infect Dis 2006; 12:1517.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/25/13722/abstract/97\">",
"      Limaye AP, Kirby KA, Rubenfeld GD, et al. Cytomegalovirus reactivation in critically ill immunocompetent patients. JAMA 2008; 300:413.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/25/13722/abstract/98\">",
"      Kalil AC, Florescu DF. Prevalence and mortality associated with cytomegalovirus infection in nonimmunosuppressed patients in the intensive care unit. Crit Care Med 2009; 37:2350.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/25/13722/abstract/99\">",
"      Roberts ET, Haan MN, Dowd JB, Aiello AE. Cytomegalovirus antibody levels, inflammation, and mortality among elderly Latinos over 9 years of follow-up. Am J Epidemiol 2010; 172:363.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/25/13722/abstract/100\">",
"      De Vlieger G, Meersseman W, Lagrou K, et al. Cytomegalovirus serostatus and outcome in nonimmunocompromised critically ill patients. Crit Care Med 2012; 40:36.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/25/13722/abstract/101\">",
"      Laing RB, Dykhuizen RS, Smith CC, Molyneaux PJ. Parenteral ganciclovir treatment of acute CMV infection in the immunocompetent host. Infection 1997; 25:44.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/25/13722/abstract/102\">",
"      Buonuomo PS, Maurizi P, Valentini P, et al. Successful treatment with oral valganciclovir in immunocompetent infant with gastrointestinal manifestations of cytomegalovirus infection. J Perinatol 2006; 26:648.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/25/13722/abstract/103\">",
"      Fern&aacute;ndez-Ruiz M, Mu&ntilde;oz-Codoceo C, L&oacute;pez-Medrano F, et al. Cytomegalovirus myopericarditis and hepatitis in an immunocompetent adult: successful treatment with oral valganciclovir. Intern Med 2008; 47:1963.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/25/13722/abstract/104\">",
"      Serna-Higuera C, Gonz&aacute;lez-Garc&iacute;a M, Milicua JM, Mu&ntilde;oz V. Acute cholestatic hepatitis by cytomegalovirus in an immunocompetent patient resolved with ganciclovir. J Clin Gastroenterol 1999; 29:276.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8289 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-190.111.122.2-74CF0474CE-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_25_13722=[""].join("\n");
var outline_f13_25_13722=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H21\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      INFECTION, LATENCY AND REACTIVATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      IMMUNOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      TRANSMISSION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      CMV MONONUCLEOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Differences between EBV and CMV mononucleosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Laboratory abnormalities",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      ORGAN-SPECIFIC COMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Gastrointestinal manifestations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Hepatic manifestations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Neurologic manifestations",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Encephalitis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Guillain-Barr&eacute; syndrome",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Other",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Pulmonary manifestations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Ocular manifestations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Cardiovascular manifestations",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10018016\">",
"      - Pericarditis and myocarditis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10018023\">",
"      - Atherosclerosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10018030\">",
"      - Venous thrombosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      REACTIVATION IN CRITICALLY ILL PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10018037\">",
"      ASSOCIATION BETWEEN SEROPOSITIVITY AND OUTCOMES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      THERAPY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/62/22504?source=related_link\">",
"      AIDS-related cytomegalovirus gastrointestinal disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/36/25160?source=related_link\">",
"      Chlamydophila (Chlamydia) pneumoniae infection as a potential etiologic factor in atherosclerosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/47/37620?source=related_link\">",
"      Cidofovir: An overview",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/21/12634?source=related_link\">",
"      Cytomegalovirus infection in pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/2/29738?source=related_link\">",
"      Cytomegalovirus infection in renal transplant recipients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/25/8597?source=related_link\">",
"      Diagnosis of cytomegalovirus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/13/44244?source=related_link\">",
"      Foscarnet: An overview",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/25/17815?source=related_link\">",
"      Ganciclovir and valganciclovir: An overview",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/29/40406?source=related_link\">",
"      Hepatic granulomas",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/18/31018?source=related_link\">",
"      Infectious mononucleosis in adults and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/5/24665?source=related_link\">",
"      Leukoreduction to prevent complications of blood transfusion",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/6/40038?source=related_link\">",
"      Pathogenesis of Guillain-Barr&eacute; syndrome in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/51/37688?source=related_link\">",
"      Pathogenesis, clinical manifestations, and diagnosis of AIDS-related cytomegalovirus retinitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?19/10/19618?source=related_link\">",
"      Patient information: Cytomegalovirus (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f13_25_13723="Initiating speech-language intervention";
var content_f13_25_13723=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F52412&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F52412&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Predictors of success and risk factors to consider when initiating speech-language intervention",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Predictors of success",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Language production",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Language comprehension",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Phonologic repertoire",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Imitation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Play skills",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Use of gestures",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Social skills",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Risk factors for speech-language impairment",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Otitis media",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Familial history of language and learning problems",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Parental needs",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from: Olswang LB, Rodriguez B, Timler G. Am J Speech Lang Pathol 1998; 7:23.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_25_13723=[""].join("\n");
var outline_f13_25_13723=null;
var title_f13_25_13724="Toll-like receptors";
var content_f13_25_13724=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ALLRG%2F55974&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ALLRG%2F55974&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Toll-like receptors",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        PRRs",
"       </td>",
"       <td class=\"subtitle1\">",
"        Localization",
"       </td>",
"       <td class=\"subtitle1\">",
"        Ligand",
"       </td>",
"       <td class=\"subtitle1\">",
"        Microbial origin of ligand",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        TLR1",
"       </td>",
"       <td>",
"        Plasma membrane",
"       </td>",
"       <td>",
"        Triacyl lipoprotein",
"       </td>",
"       <td>",
"        Bacteria",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        TLR2",
"       </td>",
"       <td>",
"        Plasma membrane",
"       </td>",
"       <td>",
"        Lipoprotein",
"       </td>",
"       <td>",
"        Bacteria, viruses, parasites",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        TLR3",
"       </td>",
"       <td>",
"        Endolysosome*",
"       </td>",
"       <td>",
"        dsRNA",
"       </td>",
"       <td>",
"        Viruses",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        TLR4",
"       </td>",
"       <td>",
"        Plasma membrane",
"       </td>",
"       <td>",
"        LPS",
"       </td>",
"       <td>",
"        Bacteria, viruses",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        TLR5",
"       </td>",
"       <td>",
"        Plasma membrane",
"       </td>",
"       <td>",
"        Flagellin",
"       </td>",
"       <td>",
"        Bacteria",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        TLR6",
"       </td>",
"       <td>",
"        Plasma membrane",
"       </td>",
"       <td>",
"        Diacyl lipoprotein",
"       </td>",
"       <td>",
"        Bacteria, viruses",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        TLR7/8",
"       </td>",
"       <td>",
"        Endolysosome",
"       </td>",
"       <td>",
"        ssRNA",
"       </td>",
"       <td>",
"        Viruses, bacteria",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        TLR9",
"       </td>",
"       <td>",
"        Endolysosome",
"       </td>",
"       <td>",
"        CpG-DNA",
"       </td>",
"       <td>",
"        Viruses, bacteria, protozoa",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        TLR10",
"       </td>",
"       <td>",
"        Endolysosome",
"       </td>",
"       <td>",
"        Unknown",
"       </td>",
"       <td>",
"        Unknown",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     ds: double-stranded; ss: single-stranded.",
"     <br>",
"      * An endosome is an intracellular membrane-bound compartment of the endocytic transport pathway from the plasma membrane to the lysosome. In the context of host defense, endolysosomal refers to localization in a vesicle containing internalized microbial debris or virus that has fused with lysosomes that contain degradative enzymes.",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_25_13724=[""].join("\n");
var outline_f13_25_13724=null;
var title_f13_25_13725="Intrapartum rx diabetes";
var content_f13_25_13725=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F76661&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=11\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F76661&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=11\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Intrapartum treatment of diabetes",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1\">",
"       Maternal plasma glucose mg/dL (mmol/L)",
"      </td>",
"      <td class=\"subtitle1\">",
"       Intravenous insulin (units/hour)*&bull;",
"      </td>",
"      <td class=\"subtitle1\">",
"       Intravenous solution",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_left\" colspan=\"3\">",
"       Protocol 1: Recommended by American College of Obstetricians and Gynecologists*&Delta;",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Start of labor",
"      </td>",
"      <td>",
"       Hold",
"      </td>",
"      <td>",
"       Start normal saline infusion",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       &lt;70 mg/dL (3.9) or active labor",
"      </td>",
"      <td>",
"       Hold",
"      </td>",
"      <td rowspan=\"2\">",
"       5 percent dextrose normal saline (D5NS) at 100-150 mL/hour to achieve CBG of about 100 mg/dL",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       &gt;100 mg/dL (5.6)",
"      </td>",
"      <td>",
"       Regular or short-acting insulin at 1.25 units per hour (10 units per 1000 mL D5NS at 125 mL/hour)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_left\" colspan=\"3\">",
"       Protocol 2: Recommended for women with type 1 diabetes",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       &lt;70 (&lt;3.9)",
"      </td>",
"      <td>",
"       0.0",
"      </td>",
"      <td rowspan=\"4\">",
"       <p>",
"        CBG &lt;130 mg/dL (7.2 mmol/L)",
"       </p>",
"       <p>",
"        5 percent Dextrose Lactated Ringers at 125 mL/hour",
"       </p>",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       71-90 (3.9-5.0)",
"      </td>",
"      <td>",
"       0.5",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       91-110 (5.1-6.1)",
"      </td>",
"      <td>",
"       1.0",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       111-130 (6.2-7.2)",
"      </td>",
"      <td>",
"       2.0",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       131-150 (7.3-8.3)",
"      </td>",
"      <td>",
"       3.0",
"      </td>",
"      <td rowspan=\"4\">",
"       <p>",
"        CBG &gt;130 mg/dL (7.2 mmol/L)",
"       </p>",
"       <p>",
"        Lactated Ringers at 125 mL/hour",
"       </p>",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       151-170 (8.4-9.4)",
"      </td>",
"      <td>",
"       4.0",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       171-190 (9.5-10.6)",
"      </td>",
"      <td>",
"       5.0",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       &gt;190 (&gt;10.6)",
"      </td>",
"      <td>",
"       Check Ketones",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_left\" colspan=\"3\">",
"       Protocol 3: \"Rotating fluids\". For use in women with gestational diabetes. This protocol should not be used in women with type 1 diabetes mellitus.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       &le;100 mg/dL (5.6)",
"      </td>",
"      <td>",
"       Hold",
"      </td>",
"      <td>",
"       D5NS at 125 mL/hour to achieve CBG of 100 mg/dL",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       101-140 mg/dL (5.6-7.8)",
"      </td>",
"      <td>",
"       Hold",
"      </td>",
"      <td>",
"       Lactated Ringers at 125 mL/hour to achieve CBG of 100 mg/dL",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       &gt;140 mg/dL (7.8)",
"      </td>",
"      <td>",
"       Regular or short-acting insulin infusion titrated to achieve CBG of 100 mg/dL",
"      </td>",
"      <td>",
"       Lactated Ringers at 125 mL/hour to achieve CBG of 100 mg/dL",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     CBG: capillary blood glucose.",
"     <br>",
"      * Jovanovic, L, Peterson, CM. Management of the pregnant, insulin-Dependent diabetic woman. Diabetes Care 1980; 3:63.",
"      <br>",
"       &bull; Mix 25 units regular insulin in 250 mL normal saline (1 unit:10 mL).",
"       <br>",
"        &Delta; Coustan, DR. Delivery: Timing, mode, and management. In: Diabetes in women: adolescent, pregnancy and menopause, Reese, EA, Coustan, DR, Gabee, SG (Eds), Lippincott Williams &amp; Wilkins 2004. p.433.",
"       </br>",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     <strong>",
"      Protocol 1",
"     </strong>",
"     : Data from: ACOG Practice Bulletin. Clinical Management Guidelines for Obstetrician-Gynecologists. Number 60, March 2005. Pregestational diabetes mellitus. Obstet Gynecol 2005; 105:675.",
"     <br>",
"      <strong>",
"       Protocol 2",
"      </strong>",
"      : Reproduced with permission from: Kitzmiller JL, Gavin L. Preexisting diabetes and pregnancy. In: Manual of Endocrinology and Metabolism, 3rd ed, Lavin N (Ed), Lippincott Williams &amp; Wilkins, Philadelphia 2002. Copyright &copy; 2002 Lippincott Williams &amp; Wilkins.",
"      <br>",
"       <strong>",
"        Protocol 3",
"       </strong>",
"       : Data from: Rosenberg VA, Eglinton GS, Rauch ER, Skupski DW. Intrapartum maternal glycemic control in women with insulin requiring diabetes: a randomized clinical trial of rotating fluids versus insulin drip. Am J Obstet Gynecol 2006; 195:1095.",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.lww.com\">",
"      file://www.lww.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_25_13725=[""].join("\n");
var outline_f13_25_13725=null;
var title_f13_25_13726="Contents: Neurologic systems and symptoms";
var content_f13_25_13726=[" <script type=\"text/javascript\">",
"  $$.inlineInitCustomer(",
"	false);",
"	var quirksmode = document.compatMode == \"CSS1Compat\";",
"	if (quirksmode) {",
"		$(\"html\").addClass(\"ie-standards\");",
"	}",
" </script>",
" <div id=\"message-wrap\">",
"  <div id=\"message-bg\">",
"  </div>",
"  <iframe id=\"message-bk\">",
"  </iframe>",
"  <dl id=\"message-container\">",
"   <dt id=\"message-title\">",
"   </dt>",
"   <dd id=\"message-body\">",
"   </dd>",
"   <dd id=\"message-controls\">",
"   </dd>",
"  </dl>",
" </div>",
" <div id=\"topPanel\">",
"  <div id=\"header\">",
"   <div id=\"header_container\">",
"    <h2 id=\"logo\">",
"     <a href=\"./toc\">",
"      Wolters Kluwer Health UpToDate",
"     </a>",
"    </h2>",
"    <div id=\"header_right\">",
"     <div id=\"searchpanel\">",
"      <a href=\"/login\" id=\"loginbutton\">",
"       Log in",
"      </a>",
"      <div id=\"cmsSearchBox\">",
"       <div class=\"header-search\">",
"        <form action=\"./search\" id=\"cmssearch\" method=\"get\" name=\"SearchForm\">",
"         <div class=\"header-search-left\">",
"          <input autocomplete=\"off\" class=\"searchfield\" id=\"cmsTxtBox\" name=\"search\" placeholder=\"Search UpToDate\" type=\"text\"/>",
"         </div>",
"         <div class=\"header-search-right\">",
"          <input alt=\"Search\" id=\"cmsSearchSubmit\" src=\"/sites/all/themes/uptodate/images/search_button.png\" type=\"image\"/>",
"         </div>",
"         <div class=\"clear\">",
"         </div>",
"        </form>",
"       </div>",
"      </div>",
"      <div id=\"cms_lang_dropdown\">",
"       <form accept-charset=\"UTF-8\" action=\"/\" id=\"lang-dropdown-form\" method=\"post\">",
"        <div class=\"form-item form-type-select form-item-lang-dropdown-select\">",
"         <select class=\"lang-dropdown-select-element form-select\" id=\"edit-lang-dropdown-select\" name=\"lang_dropdown_select\" style=\"width:100px\">",
"          <option selected=\"selected\" value=\"en\">",
"           English",
"          </option>",
"          <option value=\"ja\">",
"           ���������������������������",
"          </option>",
"         </select>",
"        </div>",
"        <input name=\"lang_dropdown_type\" type=\"hidden\" value=\"language\">",
"         <input name=\"en\" type=\"hidden\" value=\"/\">",
"          <input name=\"ja\" type=\"hidden\" value=\"/ja\">",
"           <noscript>",
"            <div>",
"             <input class=\"form-submit\" id=\"edit-submit\" name=\"op\" type=\"submit\" value=\"Go\"/>",
"            </div>",
"           </noscript>",
"           <input name=\"form_build_id\" type=\"hidden\" value=\"form-on4lUWpxHun_wp6revUkjCG6rK2IBuCGME9Cw0HXeok\">",
"            <input name=\"form_id\" type=\"hidden\" value=\"lang_dropdown_form\">",
"            </input>",
"           </input>",
"          </input>",
"         </input>",
"        </input>",
"       </form>",
"      </div>",
"      <div class=\"clear\">",
"      </div>",
"     </div>",
"     <ul id=\"utility\">",
"      <li class=\"first\">",
"       <a href=\"/home/about-us\">",
"        About Us",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/news-events\">",
"        News &amp; Events",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/contact-us\">",
"        Contact Us",
"       </a>",
"      </li>",
"      <li class=\"last\">",
"       <a href=\"/help\">",
"        Help",
"       </a>",
"      </li>",
"     </ul>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"nav\">",
"    <ul>",
"     <li id=\"productTab\">",
"      <a href=\"/home/product\">",
"       Product",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"editoralTab\">",
"      <a href=\"/home/editorial\">",
"       Editorial",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"whyUptodateTab\">",
"      <a href=\"/home/why-uptodate\">",
"       Why UpToDate",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"supscriptionOptionsTab\">",
"      <a href=\"/home/subscription-options\">",
"       Subscription Options",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"/store\">",
"       Subscribe",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"wkhcsTab\">",
"      <a href=\"/home/wolters-kluwer-health-clinical-solutions\">",
"       Wolters Kluwer Health Clinical Solutions",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"    </ul>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"greyBar\">",
"    <div id=\"greyBarTitle\">",
"     <span class=\"emphasis\">",
"      <a href=\"UTD.htm?3/3/3134\">",
"       Contents",
"      </a>",
"     </span>",
"     <img src=\"./../images/space_arrows.myextg\">",
"      <a href=\"UTD.htm?0/63/1022\">",
"       Neurology",
"      </a>",
"      <img src=\"./../images/space_arrows.myextg\">",
"       Neurologic systems and symptoms",
"      </img>",
"     </img>",
"    </div>",
"    <div id=\"greyBarButtons\">",
"     <div id=\"printGB\">",
"      <a class=\"icontxt\" href=\"?view=print\">",
"       <img align=\"middle\" alt=\"Print this page\" border=\"0\" height=\"20\" src=\"./../images/icn_print.myextg\" width=\"24\"/>",
"      </a>",
"      <a class=\"icontxt\" href=\"?view=print\" title=\"Print this page\">",
"       Print",
"      </a>",
"     </div>",
"    </div>",
"   </div>",
"   <!-- menuMessage.jsp -->",
"   <!-- /menuMessage.jsp -->",
"  </div>",
"  <!-- header -->",
" </div>",
" <!-- topPanel -->",
" <div id=\"leftPanel\">",
"  <ul>",
"   <li>",
"    <a href=\"UTD.htm?3/45/3806\">",
"     Specialties",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?18/22/18798\">",
"     Patient Information",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?3/13/3294\">",
"     What's New",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/37/606\">",
"     Calculators",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/40/654\">",
"     Authors and Editors",
"    </a>",
"   </li>",
"  </ul>",
" </div>",
" <!-- leftPanel -->",
" <div id=\"rightPanel\">",
"  <noscript>",
"   <div id=\"javascriptDisabled\">",
"    It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"   </div>",
"  </noscript>",
"  <div id=\"printHeader\">",
"   <div id=\"printHeaderLogo\">",
"    <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"    </img>",
"   </div>",
"   <div id=\"printHeaderText\">",
"    Official reprint from UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"    <a href=\"file://www.uptodate.com\">",
"     www.uptodate.com",
"    </a>",
"    <br>",
"     &copy;2013 UpToDate",
"     <sup>",
"      &reg;",
"     </sup>",
"    </br>",
"   </div>",
"   <div id=\"printHeaderLinks\">",
"    <a href=\"#\" id=\"printHeaderPrint\" rel=\"\" title=\"Click here to print\">",
"     Print",
"    </a>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"     Back",
"    </a>",
"   </div>",
"  </div>",
"  <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" id=\"tocTable\" width=\"100%\">",
"   <trs>",
"    <tds>",
"     <h1>",
"      Contents:",
"			Neurologic systems and symptoms",
"     </h1>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds valign=\"top\">",
"     <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">",
"      <trs>",
"       <tds>",
"        <strong>",
"         Delirium",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?38/10/39081\">",
"           Diagnosis of delirium and confusional states",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/33/28185\">",
"           Prevention and treatment of delirium and confusional states",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?37/27/38328\">",
"           Transient global amnesia",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Dizziness and vertigo",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?31/19/32057\">",
"           Approach to the patient with vertigo",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?19/13/19673\">",
"           Benign paroxysmal positional vertigo",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?23/6/23658\">",
"           Jerk nystagmus",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?15/8/15496\">",
"           Migrainous vertigo",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?33/23/34165\">",
"           Overview of nystagmus",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?16/38/17001\">",
"           Pathophysiology, etiology, and differential diagnosis of vertigo",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?1/0/1034\">",
"           Pendular nystagmus",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?13/15/13559\">",
"           Treatment of vertigo",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?34/15/35062\">",
"           Vestibular neuritis",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Neurologic examination",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/13/27863\">",
"           Clinical neurophysiology",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?28/24/29060\">",
"           Muscle examination in the evaluation of weakness",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?28/9/28825\">",
"           Stupor and coma in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?37/30/38377\">",
"           The detailed neurologic examination in adults",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Specific symptoms",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?13/30/13801\">",
"           Anatomy and etiology of taste and smell disorders",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?5/44/5832\">",
"           Anatomy and localization of spinal cord disorders",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?3/2/3111\">",
"           Aphasia: Prognosis and treatment",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?19/36/20041\">",
"           Approach to the patient with aphasia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?22/43/23223\">",
"           Approach to the patient with dizziness",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?26/4/26694\">",
"           Approach to the patient with muscle weakness",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?31/8/31879\">",
"           Approach to the patient with sensory loss",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?31/42/32426\">",
"           Disorders affecting the spinal cord",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?26/6/26727\">",
"           Etiology and diagnosis of tinnitus",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?10/15/10490\">",
"           Etiology of hearing loss in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?18/1/18455\">",
"           Evaluation and treatment of taste and smell disorders",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?12/41/12951\">",
"           Mechanisms, causes, and evaluation of orthostatic and postprandial hypotension",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?10/46/10984\">",
"           Overview of tremor",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?17/42/18082\">",
"           Patient information: Tinnitus (ringing in the ears) (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?28/30/29159\">",
"           Postural tachycardia syndrome",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?5/2/5161\">",
"           Treatment of orthostatic and postprandial hypotension",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?24/57/25495\">",
"           Treatment of tinnitus",
"          </a>",
"         </li>",
"        </ul>",
"       </tds>",
"      </trs>",
"     </div>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"     <img height=\"10\" src=\"./../images/spacer.myextg\" width=\"1\"/>",
"    </tds>",
"   </trs>",
"  </div>",
"  <div id=\"footer\">",
"   <div id=\"footerNav\">",
"    <ul>",
"     <li>",
"      <a href=\"file://www.wolterskluwerhealth.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Wolters Kluwer Health",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.factsandcomparisons.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Facts &amp; Comparisons&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medispan.com\" rel=\"nofollow\" target=\"_blank\">",
"       Medi-Span&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationordersets.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Order Sets",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationmedical.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Medical",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://pharmacyonesource.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Pharmacy OneSource&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medicom.com.cn/\" rel=\"nofollow\" target=\"_blank\">",
"       Medicom",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.lexi.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Lexicomp",
"      </a>",
"     </li>",
"     <li class=\"last\">",
"      <a href=\"/home/privacy-policy\">",
"       Privacy Policy",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"   <div id=\"footerLogo\">",
"    <a href=\"./toc\">",
"     Wolters Kluwer Health | UpToDate",
"    </a>",
"   </div>",
"   <div id=\"supportFooter\">",
"    <span class=\"sfInfo\">",
"     &copy; 2013 UpToDate, Inc. All rights reserved.",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Release: 21.3 - C21.34",
"    </span>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <span class=\"sfInfo\">",
"     <a href=\"/home/terms-use\">",
"      Terms of Use",
"     </a>",
"    </span>",
"    <br/>",
"    <span class=\"sfInfo\">",
"     Licensed to:",
"     <span class=\"emphasis\">",
"      UpToDate Marketing Professional",
"     </span>",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Support Tag: [0505-95.154.198.148-FCFD6546A2-14]",
"     <br/>",
"    </span>",
"   </div>",
"  </div>",
" </div>",
" <!-- rightPanel -->",
"</body>"].join("\n");
var script_f13_25_13726=[""].join("\n");
var outline_f13_25_13726=null;
var title_f13_25_13727="Evaluation alkaline phosphatase";
var content_f13_25_13727=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F78223&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F78223&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Evaluation of elevated serum alkaline phosphatase",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 400px; height: 564px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     AMA: antimitochondrial antibodies; ERCP: endoscopic retrograde cholangiopancreatography; MRCP: magnetic resonance cholangiopancreatography; ULN: upper limit of normal.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_25_13727=[""].join("\n");
var outline_f13_25_13727=null;
